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ABSTRACT OF THE DISSERTATION 
Live Cell Interferometry: A Novel Quantitative Phase Imaging Technique for Rapid 
Characterizations of Tumor Heterogeneity, Drug Resistance, Cell Fates and Biophysical 
Properties 
by 
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Doctor of Philosophy in Bioengineering 
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Professor Michael Alan Teitell, Chair 
Cell mass is an important biophysical property that provides a crucial link between 
external physical measurements and internal cellular processes such as cell cycle 
progression, division, differentiation and cell death. Advancements in quantitative phase 
imaging (QPI) techniques have enabled many in-depth studies of cell mass in the context 
of basic and translational research. This thesis describes the development and 
implementation of live cell interferometry (LCI) as a novel QPI technique that is high 
speed, high throughput, precise and label-free. It was validated as a powerful tool in 
dissecting tumor heterogeneity and drug resistance in patient derived melanoma cell lines. 
LCI analysis of cell fate in response to mitotic inhibitors provided valuable insights in 
cancer drug development and dose selection. Furthermore, it was utilized to characterize 
iii  
many other biophysical responses in fundamental research such as cardiomyocyte 
hypertrophy in cardiac wound healing responses. These studies showcased the unique 
capabilities and advantages of LCI in applications from bench to bedside. 
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Chapter 1 
INTRODUCTION 
2I. Cell mass as a readily accessible and direct cell response
Cell mass and biophysical properties 
Most fundamental biological studies in the 20th century were intricate investigative studies 
of internal cellular processes through interpretation of molecular markers and external observation. 
As biological sciences developed over the years, qualitative descriptions turn into quantitative 
measurements. However, often times scientists still rely heavily on clues and evidences of 
molecular markers that indirectly told small parts of complex stories. Recently, biophysical 
properties have gained traction in the field of biological sciences. As technologies advance in 
optics, microfluidics, microelectromechanical systems (MEMS) and nanoscience, scientists are 
able to interrogate and quantify biophysical properties of cells using direct measurements.1 One 
difficulty associated with direct measurements of biophysical properties is that these properties, 
such as cell mass, morphology, and viscoelastic properties are constantly changing with internal 
cellular processes and in response to external stimuli.2, 3 They are the externally observable outputs 
of the cell, and they play pivotal roles in all biological processes in nature. For example, neurons 
have long dendrites that allow them to make synaptic connections,4 while muscle cells have 
incredible elasticity that allow deformation and force generation.5 Plant cells have rigid cell walls 
that provide structural support and growth regulation.6 Blood cells must maintain a small size to 
pass through capillaries. The diameter of an ovum is 200 times the diameter of the head of a sperm 
cell in order to hold all vital contents and nutrition for zygote growth.7 This thesis places heavy 
focus on studying cell size, represented by the dry biomass of a cell.  
Biomass as cell size 
Traditionally, cell size is associated with the volume and dimensions of a cell. While 
morphological definition of cell size is useful in many applications, such as pathology, it does not 
3 
correlate well with molecular biology. In the past century, scientists have developed novel tools 
that allow measurements of cell mass,8,9 which reflects many intracellular pathways, such as 
protein synthesis, autophagy, cell division, differentiation and cell death.10,11 Interestingly, the 
volume and dimensions of cells do not perfectly correlate with cell mass.12 Cell mass, as the 
definition of cell size, is a powerful story teller of adaptation and evolution. It bridges studies of 
biophysics with molecular biology, and allows scientists to relate what is quantified externally to 
what is materializing internally.  
Changes in cell mass reflect cellular processes and responses to stimuli 
Recent developments in microfluidics, MEMS and optics have enabled real time 
quantification of cell mass.12-14 Measurements can be made on live cells statically and over time, 
providing quantitative and dynamic mass information during cell state progression and in response 
to stimuli.12,15 Scientists have recognized the importance of cell size in a number of cellular 
processes and maintenance of homeostasis.7 Many studies were conducted in search for 
mechanisms of cell size regulation. It is important to note that cell mass accumulation and division 
are differentially regulated but interdependent to achieve homeostasis.7, 16 Deregulation in cell 
mass accumulation or division can be pathogenic. Hypertension or valvular diseases lead to 
hypertrophy of cardiomyocyte, a permanent increase in cell mass setpoint. In Lhermitte–Duclos 
disease, increased cell size of cerebellar granule leads to seizures and death.7 Breast cancer tumors 
can exhibit rapid, intermediate or slow growth rates, which each have significant influence on 
prognosis and treatment planning.17  
Change in growth rates in response to drug treatment has been utilized in treatment 
selection for various cancers. However, commonly practiced approaches to determine treatment 
plans, such as cell viability counting assays, only offer therapy selection for the bulk tumor 
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population and overlooks tumor heterogeneity.18 Additionally, these traditional assays are not 
compatible with patient samples, which cannot be cultured for long periods of time outside the 
body. Other advanced diagnostic techniques, such as assays for molecular markers and single cell 
sequencing, provide detailed phenotype and genotype information for therapy selection and 
research. However, these assays destroy precious patient samples, only consider one timepoint and 
do not guarantee accurate predictions of treatment responses.18 Therefore, live cell mass 
measurements of patient samples over time in response to a wide array of therapeutic agents are 
more direct, rapid and efficient for diagnosis, prognosis and treatment planning.   
II. Cell mass measurements modalities
There have been many developments in cell mass measurements in the past decades, such 
as microfabricated resonators, interference microscopy and electron microscopy. The most 
common approaches can be classified into non-optical modalities and optical modalities. While 
non-optical modalities are more direct and accurate, optical modalities are more rapid and widely 
applicable.  
Non-optical modalities 
MEMS resonators can be used to measure cell mass based on the resonance frequency, 
which is determined by the total mass of the system and can be measured precisely.17 One approach 
of using MEMS resonator is with microfabricated pedestals, which generally consist of an array 
of microscale sensors supported by nanoscale springs.15, 19 Cells are adhered to the microsensors 
and any changes in resonant frequency of the sensors are due to the mass of the cells, which are 
measured by a laser doppler vibrometer. The resolution of these measurements is limited due to 
damping of resonance by surrounding fluid.20 Additionally, these resonant pedestal measurements 
are low throughput (<100 cells at a time) and are not suitable for correlative studies due to 
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incompatibility with multi-modal imaging.21 Cells can also easily migrate or lift off the pedestal, 
further preventing long-term tracking of single cell mass.22 
A major advancement of the microfabricated resonator technique is suspended 
microchannel resonator. This approach consists of a fluid microchannel that runs through a silicon 
cantilever suspended in vacuum.23 The vibrational frequency of the cantilever can be measured 
using embedded small piezoresistors or a laser doppler vibrometer. As cells flow through the 
microfluidic channel in the cantilever, vibrational patters are disturbed, recorded and subsequently 
used to derive buoyant mass of single cells.14 This approach has been utilized for growth-rate 
measurements of single bacterial, yeast and mammalian cells.21 A new development of this 
technology was recently applied in correlative studies of myeloma single cell mass accumulation 
and patient drug response. The measurement followed the same live cells for 15 minutes and 
recorded changes in single cell buoyant mass in response to drug treatments with a precision of 50 
femtograms.24 This microfluidic setup allows for rapid fluid exchange, enabling simultaneous 
measurements of cell mass and volume, as well as easy introduction of chemical stimuli to cells.20 
However, despite the benefits of this technology, it is low throughput, with a maximum capacity 
of quantifying 60-120 cells per hour.11 Further, the nature of taking single cell measurements in 
fluid suspension excludes cell types that are highly adherent or grow in large clusters/colonies.20  
Optical modalities 
The first quantitative measurements of single cell mass using optical techniques started in 
the 1950s by a group of scientists who approximated biomass using refractometry and 
interferometry.8, 25 While examining amoebocytes in earthworm blood under positive phase 
contrast microscopy, scientists made the serendipitous discovery that many cells’ cytoplasm 
appeared brighter than the surrounding fluid (earthworm blood, full of dissolved hemoglobin). 
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This observation sparked the idea that one can measure the refractive index of the cytoplasm and 
therefore the dry biomass content of the cell by submerging cells in liquids with matching 
refractive index.9 Optical approaches, such as interferometry, were quickly employed to measure 
the refractive indices of single cells in subsequent studies of live cell mass quantification.  
In a Michelson-style interferometer setup, a light beam from source illumination is split 
into two beams that travel different paths and recombine at a later point to create interferograms. 
The first sample beam travels a light path that passes through the sample (i.e. a cell surrounded by 
culture medium of certain height), while the second reference beam travels a light path identical 
to the first beam only without the sample (i.e. a reference chamber filled with water of the same 
height as culture medium but no cell). An interference pattern is created when the two light beams 
are recombined as a result of differing optical path lengths between the two. Optical path length is 
defined by the product of the geometric length of the light path and the refractive index of the 
medium that the light travels in. Geometrically, the two light beams have identical path lengths. 
However, the refractive indices of the mediums that the two beams pass through are different due 
to the presence of cellular content in the sample light path. Because the cytoplasm of a cell is 
packed with proteins, nucleic acids and other macromolecules, it is denser than water (cell culture 
medium has effectively the same refractive index as water), thus creating a longer optical path 
length for the sample light beam. This difference in optical path length can be quantified across 
the entire area of the cell to yield the optical volume of the cell, which can then be converted into 
dry biomass of the cell by multiplying a conversion factor of the average refractive indices of 
biomolecules.8  
Phase shifting interferometry (PSI) is a variation of this technique that was utilized by the 
Teitell group in early studies of single cell mass profiling, tumor drug response profiling and stem 
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cell colony differentiation and growth characterization.12, 26, 27 In PSI, a piezoelectric transducer 
rapidly alter the geometric length of light paths, generating an array of interferograms that allow 
measurements of optical path differences at high resolution. Another notable interferometry 
method is diffraction-phase microscopy (DPM), in which quantitative phase images are calculated 
from interference between light fields from imaging and reference diffraction patterns. Although 
this approach introduces more background noise compared to other interferometry methods, it is 
rapid and efficient in producing a quantitative phase map using one image acquisition.15  
Quadriwave lateral shearing interferometry is another major advancement in cell mass 
profiling. It is a common-path interferometry setup with a wavefront sensor built around a charge-
coupled device (CCD) camera. Incoming light passes through a modified Hartman mask 
diffractive grating, and is sheared into four separate light beams that interferes with each other in 
the x and y directions. The resulting interference pattern is detected by the CCD camera and 
calculated into a quantitative phase image.28 Similar to DPM, this technique only requires one 
image acquisition. It is also easily integrated with commercially available microscopy systems, 
which enables correlative studies and multi-modal imaging with florescence microscopy and many 
other experimental and analytical tools, such as microfluidics.29 Quadriwave lateral shearing 
interferometry was adopted in recent generations of live cell interferometer setup in the Teitell 
group and in our collaborator Dr. Jason Reed’s group. The method was utilized in studies of 
melanoma heterogeneity, B cell activation, prediction of breast cancer patient drug sensitivity, 
cancer cell fate response to mitotic inhibitors and many more fundamentally and clinically 
significant questions.18, 30, 31 
In addition to interferometry methods, digital holography microscopy (DHM) is also 
widely used in single cell mass profiling. In DHM, the intensity and phase information of a 
8 
biological sample is computed from a digitally recorded hologram. The images can be digitally 
autofocused, enabling lens free applications of this technique in recent developments of point-of-
care diagnostics.32-34 Although computationally heavy, this technique has the unique advantage of 
incorporating deep learning methods for resolution and imaging depth enhancements.33, 34  
Quantitative phase imaging (QPI) techniques including the ones mentioned above have 
been applied to studying topics in fundamental biology, such as cell membrane mechanics, cell 
growth, death and differentiation.15, 27, 35-37 QPI was also utilized in clinical research studies of 
wound healing, cardiac injuries, inflammation and circulating tumor cells.38-40  
III. Live cell interferometry (LCI)
This thesis highlights the development of live cell interferometry (LCI), a label-free, non-
invasive, accurate, longitudinal, wide-field imaging technique that provides real-time 
measurements of cell biomass, morphology, motion and other biophysical properties. LCI was 
originally designed in a Michelson interferometer setup to perform low-throughput PSI 
measurements on single adherent cells. The first study was the quantification of cytoskeletal 
rearrangements in NIH/3T3 embryonic fibroblasts in response to mechanical stimulation.41 The 
platform application evolved to encompass fields in fundamental biology and clinical translation 
research. Topics such as regulation of cell mass during division, differentiation, growth were 
thoroughly investigated.27, 42 More therapeutically significant studies such as characterizing tumor 
cell drug response, tumor heterogeneity, tumor-reactivity of T-cells and correlative prediction of 
patient drug response emphasized the versatility of the technology in clinical applications.18, 26, 31,
43 This thesis explores the evolution of LCI in technologies and applications, as well as its future 
directions in pushing forward basic and translational research.    
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Chapter 2 
TECHNICAL DEVELOPMENT OF LIVE CELL 
INTERFEROMETRY SYSTEMS 
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I. Bruker-Michelson phase shifting interferometry system
Hardware Overview 
The original live cell interferometry setup consists of a Michelson style interferometer that 
rests atop of a vibration isolation table (Figure 2-1). The main interferometer components are 
manufactured by Veeco Instruments Inc. and Bruker Corporation (Bruker NT9300 Optical 
Profiler). The instrument performs a variety of interferometry techniques, including phase shifting 
interferometry. The head of the Michelson interferometer consists of a beam splitter, a reference 
mirror, and a reference chamber filled with compensating fluid (distilled water or oil with the same 
refractive index as water) to account for the optical path difference introduced by culture media 
surrounding cells.  
A 660nm collimated LED light beam enters through fiber optics from the right side of the 
Michelson interferometer head module. The light is split into two beams by the beam splitter. The 
sample beam goes through a chamber with cells or beads and surrounding fluids, reflects off of 
the mirror surface of a silicon chip and travels back into the Michelson housing. The cells or beads 
are adhered to the silicon chip in the sample chamber, and the glass cover of the chamber is 
elevated off of the surface of the silicon chip by three 700 µm steel spheres. The reference beam 
goes through a reference chamber that simulates optical path of the sample beam without the cells 
or beads. The reference chamber is an aluminum frame holding two pieces of glass separated by 
three 700 µm steel spheres, and filled with either distilled water or a clear oil with the same 
refractive index as water. The reference beam then reflects off of the adjustable mirror at the end 
of the reference chamber and travels back towards the beam splitter. The sample and reference 
beams recombine at the beam splitter and travel up through the objective.  
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Due to the presence of cells or beads in the sample chamber, the optical path length of the 
sample beam is increased compared to the reference beam. This optical path difference creates 
interference between the two beams. The interferogram is then captured by a CCD camera inside 
of the Bruker optical profiler. The built-in motors and software control system of the Bruker 
Reed et Al. (2011). Biophysical 
Journal 101(5) 1025–1031
Figure 2-1 Bruker-Michelson Phase Shifting Interferometry Setup 
The Michelson interferometer setup is achieved by attaching the Michelson module to the 
objective of the Bruker optical profiler. The optical profiler has internal motors and software 
control system that enables movement of the imaging module across the stage to designated 
imaging locations. Cell samples are adhered to silicon chips and secured in cell observation 
chambers on stage. Cell culture media can be perfused through the chamber wells using a 
peristaltic pump and tubing system. 
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instrument perform timed and repeated phase shifting interferometry measurements at selected 
sample locations. Originally, acrylic sample chambers were used in all imaging experiments. 
Teflon chambers were later designed and fabricated as replacements in order to prevent small 
molecule adsorption in acrylic chamber materials (Figure 2-1). This is crucial in drug response 
profiling experiments in which the concentrations of small molecule drugs can drastically decline 
due to adsorption. 
Software Overview 
Once the interferograms were captured, Bruker software performs the first step of image 
analysis to generate quantitative phase images with phase-unwrapping. Phase-wrappings are 
integer wavelength errors due to phase shift ambiguity in quantitative phase imaging. These errors 
commonly occur at steep edges or dense points of samples where the optical path difference 
between sample and reference beams exceeds a whole wavelength of illumination light source. 
The Bruker Vision software performs the Goldstein phase unwrapping algorithm to correct some 
of the obvious phase-wrapping errors. This algorithm performs multiple random walk searches 
from each pixel to remove integer wavelength errors and non-physical excursions below 
background level. A second phase-unwrapping step is performed in MatLab using hybrid random 
walk-linear discriminant analysis method to remove remaining errors with robust and superior 
performance.1  
Phase unwrapped images are then background-corrected in MatLab. A spatial derivative 
edge detection kernel is used to segment out single cells from individual images. Single cell 
location and optical volumes are stored in cell tracking data arrays that are utilized by particle 
tracking algorithm to create mass over time data tracks.2 The entire experimental and analysis 
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process is laborious but robust, with measurement sensitivity at picograms and coefficients of 
variance at less than 0.5%. 
II. Quadriwave lateral shearing interferometry system
Hardware Overview 
A major advancement of LCI is 
switching from the Michelson PSI setup to 
quadriwave lateral shearing interferometry, 
which is a common-path interferometry setup 
(Figure 2-2). This configuration eliminates the 
complicated beam splitting setup in the 
optomechanical components and streamlines 
the image acquisition setup. The main 
component of this interferometer is a SID4BIO 
CCD camera with a modified Shack-Hartmann 
mask diffractive grating built in front of the 
wavefront sensor, sold by Phasics, Inc. This 
camera can be easily plugged into 
commercially available microscopes such as 
the Zeiss Observer A1 and Zeiss Observer Z1 
shown in Figure 2-2. The A1 setup is equipped 
with a 660nm LED light source, and a fast XY 
scanning stage top from Thorlabs, Inc., which 
enables repeated measurements at designated 
Figure 2-2 Quadriwave Lateral Shearing 
Interferometry Setup  
The quadriwave lateral shearing interferometric 
cameras from Phasics, Inc. are directly attached to 
side ports of a Zeiss Observer A1 (top) and a Zeiss 
Observer Z1 (bottom) microscopes. The top 
system is equipped with fast XY scanning stage 
from Thorlabs, Inc. and stage top incubator from 
IBIDI GMBH. The bottom system is equipped 
with scanning stage and stage top incubator from 
Carl Zeiss AG. The illustrations of optical paths 
are to the right of each setup.   
locations. The stage top is compatible with the stage top incubator from IBIDI GMBH, which 
maintains the cell culture condition at 37oC, 5% CO2 and 90% humidity at all times during 
imaging. The stage top incubator fits IBIDI 4 Well Ph+ µ-Slide, which holds a special intermediate 
plate that flattens out liquid meniscus, enabling optimal quantitative phase and florescence 
imaging. The Z1 setup is equipped with the same LED light source as A1, a fast XY scanning 
stage and a stage top incubator from Carl Zeiss AG. Additionally, there is an X-Cite florescence 
light source from EXFO Photonics and an EMCCD camera from Hamamatsu Photonics K.K. that 
allow florescence imaging parallel to quantitative phase imaging.  
Software Overview 
Both Zeiss A1 and Z1 setup with Phasics camera are controller by micromanager, through 
which BeanShell scripts execute imaging experiments of collecting quantitative phase and 
florescence images over time. A major effort in developing these two systems is creating an 
autofocus algorithm that is compatible with the optical setup. To accurately measure quantitative 
phase shift without distortion, only plan objectives without phase contrast components are used 
for imaging. Due to the lack of phase contrast, cells or beads in focus disappear and blend into the 
image background with very sharp but barely visible edge features (Figure 2-3a). Therefore, 
conventional autofocus algorithms that look for pronounced and defined objects and edge features 
do not perform optimally in this optical setup.  
A new autofocus scoring algorithm was developed to overcome this issue. The algorithm 
takes a 2D Fourier transform of an image and collapses it into a 1D power spectrum. A specific 
low frequency region of the spectrum is then further analyzed (Figure 2-3b). As shown in Figure 
2-3b-c, an in-focus image has overall lower signal amplitude and variance in the region of interest,
which is the determining factor of whether the sample is in focus. The autofocus scoring algorithm 
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Another new development in data processing for LCI is background correction (Figure 2-
4). Previous quantitative phase images collected using the Bruker optical profiler have flat and 
tilted background surfaces that can be easily fitted and subtracted using regular polynomials. The 
background surfaces seen in images collected by the Phasics cameras are due to optics in the light 
path, which produce circular aberrations in the wavefront. Zernike polynomials are a set of 
polynomials that are orthogonal over the continuous unit circle. They efficiently represent common 
18 
is then incorporated into a brute-force search algorithm to determine the optimal in-focus z-
location of the sample. An example of the autofocus scores over a range of focusing locations is 
shown in Figure 2-3d. 
Figure 2-3 Autofocus Scoring Algorithm 
The image scoring algorithm that facilitates autofocus in quantitative phase imaging using Phasics-Zeiss 
setup was developed in MatLab and C++. a) Example images of beads and red blood cells in and out of 
the focal plane. b) 2D Fourier transforms of typical sample images collapsed into 1D and region of 
interest for analysis. c) Fourier transform 1D power spectrum differences between images that are out 
of focus and in focus. d) Example focus scores of a bead over a focusing range of 5µm with 0.1µm 
increments. 
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spherical aberrations seen in optics, and represent arbitrarily complex continuous surfaces given 
enough terms. A new background correction algorithm using Zernike polynomials was developed 
to analyze quantitative phase images collected using the Zeiss-Phasics setup (Figure 2-4). Firstly, 
Object features are detected and excluded from a phase image. Secondly, the remaining phase 
image background is fitted to a given number (typically 15-30) of terms of Zernike polynomials. 
The optimal fit of the background surface is then subtracted from the original image to produce an 
image with a flattened background.  
III. High speed live cell interferometry (HSLCI) system
The most recent innovation in LCI is the dramatic increase in speed and throughput that 
elevates the platform application from basic scientific research to potential clinical diagnostics. 
The HSLCI system is entirely enclosed inside of a Steri-Cult CO2 Incubator manufactured by 
Thermo Fisher Scientific. This enclosure provides long term stable tissue culture, imaging and 
tracking capabilities that are compatible with complex experimental setup, correlative studies and 
patient sample screenings. The schematic of the HSLCI system is shown in Figure 2-5. The 
Figure 2-4 Zernike Background Correction Algorithm 
The background of a quantitative phase image can be approximated by a combination of different orders 
of Zernike polynomials. The work flow of background “flattening” is finding the Zernike polynomials 
best fit to the object excluded background, then subtracting the fitted Zernike polynomials background 
from the original image. 
20 
Phasics camera is upgraded to SID4Bio-4MP, which has 512 x 512 measurement points on the 
phase and intensity images and collects images at up to 10 frames per second. A steel plate holder 
is secured to three linear translation stages (Thorlabs, Inc., as are all components in this custom-
built system, unless noted otherwise) that facilitate programmed three dimensional movements to 
designated locations during image acquisition. The glass bottom of a multi-well cell culture plate 
Figure 2-5 HSLCI setup schematic 
Samples in a multi-well plate are moved around by motors in x, y and z directions; and are illuminated 
from the top by a collimated 660nm LED light source. The objective sits in a piezo module that rapidly 
fine tunes focus positions based laser feedback from the IR laser focusing module. Phasics SID4Bio-4MP 
camera acquires images at up to 10 frames per second. 
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has uneven height due to imperfect manufacturing processes, which requires the imaging system 
to rapidly adjust focus positions during fast image acquisition.  
An infrared laser is introduced from the right side of the optical setup and reflects off of 
the glass-air interface at the bottom of the sample plate. The reflection is then directed towards the 
back of the optical track where a position sensor generates a voltage output based on the location 
of the laser reflection. As the sample plate moves laterally, the reflection position changes 
constantly due to uneven height of the glass bottom across sample wells. The piezo module 
attached to the objective rapidly adjusts the height of the objective to compensate for the change 
in glass bottom height based on the voltage signal output from the laser position sensor. This 
automatic feedback loop is robust and flexible, and maintains optimal focus rapidly and 
consistently during lateral scanning of samples.  
A collimated 660nm LED light source is strobed by a camera generated trigger at 4 frames 
per second to synchronize with the camera’s exposure time. The light beam then passes through 
the sample and the objective, and travels to the Phasics camera at the left side of the optical setup. 
The camera takes 80 images scanning from the top to the bottom of a multi-well plate, completing 
image acquisition of one sub-column in one main column of wells. In a typical 24 well plates, 4 
sub-column scans are performed in each of the 4 main columns of the plate, with each main column 
containing 6 separate wells. This setup yields a significantly higher number of experimental 
conditions imaged per experiment and image locations per condition. The speed of imaging also 
improves from up to 15 seconds per image to up to 10 images per second.  
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ABSTRACT: We report the development of high-speed live-
cell interferometry (HSLCI), a new multisample, multidrug
testing platform for directly measuring tumor therapy response
via real-time optical cell biomass measurements. As a proof of
concept, we show that HSLCI rapidly proﬁles changes in
biomass in BRAF inhibitor (BRAFi)-sensitive parental
melanoma cell lines and in their isogenic BRAFi-resistant
sublines. We show reproducible results from two diﬀerent
HSLCI platforms at two institutions that generate biomass
kinetic signatures capable of discriminating between BRAFi-
sensitive and -resistant melanoma cells within 24 h. Like other
quantitative phase imaging (QPI) modalities, HSLCI is well-
suited to noninvasive measurements of single cells and cell clusters, requiring no ﬂuorescence or dye labeling. HSLCI is
substantially faster and more sensitive than ﬁeld-standard growth inhibition assays, and in terms of the number of cells measured
simultaneously, the number of drugs tested in parallel, and temporal measurement range, it exceeds the state of the art by more
than 10-fold. The accuracy and speed of HSLCI in proﬁling tumor cell heterogeneity and therapy resistance are promising
features of potential tools to guide patient therapeutic selections.
Prompt and repeated assessments of tumor sensitivity toavailable therapeutics could dramatically improve cancer
patients’ clinical outcomes by staying ahead of developing
therapy resistance. However, to achieve this goal, substantial
improvements in the state of the art will be required to create
eﬀective and practical therapy selection tools that rely on live-
cell and tissue responses. There are a number of relevant
performance measurables with which to evaluate live-cell drug
response assays. These include (a) the number of drugs or drug
combinations tested simultaneously, (b) the overall depth of
sampling (i.e., the number of individual cells measured), and
(c) the achievable duration of high-quality measurements. The
present study describes a new technique, high-speed live-cell
interferometry (HSLCI), that is based on rapid optical cell
biomass measurements and, as quantiﬁed by the metrics
mentioned, exceeds the current ﬁeld standard by greater than
10-fold. Here we apply HSLCI as a proof of concept to
metastatic melanoma, a disease in which tumor heterogeneity
and drug resistance are signiﬁcant obstacles to survival beneﬁts
from mutation-targeted therapy. Our results support the
potential of HSLCI as a therapy selection tool, for dissecting
overall tumor heterogeneity, and for predicting single-cell drug
resistance and treatment outcomes, and we argue for further
development of this technology in preclinical animal tests and
early-phase clinical trials.
An estimated 87 110 new cases of cutaneous melanoma with
9730 deaths will occur for the United States in 2017.1 Despite
comprising less than 2% of skin cancer diagnoses,2 melanoma is
responsible for 75% of skin cancer deaths. Genetic landscape
studies show interpatient, intrapatient, and intratumor hetero-
geneity. About 50% of melanomas harbor an activating
mutation in the BRAF gene, whereas 10−25% of cases show
an activating RAS mutation, 12−18% are mutant in NF1, and
7−28% of tumors show mutations in genes that include AKT
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and PTEN. Most of these mutations increase mitogen-activated
protein kinase (MAPK) pathway signaling activity, which
regulates cell proliferation, diﬀerentiation, and survival.3−6
Targeted therapies, most notably against BRAF V600E and
V600K activating mutations, has improved progression-free
survival for many melanoma patients.7 However, therapy
resistance emerges in most cases of BRAF or MEK inhibitor
monotherapy, often from preexisting or acquired mutations
that reactivate the MAPK pathway downstream of the drug-
targeted site.8 Current BRAF and MEK inhibitor combination
therapies aim to reduce the frequency of emergent
resistance.9,10 Drug selection guidance comes from clinical
tumor staging, mutation screening, patient health, and
prognostic factors such as lactate dehydrogenase levels.11
Despite multifactorial guidance, resistance eventually develops
for up to 80% of patients receiving combination therapy.7
Genetic heterogeneity underlying mechanisms of preexisting
and acquired resistance makes mutation screening incompletely
predictive of drug susceptibility, both prior to the start of
therapy and after the development of resistance, and increases
the diﬃculty of selecting eﬃcacious frontline and second-line
therapies.12−14
Current eﬀorts in repeat tumor assessment focus on
noninvasive liquid biopsy methodologies such as the detection
and analysis of circulating exosomes, microRNAs, circulating
tumor DNA, circulating tumor cells, and proteomic proﬁling of
serum proteins by mass spectrometry.15,16 While samples from
the circulation provide easily accessible materials that may be
more representative of a patient’s tumor heterogeneity than
single-site tumor biopsies, there are presently no reliable
molecular biomarkers from circulation sampling to guide
targeted melanoma therapy or improve outcome predic-
tions.17−19 Other limitations include a lack of standardization,
low sample yields, and the high cost of postisolation analyses,
which makes many circulation-sampling methods impractical
for broad-scale clinical implementations in their present
state.20,21
An alternative to circulating biomarkers is in vitro measure-
ment of drug responses in excised tumor cells by chemo-
sensitivity assays, such as ATP quantiﬁcation or assessments of
cell metabolic activity.22−25 Advocated by major cancer centers
and international research organizations, such as the American
Society of Clinical Oncology (ASCO), chemosensitivity assays
have seen minimal adoption in melanoma treatment. This is
mainly because of long, 3−7 day turnaround times that enable
artifacts, a lack of supporting large-scale clinical trials, and poor
compatibility with cancer heterogeneity due to the bulk,
averaging nature of measurement methods.26−29 A superior
rapid, accurate, and inexpensive approach to determine
melanoma drug sensitivity before and periodically during
therapy is therefore desirable.
We have previously shown that optical interferometric
microscopy provides an exciting potential solution by proﬁling
drug-induced growth arrest in living single cells or cell clumps
via changes in biomass over time with picogram sensitivity.30,31
Like other quantitative phase imaging (QPI) modalities,32,33
Figure 1. Schematic of HSLCI multiwell biomass accumulation assay. (a) The high-speed live-cell interferometry (HSLCI) system is conﬁgured with
(i) a wide-ﬁeld phase-detection camera, (ii) ﬁber-coupled light-emitting diode (LED) illumination source, and (iii) and ﬂuorescence imaging
capability (camera, ﬁlters, and illuminator). Motorized stages (iv) control x−y motion of the sample above the microscope objective, while focus is
automatically adjusted continuously by a piezo actuator coupled to the objective [10× Nikon Plan Fluorite, numerical aperture (NA) 0.3]. (b) Prior
to imaging, cells and medium, including drug or vehicle, are dispensed into standard-format, glass-bottom multiwell plates. (c) During imaging, the
sample plate is translated along each row of wells, collecting 30 images/well on each pass. Typical imaging time is 2 min/row of six wells. (d)
Following collection, phase images are automatically analyzed in a custom pipeline that includes background ﬂattening, cell detection and
segmentation, and biomass calculation. (e) Individual cells are observed between images on the basis of their position, and biomass versus time plots
are generated. Shown is a typical normalized mass vs time plot for single vemurafenib-sensitve (red) and vemurafenib-resistant (blue) cells.
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our technique is noninvasive and well-suited to this application
due to its lack of ﬂuorescence or dye labeling. However, our
proof-of-principle work consisted of single-agent, small-scale
studies of limited duration. The key remaining engineering
challenge is to create a reliable platform for multiagent,
multiconcentration parallel screens without sacriﬁcing measure-
ment accuracy or assay acceleration. Meeting this challenge
requires, at a minimum, an order of magnitude increase in the
number of diﬀerent conditions tested within a single experi-
ment and a corresponding increase in the number of individual
cells analyzed per hour. This is a sizable hurdle, for a variety of
methodological reasons, but is absolutely required to enable
practical, rapid response proﬁling of patterns of drug resistance
and intratumor heterogeneity and, ultimately, for development
of a reproducible therapy selection method.
To reach this goal, we created an entirely new platform,
utilizing industrial-grade imaging hardware and accelerated
automated image analysis and data processing pipelines using
low-cost, multicore PC processors and additional software
improvements. Importantly, to achieve the required order-of-
magnitude greater imaging throughput, we built the HSLCI
around a diﬀerent optical conﬁguration than that used in all
previous work. The new system consists of a custom inverted
microscope equipped with a modiﬁed Shack−Hartman wave-
front sensing camera (SID4BIO, Phasics, Inc.)34 for rapid,
vibration-insensitive cell mass measurements and a wide-ﬁeld
charge-coupled device (CCD) camera for correlative bright-
ﬁeld and ﬂuorescence imaging (Figure 1). Dynamic focus
stabilization enables continuous image collection over the
entire sample area without pause. Stage-top or whole
microscope enclosures provide long-term environment stability
for imaging under physiology-approximating conditions (37 °C,
5% CO2). The HSLCI captures images from standard-format,
glass-bottom multiwell cell culture plates, and each well can
contain a diﬀerent cell type exposed to a unique drug dose or
combination. The HSLCI experiments described here utilized
4- and 24-well glass bottom plates, although well counts of up
to 96 are possible depending on the experimental conditions,
including cell concentration, population sampling depth,
required temporal resolution, and other parameters.
This present work describes a two-center study using HSLCI
to quantify biomass kinetics for three isogenic sensitive/
resistant pairs of patient-derived, V600EBRAF mutant melanoma
cell lines in response to BRAF inhibitor (BRAFi), vemurafenib,
and a battery of U.S. Food and Drug Administration (FDA)-
approved kinase inhibitors. We show that HSLCI-quantiﬁed
biomass kinetic signatures during 24 h of drug exposure
discriminate between drug-sensitive and drug-resistant tumor
subpopulations. HSLCI data are reproducible between study
sites and consistent with longer multiday growth inhibition
assays.
Of particular practical importance for any future clinical
laboratory use is HSLCI’s compatibility with presterilized,
disposable, and standard-format multiwell sample plates. This
enables eﬃcient screening of multiple drugs and drug
combinations in a single assay, simpliﬁes sample handling,
and avoids the need to sterilize and wash dedicated microﬂuidic
components between runs.
Figure 2. Biomass accumulation response to vemurafenib treatment. (a) Normalized population median biomass versus time plots of each
melanoma line exposed to either 5 μM vemurafenib (red trace) or 0.1% dimethyl sulfoxide (DMSO, blue trace). Cells were synchronized prior to
plating in glass-bottom dishes. Each sample was imaged for 3 h, after which either 0.1% DMSO (vehicle control) or 5 μM vemurafenib (treatment)
was administered. After dosing, plates were imaged for 20−25 h by HSLCI under standard cell-culture conditions. Typical time between repeated
measurements of the same location was 10−15 min. Each graph contains pooled data from four replicates. Error bars are ± standard error of
measurement (SEM). (b) All six synchronized cell lines were plated into a single 24-well glass-bottom plate and dosed with either 0.1% DMSO or 1,
5, or 10 μM vemurafenib. After 24 h of incubation, the plate was imaged continuously for 10 h by HSLCI. Hourly growth rates were automatically
calculated for individual cells in each sample by linear ﬁt to the biomass versus time data. Data are from a single representative experiment (n = 3).
Box-plot notches are 95% conﬁdence intervals for the indicated medians. Each dot overlaid on a box plot represents the hourly growth rate of an
individual cell. (c) Corresponding receiver operator characteristic (ROC) curves for data shown in panel b.
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■ RESULTS
Isogenic BRAF Inhibitor-Sensitive and -Resistant
Melanoma Cell Lines. We evaluated three patient-derived
V600EBRAF melanoma cell lines, M229P, M238P, and M249P,
which are sensitive to the BRAFi, vemurafenib (IC50 < 1 μM),
and their isogenic BRAFi-resistant sublines, M229R5, M238R1,
and M249R4, created by vemurafenib coincubation over time
(Table S1). M229R5 and M238R1 developed BRAFi resistance
via epigenomic reprogramming, which is thought to occur in
regressing or residual melanoma tumors from patients treated
with MAPK inhibitor (MAPKi) therapy. This nongenomic
evolution results in a MAPK-redundant form of resistance.35
On the other hand, M249R4 acquired a Q61KNRAS mutation in
addition to the V600EBRAF mutation. This concurrent BRAF/
NRAS mutant conﬁguration results in MAPK hyperactivation
and a MAPK-addicted form of resistance, which is frequently
detected during disease progression or with clinical relap-
ses.36−38 Thus, these pairs of cell lines represent pre- and post-
treatment models of diﬀerential drug-sensitivity states that are
clinically relevant; therefore, we used these lines to evaluate
HSLCI performance in biomass proﬁling.
Biomass Kinetic Responses to Vemurafenib Exposure.
Our previous work in breast cancer and multiple myeloma
indicated that changes in the population median growth rates
between sensitive and resistant cell lines is detectable with
conﬁdence within a few hours of drug exposure.30,31 We also
showed that the distribution of growth rates within a
population is roughly Gaussian in both treated and control
samples. There are no existing data for the rate of biomass
change of BRAFi-sensitive or -resistant melanoma cells that
grow as adherent single cells or clumps. Therefore, we
measured the kinetics of vemurafenib response in the three
paired, molecularly characterized melanoma lines using HSLCI,
to establish rates and distributions of biomass change with or
without drug exposure. First, we performed a standard multiday
dose-escalation cell-counting assay to conﬁrm sensitivity for the
three parent and matched resistant lines at 1.0−10.0 μM
vemurafenib exposure (Figure S1). As anticipated, the parental
lines slowed and the matched resistant lines continued
replicating with drug exposure. We next used 5 μM
vemurafenib as the midpoint drug dose to measure the median
population growth rate and cell mass by HSLCI for the six cell
lines in the ﬁrst 25 h of drug exposure, in order to quantify the
average population kinetic response. (Figure 2a) Under these
conditions, drug sensitivity of the M249P population was
detectable as early as 6 h, while sensitivity of the M238P and
M229P populations was detected at approximately 15 h.
Signiﬁcant growth rate reduction occurred in all three parental
lines by 20 h. We observed signiﬁcant natural variation in the
growth rates of individual cells within each population, a result
consistent with previous LCI studies. The distribution of single-
cell hourly growth rates was typically symmetrical about the
mean, with variation of roughly ±1% (standard deviation, SD)
above and below the population mean. For example, plotting
the M249P growth rate distribution obtained by HSLCI for
each hour showed no change in the population median growth
rate nor in the cellular growth rate distribution over the course
of the 25 h experiment. (Figure S2a). In contrast, under the
same conditions, 5 μM vemurafenib exposure showed
population growth-rate heterogeneity and a decline below
zero growth rate by about 15 h for >50% of cells (Figure S2b),
indicative of the relative sensitivity of this line to the BRAF
inhibitor. Similar temporal single-cell growth-rate distributions
were seen in the other ﬁve cell lines, with kinetics proportional
to the line’s overall median sensitivity. These results were
reproduced at both experimental sites with independently
assembled HSLCI platforms.
By comparing the median cell mass of the vemurafenib-
resistant melanoma lines to the mass of their isogenic, drug-
sensitive parent lines, we found no consistent correlation
between mass and resistance (Figure S3). This observation
stands in contrast to a recent report of cell mass−drug
resistance correlation in a mouse acute myeloid leukemia
(AML) model, as measured by microﬂuidic devices.39 However,
that study did not compare isogenic paired sensitive and
resistant tumor lines, and it remains to be determined whether
or not mass itself is a useful metric of drug sensitivity.
The midpoint kinetic response data suggested that
vemurafenib sensitivity, or lack thereof, would be distinguish-
able for all lines in a drug-escalation assay, as would be expected
for cell counting, by measuring changes in sample growth rates
after 24 h of drug exposure. To test this hypothesis and to
examine the HSLCI methodology for multidose and multiagent
screening, we collected short-term,10-h growth rate measure-
ments of all three cell line pairs in parallel, at escalating
vemurafenib doses, using a 24-well format. All six melanoma
cell lines were dosed with 0.1% DMSO or 1, 5, or 10 μM
vemurafenib. The parental lines (M229P, M238P, and M249P)
showed a clear pattern of increasing growth inhibition at
escalating drug concentrations, whereas the resistant lines
(M229R5, M238R1, and M249R4) showed no growth
inhibition over the drug dosing range compared to a vehicle
DMSO control, consistent with cell-counting assays (Figure
2b).
Heterogeneity Quantiﬁcation. We used receiver operator
characteristic (ROC) analysis to determine the ability to
distinguish individual resistant cells from sensitive cells, in an in
silico mixture, by changes in their individual growth rates
during exposure to vemurafenib (Figure 2c). This analysis
indicated that cells from both M229P and M238P lines were
distinguishable from their resistant derivative counterparts at
vemurafenib doses of 5 μM [area under the curve (AUC) 0.60
and 0.85, respectively] and 10 μM (AUC 0.78 and 0.75,
respectively). The M249P cells were the most sensitive to drug
and were easily distinguishable on the basis of changes in
growth rate, with AUC greater than 0.90 at vemurafenib doses
of 1 μM and above.
We then deployed HSLCI to quantify the changes in growth
rates of an actual mixed population of green ﬂuorescent protein
(GFP)-labeled M249R4 vemurafenib-resistant (M249R4-GFP)
and unlabeled M249P vemurafenib-sensitive cells during drug
exposure. Importantly, stable GFP expression in the M249R4
line did not signiﬁcantly alter the growth rate distribution
obtained by LCI for each hour of 5 μM vemurafenib exposure
compared with unlabeled M249R4 cells (Figure S2c). Sensitive
M249P and resistant M249R4-GFP cells grown together at a
1:1 ratio with 5 μM vemurafenib were imaged over 48 h
(Figure 3a−c). In mixed culture, individual resistant cells were
discriminated from sensitive cells on the basis of diﬀerences in
growth rates (Figure 3d), and because the M249R4 cells were
GFP-marked, they were easily identiﬁed relative to the
unmarked M249P cells during the assay. Reproducibly, the
population growth rate of M249R4 cells exceeded that of
M249P cells, as expected, but each marked and unmarked
population also showed outlier cells. A small percentage of
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M249R4-GFP cells showed zero to slightly negative growth
rates, whereas a small percentage of M249P cells showed net-
positive growth rates, revealing unanticipated vemurafenib-
sensitive or -resistant outliers within each bulk population. As
predicted from the in silico analysis, ROC analysis conﬁrmed a
high level of discrimination between sensitive and resistant
melanoma cells (AUC 0.88), even when sensitive and resistant
cells were combined in the same sample wells (Figure 3e).
Similar trends were seen in 10:1 sensitive/resistant mixtures as
well (Figure S4).
MEK Inhibitors with Vemurafenib-Resistant Melano-
ma. We performed rapid HSLCI dose−response assays in
triplicate, using a panel of three FDA-approved and two
investigational kinase inhibitors tested in clinical trials for
treating metastatic melanoma, to simulate selection of salvage
therapy for patients who develop resistance to front-line
vemurafenib (Figure 4). One inhibitor in the panel targets
BRAF, whereas the other four target MEK1 or MEK1/2 (Table
S2). We selected M249R4 cells for study because of their
robust growth proﬁle and strong resistance to vemurafenib.
Figure 4 shows typical results from two individual experimental
runs, while Figure S5 shows results from all repeats ﬁtted to a
sigmoidal dose−response function for reference. Control
DMSO-treated cells exhibited a median growth rate of
∼2.5%·h−1 at 0.1% DMSO concentration (v/v), decreasing
slightly to 2%·h−1 at higher concentrations (0.3%−0.5% v/v).
For each targeted kinase inhibitor, the peak tolerated serum
concentration (Cmax, nanograms per milliliter), as measured in
clinical trials, is shown on the dose−response curves by an
asterisk (*). (See Supporting Information for details of Cmax
determination.) As expected for this highly vemurafenib-
resistant line, the BRAF inhibitor dabrafenib showed no growth
inhibition as compared to the DMSO control. The MEK1
inhibitor cobimetinib and the MEK1/2 inhibitor trametinib
were the most eﬀective growth inhibitors: cobimetinib
completely arrested median sample growth at 0.255 μM
concentration, which is roughly half of the maximum tolerated
serum concentration, while trametinib arrested growth at a
concentration between 4 and 40 nM, or between 0.1× and 1×
Cmax. MEK1/2 inhibitor selumetinib arrested growth at 2.55
μM, equal to 1× Cmax, while MEK1 inhibitor binimetinib failed
to halt growth at concentrations below 2.91 μM, or 5× Cmax,
Figure 3. Detecting resistant cells in a mixed population. (a) Optical
thickness (LCI, left) and in-register ﬂuorescence images (FL, right) of
M249R4-GFP vemurafenib-resistant cells. (b) LCI and ﬂuorescence
images of M249P vemurafenib-sensitive cells. (c) LCI and
ﬂuorescence images of a 1:1 mixture of M249P (red arrows,
unlabeled) and M249R4 (labeled) cells. (d) Plot of biomass versus
growth rate of a 1:1 M249P (blue)/M249R4-GFP (red) cell mixture
exposed to 5 μM vemurafenib for 48 h. Cell identities are marked by
ﬂuorescence signals. (e) ROC curve classifying single sensitive versus
resistant cells by their growth rates during exposure to 5 μM
vemurafenib. The blue line is calculated from M229P and M249R4
cells imaged in separate wells, whereas the red line is calculated from a
1:1 cell mixture in the same wells (representative data are shown in
panel d). Data shown are from a single representative experiment (n =
3−5).
Figure 4. Eﬀects of ﬁve kinase inhibitors on vemurafenib-resistant
melanoma measured by HSLCI. M249R4 cells were plated into 24-
well plates and dosed at increasing concentrations of each inhibitor.
After 24 h of incubation, the plate was imaged by HSLCI continuously
for 10 h. Typically four diﬀerent doses for each inhibitor, and four
DMSO controls, were measured in each run simultaneously. Data in
the ﬁgure represent two typical experimental runs, using diﬀerent dose
gradations. Hourly growth rates were automatically calculated for
individual cells in each sample by linear ﬁt to the biomass vs time data.
Each box plot summarizes the hourly growth rates of a population of
cells exposed to escalating concentrations of each drug. Individual dots
in the underlying scatter plots represent the growth rates of single
cells. Box-plot notches are indicative of 95% conﬁdence intervals for
the medians. Median number of cells per well: top panel 159 (range
79−216); bottom panel 160 (range 59−294).
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suggesting that binimetinib would be an unlikely candidate for
salvage therapy in this simulated case.
■ DISCUSSION
Here we demonstrated the ability of a rapid HSLCI platform to
quantify individual cell drug sensitivity in tumor cell
populations. This quantiﬁcation may provide critical data for
treatment selections on a whole-tumor population level and can
identify speciﬁc subpopulation drug sensitivities to predict drug
resistance at a single-cell level. Furthermore, concordant data
obtained from two institutions with independently constructed
and standardized HSLCI platforms highlights the reproduci-
bility of two similar but distinct implementations. This two-
center study design is unique among live-cell response proﬁling
approaches and provides conﬁdence that the newly conﬁgured
HSLCI has the required consistency to warrant further
development as a clinically useful approach.
In comparison to other single-live-cell biomass proﬁling
approaches,33,40,41 including our own prior interference micro-
scopic studies,30 HSLCI represents a substantial technical
advance in single-cell sampling throughput, cell-tracking
duration, and parallel measurement of multiple agents. For
example, Stevens et al.39 recently used microchannel resonators
to demonstrate that the combined measurement of single-cell
mass and growth rates could be used identify drug-resistant
cells isolated from an engineered mouse AML model. Their
high-throughput “next-gen” system with 12 microresonators
could measure up to 60 cells/hour, where cells are measured
serially, each for 15 min, resulting in simple snapshots in time.
Unfortunately, tumors that grow in small clusters or clumps, as
do many melanoma samples, are inaccessible to this platform
unless they are disaggregated, which aﬀects their growth
characteristics and drug sensitivity.
In contrast, HSLCI typically measures between 103 and 104
cells in each experiment across a total area greater than 700
mm2, tracking each cell individually for hours to days, and is
well-suited to tumors that grow in clusters or clumps without
disaggregation. In addition, identifying rare resistant clones in a
population of normal or therapy-sensitive malignant cells
requires such deep sampling. For instance, typical minimal
residual disease detection by multicolor ﬂow cytometry requires
sampling to a depth of at least 104 and up to 106 cells.42 We
believe that realistic improvements may allow HSLCI
throughput to approach 105 cells/experiment.
Quantitative phase imaging (QPI) techniques have proven to
be versatile alternatives for measuring single-cell mass,
especially in tumors that grow in clusters or clumps, without
a need for disaggregation. Examples include measuring cell
growth and death, membrane mechanics, wound healing, and
cytotoxicity and detecting circulating tumor cells.32,43−48
However, current QPI implementations utilized for longitudi-
nal biomass tracking are signiﬁcantly limited by low throughput,
measuring only several hundred cells simultaneously in areas of
less than 10 mm2.43,45 To date, maximum published durations
of other continuous, longitudinal, QPI-based single-cell experi-
ments are 48 h or less. An exception appears to be a study by Li
et al.49 of treatment responses in tumor models, which was
conducted for 240 h. However, this study was notably not
automated, requiring manual removal of samples from an
incubator every 24 h, and suﬀered from poor temporal
resolution (10-image snapshots per day per sample). Due to
the mechanical and environmental stability of the HSLCI
system, we have been able to track single cells and cell clusters
for more than 5 days, with no time limit yet found. This is a
dramatic increase over our previous 12-h maximum duration
interference microscopic work and enables the study of
behaviors that evolve over many minutes, hours, or days,
encompassing the vast majority of cellular responses. Cell
observation duration is of direct relevance to detecting drug
responses in cells isolated from patients, as it is necessary to
distinguish between growth arrest (cytostasis) and death
resulting from drug exposure versus other inﬂuences. With
HSLCI this is accomplished by repeatedly observing individual
cells before and after drug exposure-response, a process that
requires several hours or more.
The primary drawback of HSLCI compared to microscopic,
single-cell snapshot ﬂuorescent assays and microresonator mass
assays is the relatively large data footprint and extensive image
analysis required to generate a biologically interpretable result.
At present, data analysis time, not hardware capability, is
throughput-limiting. On the other hand, the single-cell images
generated by HSLCI are inherently information-rich, allowing
not only mass accumulation but also cytokinesis, motility, and
cell-shape information to be quantiﬁed. Integrating these
mutually supporting metrics will be a direction for future
research. Furthermore, system upgrades can be largely
accomplished by software rather than hardware modiﬁcations,
making the upgrade path eﬃcient and ﬂexible. Fast cell mass
measurement by phase imaging would be complementary to
high-content screening systems based on automated confocal
ﬂuorescence microscopy. Finally, on the basis of our results, it
is likely that other forms of interference microscopy can be
similarly adapted to enable faster measurement speeds.
■ METHODS
Cell Lines. M229P, M229R5, M238P, M238R1, M249P,
and M249R4 cell lines were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM), high glucose with 10% heat-
inactivated fetal bovine serum (FBS) (Omega Scientiﬁc) and
2 mM glutamine in a 37 °C, humidiﬁed, 5% CO2 incubator.
M229R5, M238R1, and M249R4 cells were exposed to 1 μM
vemurafenib every 2−3 days. Cell counting from 6-well plates
with controls and a range of vemurafenib concentrations was
performed for 5 days following overnight seeding.
Population Kinetic Response Experiments. Cells were
synchronized by growing to conﬂuence in 75 mL tissue culture
ﬂasks and collected by a shake-oﬀ technique. Cells were plated
at 1 × 105 cells/mL in 25 mm dishes and incubated overnight.
Prior to imaging, samples were equilibrated thermally for 1 h
on the microscope stage and then imaged for 3 h, after which
either 0.1% DMSO vehicle control or 5 μM vemurafenib was
administered and dishes were waimaged for another 25−30 h.
Vemurafenib Dose−Response Experiments. Cells were
ﬁrst synchronized by shake-oﬀ, each of the six melanoma cell
lines was seeded into four wells each of a 24-well glass bottom
plate at 1 × 105 cells/mL, and the plates were incubated
overnight. Each line was dosed with 0.1% DMSO carrier
control, or 1, 5, or 10 μM vemurafenib. Cells were incubated
for 24 h, and then the entire plate was imaged by HSLCI for 10
h.
Fluorescence Mixing Experiments. M249P and
M249R4-GFP (1.25 × 104 cells each) were added together in
a total volume of 1 mL tissue culture medium. A portion (0.7
mL) of the mixture was dispensed into each well of an Ibidi 4-
well Ph+ μ-slide. Cells settled over 6 h, after which 5 μM
vemurafenib was added to each well. Ibidi oil sealed the liquid
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opening of each well before the plate was placed onto the LCI
stage. All wells were imaged continuously for 48 h.
Fluorescence images were taken with a Hamamatsu EM
CCD camera (C9100-02 EMCCD) serially after every ﬁve
phase-imaging loops were completed. Green ﬂuorescence was
captured by use of a 38 HE green ﬂuorescent ﬁlter set (Zeiss)
with an excitation wavelength of 450−490 nm, a beamsplitter
wavelength of 496 nm, and an emission wavelength of 500−550
nm. Fluorescence excitation was provided by an X-Cite 120Q
wide-ﬁeld ﬂuorescence microscope excitation light source
(Excelitas).
Kinase Inhibitor Panel Assay. M249R4 cells were plated
in a 24-well optical glass-bottomed plate (catalog no. P24-0-N,
Cellvis) at 1 × 104 cells/mL (total of 1 mL in each of 24 wells)
in medium (DMEM with 10% FBS and 2 mM L-glutamine)
containing 1 μM vemurafenib. Plated cells were allowed to
adhere overnight at 37 °C in 5% CO . All cells were washed
with 1× phosphate-buﬀered saline, pH 7.4, and provided with
fresh medium. Immediately following washing and feeding, cells
were dosed with inhibitors at dose-escalating concentrations
and incubated under standard cell-culture conditions for 24 h.
After incubation, cells were imaged for 10 h by use of the
HSCLI system.
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SUPPLEMENTARY FIGURES 
Supplementary Figure 1. 7-day proliferation assay. Live cell counts by day, normalized to day 
0. All three melanoma sensitive and resistance paired cell lines were exposed to increasing doses
of vemurafenib, or vehicle (0.1% DMSO) and media controls. A representative experiment is 
shown (n = 3). 
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Supplementary Figure 2.  Example distributions of single cell growth rates over time.  a) 
M249P parental line grown in DMEM. b) M249R4 resistant line under treatment with 5𝜇M of 
vemurafenib. c) GFP-M249R4 under treatment with 5𝜇M of vemurafenib.  Hourly growth rates 
are estimated by linearly fitting selected single cell data points that were collected within each 
hour of the experiment for a span of 24 hours. Single cell tracks were quality controlled using a 
upper cutoff of 1.5% standard deviation of residuals in linear regression.  Due to the short time 
window, there is larger error in the estimation of growth rates than in data shown in Figs 2-4. 
Supplementary Figure 3.  Comparing relative mass between vemurafenib-sensitive and -
resistant isogenic lines.  Boxplots showing distribution of single cell masses measured for each 
cell line.  Boxplot notches are indicative of the 95% confidence intervals for the medians.   
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Supplementary Figure 4.  Detecting minority resistant cells in a mixed population.  Example 
biomass versus growth rate data from a 10:1 M249P (sensitive; blue) : M249R4-GFP (resistant; 
red) cell mixture exposed 5µM vemurafenib for 48 hours. Cell identities are marked by 
fluorescence signals. 
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Supplementary Figure 5. Dose response curves.   Median population growth rates from all 
kinase panel repeats are plotted and fitted with sigmoid curves. Error bars indicate the 95% 
confidence intervals for the medians.  The doses indicated by an asterisk (*) correspond to the 
maximum serum concentrations (Cmax) measured in the blood during clinical trials at FDA-
approved therapeutic doses.   
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SUPPLEMENTARY TABLES 
Supplementary Table 1.  Patient-derived melanoma lines 
Supplementary Table 2.  Kinase inhibitor dosing chart 
Cell Line Designation Molecular Lesions 
M229P BRAF V600E 
M229R5 BRAF V600E, PDGFRb up-regulation 
M238P BRAF V600E 
M238R1 BRAF V600E, PDGFRb up-regulation 
M249P BRAF V600E 
M249R4 BRAF V600E, N-RAS Q(61)K 
Trade Drug Chemical Clinical Dose Target 
Serum 
Conc. 
(ng/mL) µM (1x) 
Tafinlar dabrafenib GSK2118436 150 mg twice daily BRAF 1050 2.02 
Cotellic cobimetinib GDC-0973 / RG7420 60 mg once daily MEK1 273 0.51 
N/A selumetinib 
AZD6244 / ARRY-
142886 75 mg twice daily MEK1 1165 2.55 
Mekinist trametinib GSK1120212 2 mg once daily MEK1/2 22.2 0.04 
N/A binimetinib MEK162 / ARRY-162 45 mg twice daily MEK1/2 257.0 0.58 
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SUPPLEMENTARY METHODS 
High Speed Live Cell Interferometry 
The HSLCI platform consists of a custom-built inverted optical microscope coupled to an off-axis 
quadriwave lateral shearing interferometric camera (SID4BIO, Phasics, Inc.). Cells are imaged in 
single, standard-footprint (128 mm x 85 mm), glass-bottomed, multi-well plates. Acquired images 
are analyzed in near real-time by a downstream PC (Dell Precision Tower 5810). All of the 
platform’s hardware and software components are available commercially. We provide a simple 
schematic of the HSLCI system (Figure 1a). 
Briefly, a multi-well plate holder coupled to three linear translation stages enables automated 
sample movement in three dimensions during image acquisition. The scale of topographical 
variation within and between 24-well plates necessitates a flexible and robust focusing scheme. 
Best focus is rapidly and consistently maintained during lateral scanning using a custom-built 
automatic feedback loop consisting of a coaxial optical beam deflection position sensor coupled 
to a one-dimensional piezo stack on which the microscope objective is mounted. The sample is 
illuminated using a 660nm LED light source that is collimated and then strobed to coincide with 
the SID4BIO camera’s exposure, using a SID4BIO-generated trigger, at a rate of 4 fps. After 
passing through the sample, the light is magnified by an objective lens and directed to both the 
SID4BIO (a 1600 x 1200 pixel CCD camera (B1621, Imprex, Inc.) fitted with a modified Shack-
Hartman mask) and a wide-field CCD camera (acA645-100, Basler AG) utilized for correlative 
and fluorescent imaging. Either a 20x objective (Nikon Neofluar, NA 0.5 or Nikon Plan Fluorite, 
NA 0.3) or a 10x objective (Nikon Plan Fluorite, NA 0.3) was used for the growth kinetics and 
population mixing studies described, depending on the desired size of the field of view. 
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Experiments performed at both sites utilized identical optical hardware and layouts, excepting 
different approaches to maintaining environmental conditions (37 ⁰C, 5 % CO2, 95% Rh) for cell 
viability during image collection.  At VCU, the HSLCI platform was installed inside a standard 
cell culture incubator (Steri-Cult CO2 Incubator, ThermoFisher), while a stage-top enclosure 
(Heating & Incubation System, Ibidi) was utilized for UCLA’s platform.  The performance of both 
systems was functionally identical.  
Image Analysis 
Briefly, raw interferograms acquired by the SID4BIO are converted to optical path difference 
(OPD) images using the manufacturer’s software (Bon et al., 2009) and then analyzed with our 
custom MATLAB (Mathworks, Inc.) scripts. The phase calculation down-samples the raw 
interferogram image to 400 x 300 pixels, resulting in effective pixel sizes between 1.3 µm and 2.5 
µm, depending on the objective.  
The OPD is then used to derive the optical volume difference OVD, wherein the OPD is integrated 
over the total imaging surface (S). Hence, 
𝑂𝑉𝐷 = (𝑂𝑃𝐷(𝑥, 𝑦)𝑑𝑥𝑑𝑦	1
This value is directly proportional to the dry mass of the cell (referred to herein as “biomass”) by 
a constant known as the specific refractive increment α. The specific refractive increment is the 
rate of change in the refractive index n of a specific specimen.  
(𝑂𝑃𝐷(𝑥, 𝑦)𝑑𝑥𝑑𝑦 = 	𝛼 ∙ 𝑚1  
This can be rearranged as 
Computed OPD images are “flattened” by correcting for low-frequency background noise inherent 
to the shearing interferometry method.  Single cells are segmented from the background of the 
flattened phase images using a spatial-derivative edge detection kernel; their locations and optical 
volumes are recorded.  
Frame-to-frame cell tracking is accomplished with a previously-described particle tracking 
algorithm.5  Single-cell growth tracks are quality filtered using an upper cutoff of +/-1.5% 
uncertainty (s.d. of residuals) in the calculated growth rate, as determined by linear fitting the dry 
mass versus time data. 
HSLCI Platform Performance Metrics 
In its current configuration, the HSLCI system can, at a minimum, collect and process 960 images 
from as many unique locations in a multi-well plate every 10 minutes, yielding biomass data on at 
least 103– 104 individual cells.  
The HSLCI’s stages enable lateral scanning at a maximum velocity of 2mm per second, while the 
SID4BIO camera is capable of capturing data at rates up to 30 fps. For a 24-well plate, even at a 
capture rate of 4 fps, this translates to only 2.5 minutes needed to acquire 240 unique images (40 
images/well) in a single six-well column. After acquisition, deriving a phase image from a single 
raw interferogram typically requires 500 ms, while the remainder of post-processing (flattening, 
cell segmentation, and cell tracking) typically requires 500-1,000 ms, on a single Intel Core i7 
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𝑚 = 1𝛼 𝑆 ∙ 𝑂𝑃𝐷 
to find the mass (m), where S is the surface area of the specimen in microns. For the experiments 
8 is equal to 5.56	 <=>?@described herein, 7  (Reed et al, 2011). 
processor. Compared to our prior implementation, our current pipeline conducts image processing 
as soon as images are acquired and parallelizes these steps across eight or more processors on a 
single high-performance PC, resulting in near real-time processing.   
M249R4-GFP cell generation.  Third generation lentiviral construct pMD.G (VSV-G envelope) 
was used in combination with pMDLg/pRRE (gag/pol elements) and pRSV-REV. Lentivirus was 
produced by transient plasmid co-transfection into HEK293T cells. Infections used protamine 
sulphate, with mGFP subcloned into the FUGW vector. M249R4 GFP-positive cells were obtained 
using a BD FACSAria sorter. GFP expression was determined 4 days after sorting by a BD LSRII 
flow cytometer. FACS Diva analysis showed 98.4% of M249R4-GFP cells express mGFP.  
Drug Sourcing and Preparation. Imatinib (Cat.# S1026), dabrafenib (Cat.# S2807), selumetinib 
(Cat.# S1008), trametinib (Cat.# S2673), cobimetinib (5mg, Cat.# S8041) and binimetinib (10mg, 
Cat.# S7007) were purchased from Selleck Chemicals (Houston, TX). Imatinib, vemurafenib, 
dabrafenib, selumetinib, and trametinib were supplied at 10mM in DMSO. Cobimetinib and 
binimetinib were supplied as dry powders but suspended in DMSO to a final stock concentration 
of 10mM upon receipt. 
Kinase Inhibitor 1X Dose Determination: For each inhibitor, a “1X” dose was calculated. 
Briefly, clinical doses were obtained from publicly-available package inserts or, if none were 
available, the median dose administered in clinical trials. Doses were matched to peak serum 
concentration values (Cmax (ng/mL)) for each inhibitor as measured in clinical trials in which the 
doses were utilized. If multiple Cmax values were available, those values were averaged to yield a 
single peak serum concentration value. Using each drugs’ molecular weight, peak serum 
concentration values were converted to micromolar (uM) units and designated as “1X”.  Unless 
otherwise noted, clinical doses were sourced from package inserts and used to identify Cmax 
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values in studies. References for Cmax determinations: imatinib 1-3, dabrafenib 4, 5, cobimetinib 6, 
selumetinib 7-10 (dose determined from median of clinical trial doses), trametinib 11, and 
binimetinib 12, 13 (dose determined from median of clinical trial doses). 
Cell proliferation assay. Cells in multiple six-well tissue culture plates were incubated overnight 
at 37oC, 5% CO2.  Each six-well plate contained one well with a media control, one well with 0.1% 
DMSO vehicle control, and four wells of vemurafenib at 1 uM, 3 uM, 5 uM, or 10 uM 
concentrations. Cells were counted each day for five days following seeding. 
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Chemical dissection of the cell cycle: probes for cell
biology and anti-cancer drug development
S Senese1, YC Lo1,2, D Huang2, TA Zangle2, AA Gholkar1, L Robert3, B Homet3, A Ribas3,4,5,6, MK Summers7, MA Teitell2,6,8,9,10,11,
R Damoiseaux10 and JZ Torres*,1,6,11
Cancer cell proliferation relies on the ability of cancer cells to grow, transition through the cell cycle, and divide. To identify novel
chemical probes for dissecting the mechanisms governing cell cycle progression and cell division, and for developing new anti-
cancer therapeutics, we developed and performed a novel cancer cell-based high-throughput chemical screen for cell cycle
modulators. This approach identified novel G1, S, G2, and M-phase specific inhibitors with drug-like properties and diverse
chemotypes likely targeting a broad array of processes. We further characterized the M-phase inhibitors and highlight the most
potent M-phase inhibitor MI-181, which targets tubulin, inhibits tubulin polymerization, activates the spindle assembly checkpoint,
arrests cells in mitosis, and triggers a fast apoptotic cell death. Importantly, MI-181 has broad anti-cancer activity, especially
against BRAFV600E melanomas.
Cell Death and Disease (2014) 5, e1462; doi:10.1038/cddis.2014.420; published online 16 October 2014
The cell cycle is a set of coordinated events that culminate in
the formation of two cells from one mother cell. It’s composed
of four major phases; G1 (growth phase 1), S (DNA synthesis
phase), G2 (growth phase 2) andM (mitosis), which function to
integrate environment sensing signaling pathways with cell
growth and proliferation.1 Cancer cells often deregulate the
cell cycle and undergo unscheduled cell divisions, therefore
inhibition of the cell cycle represents an opportunity for
therapeutic intervention in treating proliferative diseases like
cancer.2 Most anti-cancer drugs perturb the proliferation cycle
of tumor cells by inhibiting/damaging cell cycle events, which
activate checkpoints, arrest cells and induce apoptosis.3 For
example, inhibitors targeting DNA replication (5-fluorouracil)
and cell division (microtubule-stabilizing paclitaxel) have been
used successfully for treating a broad array of cancers
including breast and colorectal cancers.2 Nevertheless, due
to toxicity issues, drugs targeting the cell division machinery
like mitotic kinases (AurKA/B and Plk1) and kinesins (Kif11
and CENP-E) have been developed.3 However, these drugs
have shown limited efficacy in vivo.4 Thus, there is a critical
need to identify novel drug-like molecules that inhibit cancer
cell cycle progression, which can be developed into novel
cancer therapies.
Genome wide studies aimed at depleting the expression of
human genes and characterizing their contribution to cell cycle
progression have generated a wealth of information regarding
the enzymatic machinery required for proliferation.5 These
enzymes have become the focus of targeted screening
campaigns aimed at finding inhibitors to their activities. For
example, an in vitro chemical screen targeting Plk1 identified
the small molecule BI2536.6 BI2536 was not only used to
define novel roles for Plk1 during cell division, it was further
developed into an anti-cancer drug whose efficacy is being
evaluated in clinical trials.7 Therefore, beyond their therapeutic
potential, inhibitors can be used as molecular probes for
dissecting the function of enzymes critical for cell cycle
progression in an acute and temporal manner. However, there
are no inhibitors to the majority of the cell cycle machinery and
the discovery and characterization of such inhibitors would aid
our ability to understand the mechanisms regulating cell
division.
Although molecularly targeted screens have grown in
popularity, they rely on the previous identification and
validation of specific cancer targets with druggable activities/
interactions.8 As an alternative, unbiased high-throughput
chemical screens have tried to identify inhibitors to a single cell
cycle phase,9–15 which limited their ability to identify novel anti-
proliferative agents to other phases of the cell cycle. None-
theless, G2-phase, M-phase, and cytokinesis screens suc-
cessfully identified inhibitors to Kif11, Plk1, RhoA, and
microtubules.9–15 These inhibitors aided the functional char-
acterization of these proteins and were instrumental for
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developing drugs with therapeutic potential. However, these
screens were conducted with a limited number of compounds
(100–38 000) or cell extract fractions, with several screens
using the same library of 16 320 compounds, thus limiting
compound diversity, chemical coverage, and opportunities for
novel discoveries. Most screens also lacked chemical
analyses to understand the physiochemical properties of
bioactive compounds and their cellular targets. In addition,
previous screens have not analyzed the four phases of the cell
cycle as a biological system. Thus, there is a critical need to
develop new screening strategies to discover novel anti-
cancer drugs.
This, prompted us to establish an integrated high-
throughput screening cell-based strategy for identifying small
molecule cell cycle modulators, for use in dissecting the
mechanisms of cancer cell division, and for developing novel
cancer therapies.We report the development of this novel cell-
based screening platform, the discovery of cell cycle phase
specific inhibitors, the chemical analyses of these inhibitors,
the cell culture characterization of cell division inhibitors, and
the detailed examination of MI-181, which has potent anti-
cancer activity, especially against melanomas.
Results
Discovery of cell cycle modulators. To discover novel cell
cycle phase specific inhibitors, human HeLa cancer
cells were plated into 384-well plates and a diverse
compound library (79 827 small molecules) encompassing
broad chemical space was used to place one compound
per well at 10 μM final concentration (Figures 1a and b
and Supplementary Table 1). These compounds were pre-
selected based on their drug-like properties: predominantly
conform to Lipinski’s rule of five for acceptable molecular
properties for orally active drugs in humans.16 Twenty hours
later, the cells were fixed and stained with the DNA-selective
stain Vybrant DyeCycle Green, which is cell membrane
permeant and after binding to DNA emits a fluorescent signal
that is proportional to DNA mass when exited at 488 nm.17
Plates were scanned with a fluorescence micro-plate
cytometer and a cell cycle histogram profile was generated
for each well, which had been treated with one compound
(Figure 1b). Cell cycle profiles were grouped and ranked
according to the extent of G1, S, and G2/M arrest. The top
hits from each phase were cherry picked and retested in
triplicate and only those testing positive were considered
further. In total we uncovered 69 G1-phase inhibitors (44 S.
D. from the mean), 148 S-phase inhibitors (4 5 S.D. from the
mean), and 273 G2/M-phase inhibitors (% G2/M ≥ 67%)
(Figures 1c and e and Supplementary Table 2). A represen-
tative example of each compound class and their associated
cell cycle profiles are indicated in Figures 1f–h.
To distinguish between compounds that arrest cells in G2-
phase or M-phase, the 273 G2/M compounds were subjected
to a secondary high-throughput screen, where cells were fixed
and co-stained with the DNA dye Hoechst 33342 and a Alexa-
488 fluorescently labeled antibody that recognizes phospho-
histone H3 (p-H3), which is specifically phosphorylated in
mitosis18,19 (Figure 1i). This analysis revealed that 266
compounds arrested cells in mitosis and 7 arrested cells in
G2-phase (Figure 1j and Supplementary Table 2). In total, the
screen resulted in a 0.613% cell cycle modulator hit rate, with
0.086% G1-phase inhibitors, 0.185% S-phase inhibitors,
0.009% G2-phase inhibitors, and 0.333% M-phase inhibitors
(Figure 1k). These results indicated that our cell cycle profile
based approach successfully identified inhibitors to all phases
of the cell cycle and likely a broad array of targets.
Compound chemical analysis and target prediction. To
understand the physiochemical properties of compounds
within each cell cycle class, we analyzed the chemical
structures of the top compounds from each phase using our
newly developed Chemical Similarity Network Analysis Pull-
down (CSNAP) computational program. CSNAP searched
the ChEMBL database for compounds sharing chemical
similarity to hit compounds, retrieved the bioactivity informa-
tion of each compound found in the ChEMBL database and
organized these compounds into network similarity graphs
sharing common chemotypes. An implemented scoring
function (S-score) was used to score target assignments by
counting the target annotation frequency in the nearest
neighborhood of query compounds. The predicted compound
on/off-targets represented by the S-score were visualized on
heatmaps (scaled from 0 to 1) and the most prominent targets
were selected from the top peaks, which correlated with the
cumulative S-score (∑S-Score) of each assigned target in
the target spectrum. This approach previously allowed us to
successfully identify major drug targets for M-phase com-
pounds, which included tubulin targeting compounds as well
as novel ligands not previously annotated in bioactivity
databases. CSNAP analysis of the 69 G1-inhibitors, 148
S-inhibitors, and 7 G2-inhibitors, resulted in the identification
of 64 G1 chemotypes, 68 S chemotypes, and 5 G2
chemotypes, respectively. These results indicated that our
screening had discovered phase specific and structurally
diverse cell cycle inhibitors (Figures 2a–c and Supplementary
Table 3).
CSNAP analysis of G1-phase compounds identified kinase
inhibitors like Staurosporine, Tyrphostin, and their analogs that
mimicked the ATP substrate of PKC and EGFR, which were
known to block the MAPK signaling pathway critical for tumor
proliferation20–25 (Figures 2d and g). In addition, compounds
capable of modulating the intracellular calcium concentration
including the ion channel inhibitors Thapsigargin (sarco-
endoplasmic reticulum Ca2+ ATPase inhibitor), Ouabain
(Na+/K+ ATPase inhibitor), and the ionophore antibiotic
A-23187 were also identified26–28 (Figures 2d and g). This
was consistent with reports indicating that calcium is an
important secondary messenger and that oscillatory calcium
signaling is required for MAPK activity and cyclin D1/E
synthesis at the G1/S transition.26 CSNAP analysis of
S-phase compounds indicated that a group of compounds
including 5309022 and 5113916 were likely inhibiting ribonu-
cleotide reductase (catalyzes the reduction of ribonucleotides
to deoxyribonucleotides; the building blocks for DNA replica-
tion and repair29) activities by iron chelation through a
hydrazone motif similar to that of Triapine and its analog
31129 (Figures 2e and h). In addition, two GSK3β inhibitors
(5100772 and 5583777) were identified among the S-phase
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inhibitors; consistent with its role in regulating cyclin D1
expression required for S-phase entry and progression30–32
(Figures 2e and h). CSNAP analysis of the seven G2-phase
compounds identified DNA topoisomerase II (TOP2) inhibitors
including Etoposide and Amsacrine-like analogs33 (Figures 2f
and i). These DNA intercalating agents trap TOP2 : DNA
covalent complexes, which induce DNA damage and G2
checkpoint arrest.34 Thus, CSNAP highlighted compounds
with known anti-proliferative properties and analogs of these
compounds that may be more efficacious. Most importantly,
CSNAP identified many novel compounds not sharing
chemotype similarity to compounds in bioactivity databases
that represent new anti-proliferative agents. Finally, it provided
key information for selecting lead compounds with diverse
mechanisms of action and targets that perturb distinct cellular
pathways essential for cell cycle progression.
Characterization of M-phase inhibitor potency. Due to the
large number and chemical diversity of M-phase inhibitors,
the current lack of chemical probes to study cell division and
the need for novel antimitotics, we focused on the detailed
characterization of mitotic inhibitors. To assess the potential
of the 266 mitotic inhibitors as anti-cancer agents, they were
re-synthesized and the 211 that passed quality control
Figure 1 Identification of cell cycle phase specific inhibitors through a novel cell-based high-throughput small molecule screening approach. (a) Targeting the cell cycle in the
treatment of cancer. (b) Cell-based high-throughput screening (HTS) of 79 827 drug-like molecules for cell cycle modulators. Twenty hours post compound treatment, HeLa
cancer cells were fixed and stained with Vybrant DyeCycle green, and a high-content cytometer was used to generate a cell cycle profile for each compound. (c–e) Scatter plots of
percent G1, S, and G2/M arrest for all compounds. The cutoffs for G1-phase and S-phase inhibitors were set at44 and45 S.D. from the mean, respectively. The cutoff for G2/M
inhibitors was set at ≥ 67% G2/M arrest. (f–h) Examples of G1, S, and G2/M-phase arresting compounds and their cell cycle profiles. (i) Immunofluorescence HTS assay for
distinguishing G2-phase inhibitors from M-phase inhibitors. Cells were co-stained with 1 μg/ml Hoechst 33342 (blue) and Alexa-488-phospho-histone-H3 (p-H3, green). Mitotic
cells are positive for p-H3. Bar indicates 5 μm. (j) Summary of screen results indicating that 266 compounds arrest cells in mitosis and 7 compounds arrest cells in G2-phase.
(k) Screen summary plot of percent hit rate indicates that M-phase inhibitors were the most abundant. (b–k) See also Supplementary Table 2
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Figure 2 Deconvolving cell cycle modulators. (a–c) CSNAP network similarity graphs showing 64 G1 chemotypes, 68 S chemotypes, and 5 G2 chemotypes, respectively.
Query compounds are in red and ChEMBL compounds are in gray. (d–f) CSNAP S-score function analyses and prediction of compound on/off-targets. Heatmap summaries of
S-scores are scaled from 0–1. The cumulative S-score (∑S-Score) of each assigned target in the target spectrum and the major predicted targets/off-targets are indicated.
(g–i) Highlight of representative compounds within the top clusters for each cell cycle phase. (a–i) See also Supplementary Table 3
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(Mitotic Inhibitor 1-211) were tested for their ability to arrest
cells in mitosis and to decrease cancer cell viability
(Figure 3a). For mitotic arrest assays, HeLa cells were
treated with a 20.2-fold-titration (190pM to 10 μM) of each
compound for 20 h and the half maximal inhibitory concen-
tration (IC50) was derived for each compound using the cell
cycle profile assay used in the initial screen (Figures 3b and c
and Supplementary Table 4). As an example, compound
ASN05941236 displayed a mitotic arrest IC50 of 3.34 μM
(Figure 3b). Within the titration series, all compounds
displayed a percent mitotic arrest between 48.3 and 83.6%
(Figure 3d and Supplementary Table 4). For viability assays,
cells were treated with a 14.2-fold-titration (12.2 nM to
100 μM) of each compound for 72 h and cell viability was
measured using the CellTiter-Glo luminescent cell viability
assay (Figures 3e and f and Supplementary Table 4). As an
example, compound ASN05941236 displayed a cell death
IC50 of 3.38 μM (Figure 3e). Interestingly, all 211 compounds
arrested cells in mitosis and decreased cell viability
(Supplementary Table 4). Most of these compounds were
potent; 16 had a mitotic arrest IC50 of ≤100 nM, 56 had
≤ 500 nM, and 98 had ≤ 1 μM (Figure 3g and Supplementary
Table 4). Similarly, 13 compounds had a cell viability IC50 of
≤ 100 nM, 56 had ≤500 nM, and 95 had ≤1 μM (Figure 3h
and Supplementary Table 4).
Multiparametric phenotypic analyses of M-phase
inhibitors. To investigate the mechanism of action of each
anti-mitotic compound we performed high-resolution immu-
nofluorescence (IF) microscopy to analyze the mitotic defects
induced by these compounds (Figure 4). HeLa cells were
treated with each of the 211 compounds at a concentration
corresponding to their mitotic arrest IC90 for 20 h. Cells were
then fixed, permeabilized, and co-stained for DNA and
α-tubulin. Six major classes of phenotypes were observed:
multipolar spindle, normal bipolar spindle with unaligned
chromosomes, defective bipolar spindle with unaligned
chromosomes, mixed phenotype (containing more than one
of the six phenotypes), depolymerized microtubules, and
stabilized microtubules (Figure 4a and Supplementary Table 4).
Figure 3 Anti-mitotic compound potency. (a) Determination of compound mitotic arrest and cell viability IC50. HeLa cells were treated with increasing concentrations of each
compound for 20 or 72 h and assayed for mitotic arrest and cell viability, respectively. (b) Example of mitotic arrest IC50 curve. x-axis is drug concentration in μM scale and y-axis is
percent cells arrested in mitosis. (c) Scatter plot of mitotic arrest IC50 in μM scale (y-axis) for all mitotic compounds (x-axis). (d) Scatter plot of the percent mitotic arrest IC50 in μM
scale (y-axis) for all mitotic compounds (x-axis). (e) Example of the cell viability IC50 curve. x-axis is drug concentration in μM scale and y-axis represents cell viability in relative
light units (RLU). (f) Scatter plot of the cell viability IC50 in μM scale (y-axis) for all mitotic compounds (x-axis). (g, h) Summary graphs of mitotic arrest and cell death potency for
all compounds. x-axis is drug concentration in μM scale and y-axis represents the number of compounds within each category. Note that 56 compounds showed a mitotic arrest
IC50 below 500 nM. (b–h) See also Supplementary Table 4
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The compound class that induced microtubule depolymeriza-
tion was the most abundant with 84 compounds falling into
this category, followed by the mixed phenotype (54 com-
pounds) and the multipolar phenotype (37 compounds)
(Figure 4b and Supplementary Table 4).
Selection of MI-181 as a lead compound. To aid the
selection of lead compounds to pursue for further character-
ization, we performed a clustering analysis of the compounds
and their bioactive properties, including mitotic arrest IC50,
cell death IC50, phenotypic class of mitotic arrest, and
percentage of cells arrested in mitosis (Figure 5a). This
analysis revealed that MI-181 was the most potent (mitotic
arrest IC50=23 nM and cell death IC50= 17 nM) compound,
similar to the taxol (mitotic arrest IC50=37 nM and cell death
IC50=27 nM) and colchicine (mitotic arrest IC50= 24 nM
and cell death IC50=12 nM) controls (Figure 5a and
Supplementary Figures 1 and 2). In addition, MI-181 arrested
more cells in mitosis compared with colchicine and taxol,
77% versus 76%, and 74%, respectively (Supplementary
Table 4). MI-181 is a small (266Da) synthetic benzothiazole-
based compound, and in silico analysis of its physiochemical
properties indicated that it conformed to parameters needed
for oral bioavailability in humans16 (Figure 5b and
Supplementary Figure 3). Unsurprisingly a substructure
search for FDA-approved benzothiazole-based and structu-
rally related benzimidazole-based drugs revealed 8
benzothiazole-based drugs and 10 benzimidazole-based
drugs approved for various clinical uses (Supplementary
Figure 4). For example, benzothiazoles included the vasodi-
lator Fostedil and a tetrodotoxin-sensitive sodium channel
blocker Riluzole approved for the treatment of heart
disease and amyotrophic lateral sclerosis, respectively
(Supplementary Figure 4).35–38 Whereas benzimidazoles
included inhibitors of tubulin polymerization like nocodazole
and mebendazole approved for the treatment of neoplasms
and warm infestations (Supplementary Figure 4).39,40 Thus
benzothiazoles that inhibit tubulin polymerization, like MI-181,
have potential for clinical use. Although the benzothiazole
and benzimidazole substructures share strong chemical
similarity, the chemical diversity of FDA-approved drugs with
these substructures is diverse, indicating that these sub-
structures have been effectively used as scaffolds for
generating specificity to various cellular targets for the
treatment of various diseases (Supplementary Figure 4).
MI-181 inhibits tubulin polymerization. To evaluate MI-
-181’s mechanism of action, we treated HeLa cells with
MI-181 for 20 h, fixed them, co-stained them for DNA and α-
tubulin, and imaged them by IF microscopy (Figure 5c).
These analyses revealed that MI-181-treated cells failed to
form a mitotic spindle and only small tubulin puncta were
observed, indicative of microtubule depolymerization
(Figure 5c). This was further confirmed in vitro where
MI-181 inhibited tubulin polymerization in an in vitro tubulin
polymerization assay, similar to colchicine (Figure 5d).
MI-181 arrests cells in mitosis, activates the SAC, and
triggers cell death. To explore the nature of the MI-181-
induced mitotic arrest, we asked if it was activating the
spindle assembly checkpoint (SAC) to arrest cells in mitosis.
First, we confirmed that MI-181 was indeed arresting cells in
mitosis. HeLa cells were treated with DMSO, MI-181, or
colchicine for 18 h, cells were fixed, co-stained for DNA,
microtubules, kinetochores, and the mitotic marker p-H3, and
imaged by fluorescence microscopy. Similar to colchicine
treatment, MI-181 treatment arrested cells in mitosis with
p-H3-positive staining and unaligned tightly condensed
chromosomes (Figure 5e). Next, we asked if the SAC was
activated in these cells by co-staining for the SAC component
Bub1. Indeed, Bub1 remained localized to the kinetochore
region in colchicine-and MI-181-treated cells (Figure 5f).
Similarly, in cells co-stained for the SAC kinase AurKB,
AurKB remained localized to the kinetochore region and
never transitioned to the central spindle as in control DMSO-
treated cells (Figure 5g). These data indicated that MI-181-
treated cells were arrested in early mitosis with an active
SAC. To further validate this, cells were synchronized in
Figure 4 High-resolution phenotypic analysis of mitotic inhibitors. (a) Summary of the six phenotype classes observed upon treatment with MI-1 through MI-211: bipolar
spindle with unaligned chromosomes, defective bipolar spindle with unaligned chromosomes, multipolar spindle, mixed phenotype, depolymerized microtubules, and stabilized
microtubules; imaged by immunofluorescence microscopy. Cells were treated with compounds for 20 h, fixed, and co-stained for α-tubulin (anti-tubulin antibodies, red) and DNA
(Hoechst 33342, blue). Bar indicates 5 μm. (b) Summary of the percentage of the total M-phase inhibitors in each phenotypic category. See also Supplementary Table 4
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G1/S, released into the cell cycle in the presence of DMSO or
MI-181 and cell extracts were prepared at several time points
post release. Consistent with our fixed-cell IF results,
immunoblot analysis of these extracts revealed that MI-181-
treated cells arrested in mitosis (p-H3 positive), activated the
SAC (BubR1 remained phosphorylated), and stabilized cyclin
B while degrading cyclin A (Figure 5h). In addition, the
MI-181-induced mitotic arrest was reversible, as cells exited
mitosis within 2 h of drug washout (Supplementary Figure 5).
To further analyze the cellular consequences of treating
cancer cells with MI-181, we coupled cell synchronization with
live-cell time-lapse IF microscopy. Synchronized HeLa
Figure 5 Selection of lead compound MI-181. (a) Clustering of 211 M-phase compounds based on their bioactive properties. For each compound the following data were
grouped and the compounds were sorted based on mitotic arrest IC50: phenotype class, mitotic arrest IC50, cell death IC50, and percent mitotic arrest. Note that MI-181 was the
most potent inhibitor (mitotic arrest IC50= 24 nM). (b) Chemical structure of MI-181. (c) Cells were treated with DMSO or MI-181 for 20 h, fixed, co-stained for DNA (Hoechst
33342) and microtubules (anti-α-Tubulin antibodies), and imaged by immunofluorescence (IF) microscopy. Images show that MI-181-treated cells arrest with condensed
chromosomes and depolymerized microtubules. (d) Results from in vitro tubulin polymerization reactions in the presence or absence of DMSO, MI-181, colchicine, and taxol.
Note that MI-181 inhibits tubulin polymerization. (e–g) IF microscopy showing that MI-181-treated cells arrest in mitosis (p-H3 positive) (e) and activate the SAC (Bub1 remains at
the kinetochore region (f) and AurKB remains on chromosomes and kinetochores and does not transition to the central spindle (g)). (h) Immunoblot analysis of extracts prepared
from DMSO or MI-181-treated cells, which were synchronized in G1/S and released into the cell cycle. Note that cyclin A levels decrease as cells enter mitosis concomitant with
an increase in p-H3 signal, and cyclin B, while BubR1 remains phosphorylated only in MI-181-treated cells, indicative of an active spindle assembly checkpoint. (c, e–g) Bar
indicates 5 μm
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fluorescent ubiquitination-based cell cycle (FUCCI) indicator
cell line cells were treated with DMSO, MI-181, colchicine, or
taxol 2 hours prior to mitotic entry and their effect on mitosis
was assessed41 (Figure 6a). Images were captured at 15-min
intervals and processed into movie format (Figure 6a and
Supplementary Movies 1). The movies were then analyzed to
determine the percentage of cells with a defective mitosis and
the length of time between mitotic entry and cell death42
(Figures 6b and c). Whereas control DMSO-treated cells
transitioned through mitosis (green fluorescence) and into G1
(red fluorescence) normally, MI-181-treated cells arrested in
mitosis and failed to divide similar to colchicine- and
taxol-treated cells (% normal cell divisions for MI-181=0,
Po0.0001; colchicine=0,Po0.0001; taxol=3±0.8,Po0.0001;
compared with DMSO=89.11±2.9) (Figure 6b). Although
individual cell responses to drugs differed widely,
colchicine-and MI-181-treated cells arrested for a shorter
time-length than taxol prior to apoptosing (MI-181=
5.3± 0.96 h, colchicine= 6.2± 1.27 h, compared with
taxol= 23.78±9.03 h) (Figure 6c). These data indicated that
MI-181 was a potent cell cycle-specific inhibitor, which
arrested cells in mitosis, activated the SAC, and induced an
apoptotic cell death with faster kinetics than taxol.
MI-181 is active in a broad array of cancers, especially
melanomas. To determine if MI-181 had broad anti-cancer
activity, we treated a diverse panel of cancer cell lines
including cervical adenocarcinoma (HeLa), breast adenocar-
cinoma (MCF7), melanoma (M233), osteosarcoma (U2OS),
acute lymphoblastic leukemia (CCRF-CEM), non-small cell
lung carcinoma (NCI-H460), and breast adenocarcinoma
(MCF7) with MI-181 and determined its cell viability IC50
(Figures 7a and b). Interestingly, MI-181 showed great
efficacy across most cancer cell lines with a cell viability
IC50 ranging from 0.03 to 0.36 μM, with the exception of
MCF7 cells (IC50=11 μM) (Figures 7a and b). These results
indicated that MI-181 was potent across a broad array of
cancers and was most effective against cervical adenocarci-
noma and melanoma cell lines. Therefore, we analyzed the
efficacy of MI-181 in a panel of melanoma cell lines with
defined genetic backgrounds including BRAFV600E and
NRASQ61L mutations and varied sensitivities to Vemurafenib
(BRAF inhibitor) and Trametinib (MEK inhibitor), which
are currently used to treat BRAFV600E melanomas43,44
(Figure 7c). MI-181 displayed great potency across this panel
(IC50=18–90 nM) (Figure 7c and Supplementary Table 5).
As a general trend BRAFV600E cell lines were slightly more
sensitive than NRASQ61L cell lines and MI-181 was effective
in Vemurafenib- and Trametinib-resistant cell lines (Figure 7c
and Supplementary Table 5). Finally, we tested the ability of
MI-181 to inhibit melanoma colony formation using the M233
and M308 cell lines (both resistant to Vemurafenib). Indeed,
MI-181 was a potent inhibitor of colony formation (percentage
colony formation for 10 nM MI-181= 0.2±0.1 and 0.8± 0.7;
for 10 nM colchicine= 0.1±0.06 and 1.5± 0.5; and for 10 nM
Vemurafenib= 94±7 and 102±5) (Figure 7d). Thus, MI-181
is a potent inhibitor of melanoma cell lines.
Discussion
Chemical inhibition of the cell cycle and cell division has been
a fruitful approach for understanding the mechanisms that
cancer cells rely on to proliferate and for the development of
therapeutics to inhibit these processes. Previous studies
taking unbiased chemical screening approaches to identify
anti-proliferative agents were limited by screening assay
output, chemical library composition, lack of chemical analysis
on hits, and a narrow focus on specific phases of the cell cycle.
Here, we devised a cell cycle profiling high-throughput
chemical screening approach that enabled the identification
Figure 6 MI-181 is a potent cell division inhibitor. (a) Live-cell time-lapse microscopy of HeLa FUCCI cells treated with DMSO, MI-181, colchicine, or taxol. Time is in minutes.
(b) The percentage of cells undergoing normal cell division was quantified for DMSO, MI-181, colchicine, or taxol-treated cells. Asterisk denotes P-valueo0.0001. (c) The time
from mitotic entry to cell death was quantified for DMSO-, MI-181-, colchicine-, or taxol-treated cells. Error bars indicate ±S.D. from the mean
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of cell cycle modulators specifically inhibiting G1, S, G2, and
M-phases while avoiding the difficulties associated with high-
throughput fluorescence activated cell sorting screening. The
utility of this approach was validated by the identification of
well-validated cell cycle-specific inhibitors and their analogs.
Most importantly, this screen uncovered numerous novel
compounds representing variable chemotypes, which warrant
further validation and characterization as anti-cancer agents.
In our approach, the use of computational chemoinformatics
enabled the generation of hit compound network similarity
graphs that grouped compounds based on chemotypes,
facilitated compound target and off-target prediction, and
identified analogs of validated inhibitors with the potential to be
more potent, more specific, or less toxic. The wealth of
information derived from these computational analyses could
aid future studies aimed at discovering/developing anti-cancer
agents. Thus, we propose that similar chemical deconvolution
approaches be part of every future high-throughput chemical
screen. Similarly, the characterization of compounds based on
potency and multiparametric phenotypic analysis adds valu-
able information to the selection of lead compounds for the
purposes of being used as chemical probes to dissect the
mechanisms driving the cell cycle, as anti-cancer agents, or
both and should be considered an integral part of cell-based
chemical screening campaigns.
The chemical diversity of the mitotic inhibitors and the array
of mitotic defects induced by these compounds indicate that
they are likely targeting a broad array of mitotic targets.
Therefore, these inhibitors could be used to study the function
of these targets in an acute and temporal manner and they
warrant further evaluation and target identification/validation.
The selection of MI-181 as a lead anti-cancer compound in our
study highlights the utility of cell-based chemical screening for
the identification of potent cell permeable drug-like phase
specific drugs. MI-181 targets tubulin, inhibits tubulin poly-
merization, activates the SAC, arrests cells in mitosis, and
triggers an apoptotic cell death. Most importantly, MI-181 has
broad anti-cancer activity and is especially potent against
melanomas.
Microtubule depolymerizers like vinblastine and vincristine
are currently in clinical use for the treatment of testicular
cancer, lung cancer, leukemias, and lymphomas45 and there is
a critical need to identify novel synthetic molecules that can
address the limitations of these drugs (synthesis, toxicity,
resistance, and so on). Thus, MI-181 represents an opportu-
nity to develop improved alternatives to these drugs.
Figure 7 MI-181 is a potent cancer cell division inhibitor, especially melanomas. (a, b) MI-181 is potent against a broad panel of cancer cell lines. Cervical adenocarcinoma
(HeLa), breast adenocarcinoma (MCF7), melanoma (M233), osteosarcoma (U2OS), acute lymphoblastic leukemia (CCRF-CEM), non-small cell lung carcinoma (NCI-H460), and
breast adenocarcinoma (MCF7) cells were treated with increasing concentrations of MI-181 (190pM-10 μM) for 72 h and their cell viability IC50 was assessed using the CellTiter-
Glo assay. (c) A panel of melanoma cells were treated with increasing concentrations of MI-181 and the IC50 was determined for each cell line as described in a. B, BRAF
V600E;
N, NRASQ61L; R, resistant; S, sensitive; Tram, Trametinib; Vem,Vemurafenib; W, wildtype. (d) MI-181 inhibits melanoma colony formation. M233 and M308 melanoma cells
were treated with DMSO, Vemurafenib (1 μM), colchicine (100 nM), or MI-181 (100 nM) for 7 days and the percent colony formation, normalized to DMSO, was quantified.
Percent colony formation and standard deviation are indicated at the bottom of each panel for each drug and cell line
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Materials and Methods
Cell culture. Non-melanoma cell lines were purchased from ATCC (Manassas,
VA, USA), which verified identity by short-tandem repeat profiling, and were
passaged for o6 months following receipt and were maintained in F12 : DMEM
50 : 50 medium (GIBCO, Grand Island, NY, USA) with 10% FBS, 2 mM
L-glutamine, and antibiotics, in 5% CO2 at 37 °C. Melanoma cell lines were
established from patient biopsies under UCLA IRB approval #02-08-067, as
described previously.46 Melanoma cell lines were genotyped using Oncomap3
platform for 33 genes, Affymetrix Gene Chip for SNP and IonTorrent for next-
generation sequencing, and were passaged for o6 months following verification,
and were maintained in RPMI (GIBCO) with 10% FBS and antibiotics in 5% CO2 at
37 °C, as described previously.46 For G1/S arrests, cells were treated with 2 mM
thymidine (Sigma-Aldrich, St. Louis, MO, USA) for 18 h.
High-throughput cell cycle modulator assay. HeLa cells were plated
in 384-well plates (1500 cells/well) and treated with 10 μM drugs for 20 h. Cells
were fixed and stained with 5 μM Vybrant DyeCycle Green (Invitrogen, Grand
Island, NY, USA) for 1 h at room temperature and plates were scanned with an
Acumen eX3 (TTP Labtech, Cambridge, MA, USA) fluorescence cytometer using
its 488 nm laser and a cell cycle histogram profile was generated for each well. For
the G2/M secondary screen, 20 h post drug addition cells were fixed with 4%
paraformaldehyde, permeabilized with 0.2% Triton X-100/PBS, and stained with
Alexa-488-phospho-histone-H3 (Ser10, Cell Signaling, Danvers, MA, USA) and
1 μg/ml Hoechst 33342 for 1 h. Plates were imaged with an ImageXpress Micro
(Molecular Devices, Sunnyvale, CA, USA) high-content fluorescence microscope.
Data analysis was performed using the Collaborative Drug Discovery (CDD,
Burlingame, CA, USA; www.collaborativedrug.com) software and outputs were
exported to Excel. The quality of the screen was assessed by calculating the Zʹ
factor (Zʹ factor = 1–3 x (σp+σn)/(|μp− μn|)), which takes into account the dynamic
range of the assay and variance of the data.47 The screen performed with an
average plate Zʹ factor of 0.51± 0.09, within the optimal performance range
of 0.5–1.47
Compound potency. For mitotic arrest IC50s, cells were treated with a 20.2-
fold-titration (190pM to 10 μM) of each compound for 20 h. For cell viability IC50s,
cells were treated with a 14.2-fold-titration (12.2 nM to 100 μM). Mitotic arrest IC50
was determined by measuring the percent G2/M arrest using the Vybrant DyeCycle
Green (Invitrogen) assay described above. Cell viability IC50 was determined using
the CellTiter-Glo Assay (Promega, Madison, WI, USA), which measures total ATP
levels. Plates were read with a Tecan M1000 micro-plate reader (Tecan, San Jose,
CA, USA) at 540 nm. The CDD software (Burlingame, CA, USA, www.
collaborativedrug.com) was used for generating IC50 and IC90 values.
IF and time-lapse microscopy. IF microscopy was carried out as described
previously.48 Except that images were captured with a Leica DMI6000 microscope
(Leica Microsystems, Buffalo Grove, IL, USA) and deconvolved with Leica
deconvolution software. Time-lapse microscopy was performed as described
previously.18 Briefly, HeLa FUCCI (where S through M-phase cells are green due to
expression of the mAG–hGeminin fusion protein, and G1-phase cells are red due to
expression of the mKO2-hCdt1 fusion protein) cells were released from G1/S in the
presence of indicated drug or control DMSO, and ten Z-stack images (0.9 μm steps)
were captured 6 h post release at 15-min intervals. Images were deconvolved and
converted to AVI movie files.
CSNAP chemical analysis. CSNAP was used to predict the targets of
G1, S, and G2-phase inhibitors as described previously. Briefly, compounds were
queried in the annotated ChEMBL database version 18 (The EMBL-European
Bioinformatics Institute, Cambridge, UK) using the following search parameters:
tanimoto cutoff= 0.75, Z-score cutoff= 2.5. The ChEMBL target annotations were
retrieved from the database based on the following criteria: confidence score= 4,
assay-type= binding. Finally, chemical similarity networks and ligand–target
interaction fingerprint analyses were analyzed using Cytoscape (Cytoscape
Consortium, San Diego, CA, USA; www.cytoscape.org) and the R statistical
package (R Foundation Institute for Statistics and Mathematics, Wien, Austria;
www.www.r-project.org), respectively.
Clonogenic assays. M233 and M308 melanoma cells were seeded at 15 000
cells/well in six-well plates. The next day, cells were treated with indicated drugs or
DMSO. Seven days post incubation, cells were fixed with 4% paraformaldehyde,
stained with 0.05% Crystal violet, and colonies were counted for each treatment.
In vitro tubulin polymerization assays. Tubulin polymerization
reactions were carried out according to the manufacturer (BK011P, Cytoskeleton,
Denver, CO, USA) in the presence of 3 μM colchicine, MI-181, taxol, or DMSO.
Polymerization was monitored with a Tecan M1000 micro-plate reader (Tecan) at
420 nm for 70 min at 37 °C.
Antibodies. Phospho-histone-H3-488 (Cell Signaling), Phospho-histone-H3
(p-H3, Millipore, Billerica, MA, USA) α-tubulin (Serotec, Raleigh, NC, USA), AurKB
(BD Transduction, San Jose, CA, USA), Anti-Centromere-Antibodies (ACA, Cortex
Biochem, Madison, WI, USA), cyclin A and B (Santa Cruz Biotechnology, Dallas,
TX, USA), and SECURIN (Gene Tex, Irvine, CA, USA). BubR1 and Bub1 were from
Hongtao Yu. FITC-, Cy3-, and Cy5-conjugated secondary antibodies were from
Jackson Immuno Research.
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LCI Results and Discussion 
Single cell responses to cell division inhibitors compound 215, colchicine and paclitaxel 
were quantified and characterized using LCI imaging and manual data processing. Quantitative 
phase images of synchronized HeLa cells were acquired over time under treatment conditions of 
0.01% DMSO, 1µM compound 215, 500nM colchicine and 100nM paclitaxel. Single cell biomass 
accumulation tracks and morphology tracks such as mean phase shift and shape factor were 
extracted from each treatment condition to analyze the effects of inhibitors on time, duration and 
subsequent cell fates of divisions. LCI analysis showed that population mass accumulation rates 
rapidly declined after 700 minutes of inhibitor treatments and lowered to the negative range after 
1000 minutes (Figure 4-1a). Meanwhile growth rates sustained in normal range in the DMSO 
vehicle control condition (Figure 4-1a). Analysis of single cell morphology indicated that 
synchronized cells started mitotic rounding at between 700-900 minutes after treatments began. 
This result explained the decline in growth rates after 700 minutes, which is due to mitosis entry 
and mitotic arrests in treatment conditions. There is no statistically significant difference in mitosis 
start time between treatments, even though the data showed a slight trend of quicker mitotic entry 
in inhibitor treatments compared to the control condition. (Figure 4-1b). Cell fate analysis showed 
that HeLa cells naturally exhibited small percentage (7%) of aberrant division events under vehicle 
control condition (0.01%DMSO), including endocycle, tripolar division and mitotic arrest (Figure 
4-1c). This was expected in an immortalized human cancer cell line that has abnormal gene
expression patterns in cell cycle and DNA repair pathways.1 Two of the three division inhibitors, 
colchicine and paclitaxel, induced apoptosis in the majority of cells. 3% and 9% of the cells 
exhibited endocycle and mitotic arrest respectively in colchicine treatments. 1% and 18% of the 
cells exhibited successful division and mitotic arrest respectively in paclitaxel treatments. Mass 
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Figure 4-LCI-1 Cell fate decision analysis using LCI 
a) fractions and absolute numbers of HeLa cells that exhibited each of the 5 cell fate categories (division,
endocycle, dead, tripolar division, arrest) under treatments of either 0.01% DMSO, 1µM compound 215,
500nM colchicine or 100nM paclitaxel. b) Normalized specific population biomass accumulation rates
of HeLa cells over time under four treatment conditions listed above. Grey regions indicate the population
range of the growth rates and colored solid lines indicate population average growth rates. c) Population
average time at which synchronized HeLa cells start rounding up for mitosis. The time is defined as
number of minutes after the start of treatments. d) Waterfall plots of single HeLa cell mitosis time under
each treatment condition. Each bar represents a single HeLa cell. The color of the bar indicates the cell
fate decision after mitosis or mitotic arrest. The left edge of the bar indicates the start of mitotic rounding
and the right edge of the bar indicates the end of mitosis or mitotic arrest. The length of the bar shows
the amount of time a cell spent in mitosis or mitotic arrest. e) Waterfall plots of the amount of time each
single HeLa cell spent in mitosis or mitotic arrest under each treatment condition, color coded and
categorized by subsequent cell fates. f) Bar plots that show HeLa cells population average amount of
time spent in mitosis or mitotic arrest under each treatment condition. Whiskers represent standard
deviations.
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apoptotic events quantified in all inhibitor treatment conditions explained the decline of population 
growth rates to the negative range. However, compound 215 induced 17% tripolar divisions and 
12% endocycle events in addition to 27% successful division due to drug failure. The high 
percentage of abnormal division events at 1µM concentration of compound 215 raises alarms that 
dosing window on the same log scale can yield similar results in in vivo. Tripolar divisions and 
endocycling events lead to chromosomal abnormalities, instabilities and increased tumor 
aggression.2-4 Therefore the results suggest that 1µM is a suboptimal and dangerous dosing 
window for compound 215. Both inhibitor concertation and mechanism can play crucial roles in 
cell fate outcomes after mitotic exit.5, 6 Further studies of single cell responses to mitotic inhibitors 
at a range of concentrations will provide more insights on undesirable effects over time and 
detrimental dosing ranges (see Chapter 5). 
Another notable observation from this study is the correlation between time spent in mitosis 
or mitotic arrest and cell fate outcomes (Figure 4-1d-f). Time analysis showed that tripolar 
division, endocycle and death all exhibit long periods of time in mitosis or mitotic arrest. 
Successful divisions were shown to require short periods of time in mitosis. This trend is consistent 
in all treatment conditions for HeLa cells. Further studies of mitosis time and cell fate correlation 
in multiple cell lines under a panel of division inhibitors will provide more data points for in-depth 
analysis.   
In conclusion, LCI imaging and analysis validated promising anti-cancer potentials of 
compound 215, which effectively induced massive apoptotic events in HeLa cells, supporting 
molecular studies from Senese et al., 2014 (results not included in this thesis). However, LCI data 
revealed that compound 215 induced aberrant division events that can lead to increased tumor 
aggression and additional tumorigenesis at suboptimal concentration of 1µM. Cell fate analysis of 
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single cell responses to a range of compound 215 concentrations are needed to determine its fitness 
for therapeutics application.  
LCI Methods 
Live cell interferometer (LCI) measurements 
HeLa cells were suspended in 2mL of cell culture media at a density of 1.25×104 cells/mL 
and plated onto a 2cm×2cm silicon chip in a 3.5cm diameter cell culture dish (approximately 2600 
cells/cm2). Cells were grown in 5% CO2 at 37oC for 24 hours, after which they were arrested in 
G1/G0 by 2mM thymidine treatment (Sigma-Aldrich) for 18 hours. The cells were released from 
arrest by washing with PBS and then immediately treated with cell culture media containing either 
1μM MI-181, 0.01% DMSO, 500nM Colchicine or 100nM Taxol. After 4 hours of treatment, the 
silicon chip was transferred into a custom Teflon continuous perfusion cell culture chamber that 
maintains temperature at 37oC and equilibrates cell culture media at 5% CO2. The system was 
equilibrated for 1 hour before the start of imaging. 30 locations on the silicon chip were imaged 
every 2 to 3 minutes from approximately 5 hours to 27 hours after treatment, to allow the 
completion and analysis of the first cell division. A 20×, 0.28 numerical aperture Michelson 
through transmissive media interference objective was used with an 850nm fiber coupled infrared 
LED (Thorlabs), on a modified GT-X8 optical profiler (Bruker) in phase shifting interferometry 
(PSI) mode.7 
LCI Data phase unwrapping 
Before processing to quantify cell mass, phase data were processed to remove the integer 
wavelength discontinuities inherent to quantitative phase imaging, a process known as phase 
unwrapping.8 First, a modified Flynn phase unwrapping algorithm was used. Second, a random 
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walk image segmentation algorithm was used to detect and correct any remaining phase wrapped 
regions.9 
Cell mass quantification 
Individual cells were segmented using a watershed algorithm in a custom Matlab 
(Mathworks) script. Cell mass was estimated from phase shift measurements using a specific 
refractive index of 1.8 x 10-4 m3/kg, which represents a whole-cell average value.10 Cell mass is 
computed as the sum of the mass per pixel over the segmented area of the cell. Cell tracking to 
link individual cell mass measurements over time was performed using a particle tracking code 
implemented in Matlab by Daniel Blair and Eric Dufresne, based on an algorithm published by 
Grier et al.11 
Mitosis duration from LCI data 
Mitotic entry was determined by finding the time at which the mass per area of a given cell 
increased abruptly as it detached from the substrate and rounded up. Time in mitosis is defined as 
the time from the midpoint of this abrupt increase in mass per area until the cell either divided, 
showed an abrupt decrease in mass per area, or showed an abrupt decrease in shape factor (defined 
as 4*pi*A/D2, a measure of how round the cell is).  
Cell fate determination from LCI data 
Cell fate was determined by manually screening images and mass versus time data from 
individual cell tracks and calling each track as division, death, endocycle (cell returns to G0/G1 
state without dividing, tripolar division, arrest (cell remains rounded until the end of the imaging 
experiment), or inconclusive. Cell tracks classified as inconclusive (about 9% of all tracks) were 
excluded from the analysis. Cell tracks classified as arrest were excluded from the analysis of time 
spent in mitosis, as the exit from mitosis was never observed. 
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SUPPLEMENTARY FIGURES 
Supplementary Figure 1.  MI-181 chemical information. 
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Supplementary Figure 2.  HeLa cell mitotic arrest and cell viability dose response curves for 
nocodazole, colchicine, taxol and MI-181.   
MI-181! MI-181!
Taxol! Taxol!
Nocodazole!Nocodazole!
Colchicine! Colchicine!IC50=0.013 μM!
Cell viability Mitotic arrest !
IC50=0.045 μM!
IC50=0.017 μM!
IC50=0.027 μM!
IC50=0.024 μM!
IC50=0.129 μM!
IC50=0.023 μM!
IC50=0.037 μM!
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Supplementary Figure 3.  In silico prediction of ADMET properties for colchicine, taxol and MI-
181. 
 
 
ADMET properties in-silico prediction Ideal Taxol MI-181 Colchicine 
BBB permeability (Clark and Lobell et al.) yes no no no 
logP ~4 4.34 4.49 2.2 
H-bond donors <7 4 0 1 
Polar surface area (PSA) 40 –90 A 189.9 25.78 83 
Molecular weight ~400 853.9 266.4 399.4 
oral bioavailability (Veber Rules) yes no yes yes 
Rotatable bonds <10 15 2 6 
Polar surface area (PSA) <140 189.9 25.78 83 
absorption/permeability (Lipinski Rules) yes no yes yes 
H-bond donors <5 4 0 1 
Molecular weight <500 853.9 266.4 399.4 
logP <5 4.34 4.49 2.2 
H-bond acceptors <10 15 2 6 
solubility (logS) > -5.7 -8.43 -3.84 -4.18 
Pgp efflux no yes no yes 
H-bond donors <8 4 0 1 
Molecular weight <400 853.9 266.4 399.4 
*logP: lipopholicity 
*Lipinski rules (HD<5, MW<500, logP<5, 
HA<10) 
*Veber rules (RotB<=10, PSA<=140A) 
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Supplementary Figure 4. Substructure search for FDA approved benzothiazole-based and 
structurally related benzimidazole-based drugs.   
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Supplementary Figure 5.  MI-181 is a reversible mitotic inhibitor. HeLa cells were treated with 
the indicated drugs for 18 hours.  Cells were then washed and released into the cell cycle. Protein 
samples were prepared at the indicated time points and were analyzed by immunoblotting with 
anit-p-H3 and anti-a-Tubulin antibodies.   
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SUPPLEMENTARY TABLES 
Category Parameter Description 
Assay Type of assay Cell-based 
Target Cell cycle modulators 
Primary measurement Cell cycle profile, detection of G1, S, G2, and G2/M 
arrest 
Key reagents Vybrant DyeCycle Green Stain (Invitrogen) 
p-H3-488 Antibody (Cell Signaling)
Assay protocol See Online Methods 
Additional comments 
Library Library size 79,827 compounds 
Library composition Drug-like molecules 
Source UCLA Molecular Screening Shared Resource 
Additional comments 
Screen Format 384-well plates
Concentration(s) tested 10µM, <1% DMSO  
Plate controls Internal controls DMSO, Taxol 
Reagent/ compound dispensing system Biomek FX (Beckman Coulter) and Multidrop 384 
(Thermo LabSystems) liquid handlers 
Detection instrument and software Acumen eX3 (TTP Labtech) 
Assay validation/QC Z’ score 0.51 ± 0.09 
Correction factors 
Normalization To internal controls DMSO and Taxol 
Additional comments 
Post-HTS analysis Hit criteria G1-phase inhibitors (>4 STDs from the mean), S-
phase inhibitors (> 5 STDs from the mean), G2/M 
inhibitors (>67% G2/M arrest) 
Hit rate Total 0.613% cell cycle modulator hit rate = 0.613%; 
0.086% G1-phase inhibitors, 0.185% S-phase 
inhibitors, 0.009% G2-phase inhibitors and 0.333% 
M-phase inhibitors
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Additional assay(s) G2/M deconvolution screen for p-H3-488 antibody 
positives cells, CellTiter-Glo luminescent cell viability 
assay and immunofluorescence microscopy-based 
multiparametric phenotypic analyses. 
Confirmation of hit purity and structure Compounds were repurchased from MolPort and 
compound structure and purity were verified 
analytically 
Additional comments 
Supplementary Table 1.  Small-molecule high-throughput screening data. Summary of screening 
assays, chemical library, screening conditions and post-HTS analysis.  
Supplementary Table 2.  High-throughput cell cycle profiling data. 
Excel file with G1, S, G2 and M-phase inhibitor compound name and percent arrest. Standard 
deviations from the mean for each phase are indicted.  
Supplementary Table 3. Chemical similarity network analysis pulldown (CSNAP). 
Excel file with CSNAP analysis of the top G1, S, and G2-phase inhibitors.  
Supplementary Table 4. Potency and phenotypic data for antimitotic compounds.  
Excel file listing M-phase inhibitors by compound name, mitotic arrest IC50, cell viability IC50, 
and mitotic phenotype classification.  
Supplementary Table 5. MI-181 melanoma cell line screening data.  
Excel file listing cell viability IC50 for MI-181 across a panel of melanoma cell lines. 
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SUPPLEMENTARY MOVIES 
Supplementary Movie 1. DMSO-treated control cell undergoing mitosis.  
Live cell time-lapse microscopy of control DMSO-treated cells. HeLa-FUCCI cells were arrested 
with Thymidine for 18 hours, washed, released into fresh media and DMSO was added 6 hours 
post release. Images from 3 channels (phase contrast, FITC and Cy3) were captured every 15 
minutes at 20X magnification with a Leica DMI6000 microscope and processed using Leica 
deconvolution software (Leica Microsystems) and converted to an AVI movie. Each frame 
represents a fifteen-minute interval.  
Supplementary Movie 2. MI-181-treated cell undergoing mitosis.  
HeLa-FUCCI cells were synchronized, treated with MI-181, and imaged by live time-lapse 
microscopy as described for Supplementary Movie 1.  
Supplementary Movie 3. Colchicine-treated cell undergoing mitosis.  
HeLa-FUCCI cells were synchronized, treated with colchicine, and imaged by live time-lapse 
microscopy as described for Supplementary Movie 1.  
Supplementary Movie 4. Taxol-treated cell undergoing mitosis.  
HeLa-FUCCI cells were synchronized, treated with taxol, and imaged by live time-lapse 
microscopy as described for Supplementary Movie 1.  
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Chapter 5 
HIGH-SPEED LIVE-CELL INTERFEROMETRY: A 
NEW METHOD FOR QUANTIFYING TUMOR DRUG 
RESISTANCE AND HETEROGENEITY 
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Introduction 
Developing effective anti-cancer treatment regimens remains a significant therapeutic 
challenge. Treatment selection based on available diagnostic data including assessment of 
histologic tumor subtype, clinical grade and stage, molecular biomarkers, and genome-profiling 
studies can still lead to variable patient outcomes. This indicates a pressing need to continue 
developing new agents and regimens.1 The prediction of treatment outcomes and selection of 
therapeutic agents typically relies upon drug performance studies from preclinical research and 
clinical trials. In these settings, drug performance assessments are most commonly by multi-day 
growth inhibition assays in vitro and tumor shrinkage in vivo. However, data from these binary 
analyses may fail to uncover processes within cancer cells that further increase drug resistance and 
tumor aggressiveness. Cancer cells that persist after therapy may acquire additional genetic or 
epigenetic changes that make future treatments progressively more difficult.2 Therefore, a method 
that captures the full range of cell fates after a specific treatment, for example with a mitotic 
inhibitor, could reveal unsuspected suboptimal drug regimens with an elevated risk of promoting 
more aggressive tumors. 
Specific mitotic inhibitors have frequent use to treat specific cancers, such as paclitaxel for 
breast and ovarian cancers. As a group they target the microtubule system or associated cell 
division kinases with the goal of activating growth checkpoints to induce mitotic arrest and 
apoptosis of cancer cells.3 Despite widespread use, most mitotic inhibitors show neurotoxicity, 
poor in vivo efficacy, and are difficult to dose adequately, thereby limiting applications.4 
Preclinical studies also reveal that post-treatment surviving cancer cells may aberrantly exit from 
mitosis with multipolar cell divisions or endocycling from a weakened mitotic checkpoint caused 
by suboptimal mitotic inhibitor dosing.5, 6 These mitotic aberrations may cause aneuploidy, 
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chromosome instability, and increased tumor aggression.7-9 A rapid method to detect and classify 
aberrant mitotic outcomes for mitotic inhibitor treated cancers could improve drug development 
and selection.  
Flow cytometry that uses DNA intercalating dyes, confocal microscopy, fluorescence time-
lapse microscopy, and multi-day growth inhibition assays are current methods for assessing 
cellular responses to mitotic inhibitors.5, 6, 10 Unfortunately these approaches are often laborious, 
can be cell destructive, are limited to discrete measurement time points that can miss emerging 
therapy resistance, or require labeling that may interfere with cell behavior. For example, the most 
commonly practiced multi-day growth inhibition assays only provide total numbers of viable or 
dead cancer cells in tissue culture at specific treatment time points. EC50 values generated from 
this type of counting assay only shows population trends and overlooks phenotypic outcomes of 
individual cancer cells that survive treatment. This approach therefore yields limited insight into 
drug response kinetics and potential aberrant outcomes.  
To overcome limitations in current screening methods and to increase throughput, we 
deployed a version of QPI we refer to as live cell interferometry (LCI) to measure single cell 
responses to three mitotic inhibitors with different mechanisms of action using dose-escalating 
drug concentrations. Our approach uses quadriwave lateral shearing interferometry (QWLSI) to 
precisely quantify the phase-shift of incident light interacting with the non-aqueous mass, or 
biomass, of individual cells.11 Conversion of measured phase-shifts in light into biomass uses an 
experimentally determined cell average specific refractive index, which enables quantifying 
changes in cell biomass over time.12, 13 Prior LCI studies revealed breast cancer cell line 
sensitivities to trastuzumab (Herceptin) within 6 h, a speed compatible for studies of patient biopsy 
materials, with results replicating multi-day growth inhibition assays.14, 15 More recently, LCI 
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successfully dissected tumor heterogeneity and drug resistance for melanoma cells in a mixture 16 
and could replicate known tumor sensitivities to cisplatin in mouse patient-derived xenograft 
(PDX) models of breast cancer.17 These prior LCI studies validated QPI utility in cancer, but did 
not evaluate cancer cell outcomes beyond binary growth inhibition results. The use of multi-
parametric QPI response profiling data that could further inform preclinical drug development and 
clinical drug selection is an exciting possibility explored here. 
In this proof-of-concept study, we provide a new multi-parametric analytical method to 
identify different cell fate outcomes to mitotic inhibitors using QPI measurements of cell biomass, 
morphology, and mean phase-shift of light. Our study provides dynamic data on mitotic inhibitor 
activities and the frequencies of abnormal and undesirable outcomes during early exposure time 
points that may make tumors more difficult to treat.7 Our cell fate identification strategy may also 
be useful for developing and testing other anticancer agents and regimens. 
Results 
Identifying post-mitotic cell fate outcomes using QPI 
We deployed QPI to measure synchronized HeLa and M202 single cancer cell biomass and 
morphology responses after mitotic entry, in the presence of escalating doses of several mitotic 
inhibitors (Figure 5-1, Table 5-1). We chose paclitaxel, a microtubule stabilizing agent, 
colchicine, a microtubule destabilizing drug, and VX-680, an Aurora kinase A inhibitor that 
represent a range of mitotic inhibitor modes of action. Cells were treated with each drug for 5 h 
before QPI of randomly selected locations at 10 min imaging intervals over the next 24 h (Figure 
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5-1A). Changes in biophysical and
morphological parameters over the 
imaging period provided data to 
determine cell fate outcomes of 
single cancer cells in each condition 
(Figure 5-1B-C). Two EC50 values, 
one for successful bipolar divisions 
representing drug failure and one for 
cell death/arrest, were calculated 
based on the distributions of cell fate 
outcomes in the sampled cell 
populations (Figure 5-1D). ΔEC50, 
the difference between these two 
EC50 values, therefore describes the 
concentration range over which 
cancer cells display aberrant mitotic 
exits at suboptimal dosages for each 
type of drug treatment (Figure 5-
1D). 
We classified the mitotic 
fate of each tracked cancer cell into 
one of five categories: (1) successful 
bipolar division, (2) multipolar 
Release, 
Add Drug 
18h 5h 24h 
A 
B
Thymidine Arrest Start Imaging 
C D 
Figure 5-6 Experimental design and analysis schematics 
A) Timeline of the experiment, showing cell synchronization
and period of QPI. B) Example QPI images of single HeLa
cells under 50nM of colchicine treatment. The same cells
outlined in green and purple were tracked continuously over
time to determine their post-mitotic entry fates, in this case are
death and prolonged mitotic arrest. Color bar indicates phase
shift in nm. Time stamps indicate time since start of drug
exposure. C) Representative schematic of biomass, mean
phase-shift and shape factor data over time for two cell fates
shown in B): death and mitotic arrest. D) Representative
schematic of two EC50 curves generated based on normalized
cell-fate outcomes distributions from randomly sampled single
cells over a range of drug concentrations. The difference
between the two EC50 values, ΔEC50, provides a dosing range
in which the drug can potentially cause aberrant mitotic exits.
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division, (3) endocycling, (4) cell death, and (5) prolonged mitotic arrest. (Figure 5-2A). We then 
subjectively divided these five outcomes into three groups. Group 1 is successful bipolar divisions, 
representing the failure of a drug to block mitosis at the surveyed doses. Group 2 includes 
prolonged mitotic arrest and cell death, which are desirable anticancer cell fates. Group 3 fates are 
hidden in growth inhibition assays and include multipolar divisions and endocycling. Group 3 fates 
can yield chromosomal aberrations and make tumor cells increasingly aggressive and difficult to 
eradicate.7-9 Importantly, conventional multi-day growth inhibition counting assays combine 
Group 1, Group 2 mitotic arrest, and Group 3 outcomes to report on the cumulative number of live 
cancer cells at specific time points during and post-drug treatment without discriminating Group 
3 unfavorable and potentially dangerous outcomes.  
Cell Lines Paclitaxel (nM) Colchicine (nM) VX-680 (nM) 
HeLa 10, 50, 100, 500 50, 150, 500, 1500, 2500 100, 300, 600 
M202 1, 3, 9, 50, 100, 500 1, 5, 10, 20, 50 30, 90, 150, 300, 600 
Table 5-1 Mitotic Inhibitors Drug Concentrations Administered to M202 and HeLa Cell Lines in 
Live Cell Interferometer Study 
Criteria for classifying cell fates relies upon specific biophysical and morphological QPI 
measurements. A sharp surge in mean phase-shift above 140 nm and shape factor, a measurement 
of roundness, above 0.7 defines the time point of mitotic entry as cells ‘round up’ (Figure S5-1).18 
During a successful bipolar division, a single cell separates into two cells and then flattens to 
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resume growth during 
interphase. The mitotic 
interval with cytokinesis is 
complete when two cells 
emerge at or near the former 
parent cell location with 
mean phase-shift and shape 
factor below 140 nm and 0.7 
thresholds (Figure 5-2A-
B).18 A cell death fate 
occurs when cell biomass 
shows either a sudden or a 
slow decline following 
mitotic entry (Figure 5-2A, 
5-2C).19 During cell death
the mean phase-shift
through the cell decreases 
but stays above the 140nm 
threshold due to pyknosis, 
karyorrhexis, and cytoplasm 
content condensation.20 The shape factor value also decreases when severe membrane blebbing or 
cell disintegration occurs (Figure 5-2C). A prolonged mitotic arrest is identified by stagnation of 
changes in cell biomass, with mean phase-shift and shape factor remaining above 140nm and 0.7 
Figure 5-7 Cell fate algorithm with examples 
A) A decision tree diagram showing the MATLAB algorithm for
determining cell fates based on dynamic changes in cell biomass, mean 
phase-shift, and shape factor measured by QPI. B) Example of a HeLa 
cell undergoing a bipolar division. C) Example of a HeLa cell dying. D) 
Example of a HeLa cell in prolonged mitotic arrest. E) Example of a 
HeLa cell undergoing a multipolar division. F) Example of a HeLa cell 
undergoing endocycling. 
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thresholds, and no cell division or other morphological changes occurring (Figure 5-2A, 5-2D). A 
multipolar cell division fate shows the same time-dependent tracing pattern in mean phase-shift, 
shape factor, and biomass accumulation as bipolar divisions with three or more cells arising at or 
near the previous parent cell location (Figure 5-2A, 5-2E). Following multipolar divisions, not all 
daughter cells grow or thrive, likely due to aberrant chromosome partitioning.21 Finally, QPI 
identifies endocycling when a cancer cell shows a sudden surge in mean phase-shift and shape 
Figure 5-8 Cell fate distribution analysis 
A) Cell fate distribution of HeLa cells with paclitaxel exposure. B) Cell fate distribution of HeLa cells
with colchicine exposure. C) Cell fate distribution of HeLa cells with VX-680 exposure. D) Cell fate
distribution of M202 cells with paclitaxel exposure. E) Cell fate distribution of M202 cells with colchicine
exposure. F) Cell fate distribution of M202 cells with VX-680 exposure. A solid line in each panel
represents a dose response curve fit to the biopolar division distribution. A dotted line in each panel
represents a dose response curve fit to the prolonged mitotic arrest or cell death distribution. Numbers
represent EC50 values of for each curve. Legend shows color code for cell fate outcomes.
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factor, indicative of mitotic ‘rounding’, but returns to a G0/G1 flat morphology, mean phase-shift 
under 140nm, and shape factor less than 0.7 without cell division (Figure 5-2A, 5-2F).22 In cases 
when single cells are hard to dissect from neighbors or are difficult to track over time, we apply 
manual screening corrections to the results of the cell fate algorithm. 
Calculating EC50,growth and EC50, death using QPI quantified cell fate outcomes 
In growth inhibition assays, cell fate outcomes are binary, meaning that a drug does or does 
not alter live cell numbers compared to control conditions over time from the sum of cell divisions, 
arrests, and deaths. Thus, conventional preclinical drug development assays generate one EC50 
curve to fit a binary outcome. By contrast, QPI yields three cell fate groups (Groups 1 – 3) with 
qualitatively distinct outcomes available for quantification. Therefore, instead of analyzing total 
live cell numbers, we generated two dose-response curves from QPI data. One dose-response curve 
corresponds to successful bipolar divisions from drug insensitivity (Figure 5-3, solid line). The 
second dose-response curve describes desirable outcomes with prolonged mitotic arrest or cell 
death (Figure 5-3, dotted line). We characterized these curves based on a standard log-scale 
normalized response equation: 
  𝑓(𝑥) = 	 7(7B7C(DEFGHI))   (1).  
We next compared calculated EC50 values between drug treatment panels (Table S5-1). In 
particular, the ability of QPI to identify multiple cancer cell fates enables the characterization of 
mitotic inhibitors for both sensitivity, represented by a low average EC50 value, as well as 
avoidance of undesirable fates. The concentration window in which undesirable fates occur is 
described by ΔEC50 = EC50,death – EC50,growth. Therefore, QPI also enables the identification of 
mitotic inhibitors with a low ΔEC50, indicating a small concentration window that results in 
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undesirable cell fates. When comparing ΔEC50 between inhibitors and cell lines, we used 
normalized value of ΔEC50/EC50,growth because relative ΔEC50 shows the impact of concentration 
variance relative to the target dose of a specific inhibitor (Table S5-1). Colchicine had the smallest 
relative ΔEC50, for both HeLa cells (0.35) and M202 cells (0.72) (Figure 5-3B, 5-3E). This result 
is consistent with previous results showing that colchicine induces negligible or low amounts of 
aneuploidy.6 Paclitaxel showed a slightly larger relative ΔEC50 for both HeLa cells (1.1) and M202 
cells (2.0), due to the increase in multipolar divisions and endocycling events compared to 
colchicine (Figure 5-3A, 5-3D). VX-680 presented by far the largest relative ΔEC50 for HeLa cells 
(110) and M202 cells (17), due to a large proportion of endocycling events (Figure 5-3C, 5-3F).
Lastly, Kolmogorov-Smirnov test results show that bipolar divisions and prolonged mitotic arrest 
or cell death dose response distributions statistically differ (Table S5-1), with the exception of 
M202 cells under increasing paclitaxel doses (p = 0.052).   
To confirm that a wide range of VX-680 dosing generates QPI detected endocycling, as 
predicted by a large ΔEC50, we analyzed the DNA content of HeLa and M202 cells exposed to 
VX-680 using flow cytometry (Figure S5-2). As an example, there was a large increase in the 
number of cells with 4n DNA compared to those with 2n DNA in cells exposed to 300nM and 
600nM VX-680. A small population of HeLa cells with 8n DNA content emerged at 300nM VX-
680 that dramatically increased with 600nM VX-680 (Figure S5-2C–F), in agreement with the 
features of endocycling.22 
Comparing EC50,growth and EC50, death to conventional EC50 from live cell counting assays 
In parallel, we performed live cell counting assays for HeLa and M202 cancer cells exposed 
to paclitaxel, colchicine, and VX-680 at 24 hours and multi-day timepoints (Figure S5-3, S5-4). 
As anticipated, these agents markedly reduced the accumulation of cancer cells at 24 hours and 
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over 6 days (Figure S5-3, S5-4). Growth inhibition studies are the standard for drug development, 
although drug effects beyond changes in total live cell numbers were indiscernible. It is important 
to note that EC50 values from live cell counting assays are defined by concentrations at which the 
total number of live cells present in the treatment well is 50% of the total number of live cells 
present in the control well. Whereas, EC50 values from QPI analysis are defined by concentrations 
at which 50% of the sampled cells in a specific treatment undergo a certain cell fate within the first 
division after treatment. When compared to QPI measured EC50 values, live cell counting EC50 
values are therefore on the same or nearest log scale, but greater than both EC50,Growth and EC50,Death 
for paclitaxel and colchicine treatments. However, in the case of VX-680, many endocycling 
events occur that do not lead to immediate cell deaths. This leads to large differences between 
EC50,Growth and EC50,Death values measured by QPI. The EC50 measured by live cell counting assay 
falls in the middle of the two on the log scale. This result therefore indicates that the QPI EC50,Growth 
and EC50,Death correspond differently to the standard live cell counting EC50 for different mitotic 
inhibition mechanisms. 
We also assessed whether inhibitor dosage statistically associates with outcome by 
applying chi-square tests of independence for each cancer cell type and drug combination (Figure 
5-3). Our analyses show that within each of the six cancer cell-drug treatment pairings, cell fate
outcomes were dose-dependent. Increasing dose shifts cell fate distributions from mostly 
successful bipolar divisions to mostly mitotic arrests and deaths (p < 0.0001 for each condition) 
(Table S5-2). For example, HeLa cells showed a range of outcomes at lower doses of paclitaxel 
and VX-680 (Figure 5-3A, 5-3C). At 10 nM of paclitaxel, a dose between the two observed QPI 
EC50 values, all outcomes except endocycling occurred, with only a small amount of endocycling 
appearing at slightly higher drug concentrations (Figure 5-3A). By contrast, the majority of HeLa 
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cells endocycle at all VX-680 
concentrations within the first 24 
hours of treatment, whereas 
prolonged mitotic arrest or cell 
death increased in outcome 
frequency only at 600nM VX-
680. This concentration is 4-12
times higher than the 
recommended effective dose (50 
– 150nM) in vitro against thyroid
and blood-cancer cell lines 
(Figure 5-3C),23, 24 yet well 
within the range of mean plasma 
concentration of the maximum-
tolerated dose (64 mg/m2-h)  in 
patients, determined in phase I 
clinical trial.25 
Analyzing correlation between 
mitosis durations and cell fate 
outcomes 
Finally, there has been 
debate over whether the duration 
of mitosis during anticancer drug 
Figure 5-9 Cell fate responses and mitosis durations 
A) Time spent in mitosis for HeLa single cells with colchicine
exposure. The length of each color bar indicates the amount of time
spent in mitosis for that individual cell. The color of the bar
corresponds to its cell fate outcome. B) Time spent in mitosis for
HeLa single cells with palitaxel exposure. C) Time spent in mitosis
for HeLa single cells with VX-680 exposure. D) Box plot of time
spent in mitosis for five cell fate outcomes. One-way ANOVA with
unbalanced sample groups was performed comparing all samples.
There are statistically significant differences between the mean
values of mitosis durations for different cell fate outcomes (p =
1.8E-54).
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exposure affects cancer cell outcomes.10, 26 This data is quantifiable from QPI data showing the 
period from onset of mitosis to scored cell outcomes.3, 10 Single HeLa cell tracking data show that 
time spent in mitosis statistically differ between cell fate outcomes (p = 1.8e-54). Multipolar 
divisions, cell death, or arrest are frequent outcomes of extended mitosis time, whereas 
endocycling usually results from shorter periods of mitosis (Figure 5-4). For M202 cells, even 
though the mean values of time spent in mitosis for cell fate outcomes are statistically different (p 
= 2.3e-4), there is no significant trend for mitosis durations between outcomes categories (Figure 
S5-5). Mitosis durations less than 100 minutes more frequently (45% for HeLa and 34% for M202) 
resolve as drug insensitivity with successful bipolar cell divisions compared to other fates in both 
cell lines (Figure 5-4D, S5-5D). These data clearly reveal variability in responses to the same 
mitotic inhibitor treatments from different cancer cell lines. Thus, QPI-derived outcomes 
classifications reinforce the importance of studying responses in multiple cancer cell lines and 
types during preclinical drug development that may correspond to differences in personalized 
responses to different treatment agents and regimens for individuals with cancer. 
Discussion and Conclusion 
Changes in cell biomass as a response indicator for screening cancer drugs has gained 
traction in recent years because of multiple technological breakthroughs.14, 16, 17, 27-29 A common 
thread in this emerging area is the increasing linkage between biomass accumulation rates with 
traditional measures of drug efficacy and preclinical outcomes of growth inhibitors in many types 
of modeled malignancies. QPI methods in particular are providing additional biophysical insights 
based on changes in cell morphology during studies of cell division and cancer-immune cell 
interactions.18, 30 Here, we expanded the application spectrum for quantitative phase methods by 
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combining biomass and morphological analyses in studies of the pharmacodynamic characteristics 
of small molecule mitotic inhibitors against two types of cancer.  
We showed that during exposure to mitotic inhibitors QPI classification into three outcome 
Groups yields useful concentration windows in which undesirable fates that include multipolar 
cell divisions and endocycling occur, as described by ΔEC50. Cancer cells exposed to inadequate 
mitotic inhibitor concentrations resolve transient cell cycle arrest by apoptosis or ‘mitotic slippage’ 
to resume growth and cycling 31, which can result in chromosome abnormalities such as aneuploidy 
and tetraploidy.32 Numerical and structural chromosome aberrations, which often occur with 
multipolar cell divisions and endocycling, may contribute to increased therapy resistance 33 
through a range of molecular mechanisms.7, 8 Aneuploidy paradoxically can promote or suppress 
tumor growth and may cause an elevated rate of tumor recurrence by generating drug-resistant 
heterogeneity with evolving growth and survival advantages.33, 34 Tetraploid cells and cells with 
certain chromosomal rearrangements act as intermediates to further chromosome instability and 
the development of aneuploidy.7 Unfortunately, tetraploidy and chromosomal aberrations that can 
contribute to therapy resistance have also been linked to mitotic inhibitor exposure at sub-lethal 
concentrations.6 It has been shown that mitotic slippage occurs far more frequently in vivo than in 
vitro, suggesting possible underestimation of Group 3 outcomes with QPI compared to 
inefficacious agents and malignancy augmentation that may occur in patients.35 Interestingly, 
proteotoxic and metabolic stress are reported for aneuploid cells,36 which may result from 
multipolar divisions and endocycling events identified using our QPI methods.  
Inhibitor mechanisms, concentrations, and mitotic arrest duration are major determinants 
of cancer cell outcomes following escape from mitotic arrest.26, 37, 38 Our QPI approach analyzed 
these key characteristics for different mitotic inhibitors. Because of off-target cytotoxicity, mitotic 
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inhibitors typically have low therapeutic indices that can limit clinical dosages 36 and cause 
abnormal exits with viable cells containing chromosomal abnormalities.6, 37 In vivo, this 
undesirable outcome can occur in under-dosed or poorly perfused tumors and potentially 
jeopardizes clinical outcomes by adding to therapy resistance and tumor aggressiveness.  
In vitro multi-day growth inhibition binary assays yield a single EC50 curve that overlooks 
a range of potential mitotic slippage events that add to chromosomal aberrations. Advances in non-
QPI techniques such as in vivo microscopy and real time FUCCI imaging enable quantifying 
mitotic exits for a small number of cells.39, 40 Additional methods, such as microchannel resonators, 
have limitations in measurement longevity and are low throughput. By contrast, the QPI method 
exposed differences in outcomes between a microtubule-destabilizing agent, paclitaxel, a 
microtubule-stabilizing agent, colchicine, and a cell division inhibitor, VX-680. Our decision tree 
algorithm provided five cancer cell outcome categories and three subjective Groups to enable 
determination of dual EC50 curves for each drug and tumor cell type examined. For a particular 
drug and tumor type, the extent of EC50 value separation, ΔEC50, predicts the likelihood of 
undesirable multipolar divisions or endocycling that can result in aneuploidy and increased therapy 
resistance, providing useful concentration ranges to avoid in which aberrant mitotic exits prevail. 
QPI analyses revealed that HeLa and M202 bipolar divisions from drug failure show the 
shortest mitosis periods, consistent with previous studies in which prolonged mitotic arrest resulted 
in hypersensitivity to additional death cues.26 Additional studies showed several existing 
chemotherapeutics that induce apoptosis at normal dosages can trigger mitotic catastrophe that 
directly lead to apoptosis at very low dosages in aneuploid and polyploid cells.41 This can 
dramatically increase chemotherapeutic tolerance in patients and hint at effective combinatorial 
therapies in cancer treatments using mitotic inhibitors. Therefore, future QPI studies include 
Twelve-well flat bottom plates (Thermo Fisher Scientific) received 5 x 104 cells/well. 
Paclitaxel (Sigma-Aldrich), colchicine (Sigma-Aldrich), or VX-680 (Selleckchem) small molecule 
mitotic inhibitors, or DMSO (Sigma-Aldrich) carrier-control, were added to cell culture media at 
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screens for cell fate outcomes under combined exposure of energy stressors or low dose 
chemotherapeutics and mitotic inhibitors that induce aneuploidy.  
In conclusion, we demonstrate a novel application of QPI in screening and identifying 
aberrant cell fate outcomes as a result of suboptimal mitotic inhibitor doses. Conventional growth 
inhibition assays rely on live cell counting to generate EC50 values that infer pharmacokinetics of 
mitotic inhibitors, and fail to reveal vital information on negative effects of the inhibitors. QPI 
analyzes cell fate outcome profiles, EC50,Growth, and EC50,Death values that provide in-depth insights 
into mechanism of action and risky dosing windows of mitotic inhibitors. Importantly, this QPI 
technique is compatible with patient derived organoids that resemble heterogeneous patient tumors 
better than in vitro single cell type cultures. Screening mitotic inhibitor cocktails on tumor 
organoids with QPI can facilitate the development of next generation cancer therapies. 
Methods 
Cells and cell culture 
HeLa human cervical adenocarcinoma cells were from the American Type Culture 
Collection (ATCC) and M202 human melanoma cells were a gift from Dr. Owen Witte (UCLA). 
HeLa cells were maintained in 1:1 DME/F-12 media (Thermo Fisher Scientific) and M202 cells 
were maintained in RPMI 1640 media (Thermo Fisher Scientific), with each media supplemented 
by 10% FBS (Omega Scientific), 100 U/mL penicillin (Corning), 100 µg/mL streptomycin 
(Corning) and 2 mmol/l-glutamine (Thermo Fisher Scientific). 
Growth inhibition assay 
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the indicated doses and durations (Figure S5-3, S5-4). Cells from three replicate wells per 
treatment condition were harvested each day, stained with trypan blue, and counted using an 
automated cell counter (Countess; Invitrogen). 
Cell preparation for QPI 
ibidi 4-well Ph+ µ-slides received 1.5x104 cells/mL that were then grown for 7-10 h to 
homeostasis. Media containing 2mM thymidine (Sigma-Aldrich) was added to arrest HeLa cells 
in G0/G1 phase for 18 h and M202 cells for 20 h. Synchronized cells were released from cell cycle 
block by media washing three times. Fresh media with the indicated doses of paclitaxel, colchicine, 
VX-680, or DMSO were then added to the 4-well µ-slide and then sealed with anti-evaporation oil 
(ibidi) before QPI on the microscope stage.  
Live cell interferometry 
QPI of HeLa and M202 cells was performed on an Axio Observer A1 inverted microscope 
(Zeiss) with a SID4Bio quadriwave lateral shearing interferometry (QWLSI) camera (Phasics). A 
temperature and CO2 regulated stage-top cell incubation chamber (ibidi) was fit to a motorized xy 
stage (Thorlabs) to maintain environmental homeostasis and enable QPI at multiple locations. A 
Zeiss LD Plan Neofluar 20x NA 0.4 objective was heated and maintained at 37oC with a custom 
built copper objective heater driven by a heat controller (Thorlabs). Trans-illumination was by a 
660 nm center wavelength collimated LED (Thorlabs). Image collection occurred every 10 min 
for 24 h at 15 imaging locations per well containing cells plated with sufficient spacing to enable 
automated image processing and biomass segmentation. 
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QPI data analysis 
Interferograms captured by the SID4Bio QWLSI camera were converted to phase-shift and 
intensity images using the Phasics MATLAB software development kit. These images were 
analyzed using custom MATLAB (MathWorks) scripts that eliminated background aberrations by 
fitting a 4th order Zernike surface to cell-free regions and subtracting the fitted surface from the 
image. Cell biomass data was extracted from background corrected images by integrating light 
phase-shift in segmented cell projected areas and multiplying by the experimentally determined 
specific refractive increment of 0.001812, 42, 43 
Morphology metrics 
Mean phase shift: The mean phase-shift of a cell is obtained by dividing the total integrated 
phase- shift for that particular cell by its projected area.  Interphase flat and spread-out versus 
round and mitotic phase HeLa cells were sampled to establish average mean phase-shift values for 
both morphologies. Since HeLa and M202 cells share comparable sizes, morphologies, optical 
densities and the same tracking criteria for the MATLAB tracking algorithm, the same average 
mean phase- shift values are representative for both cell types (Figure S5-3). Shape factor: The 
shape factor of a cell, also called circularity or isoperimetric quotient, is calculated by dividing the 
projected area, A, of a cell by its circumference or the length of its perimeter, P, (4πA/P2). Random 
flat HeLa and M202 cells and mitotic HeLa cells were sampled to establish average shape factor 
values for both morphologies (Figure S5-3). A perfect circle has a shape factor of 1.0 and an 
irregular shape, such as an interphase adherent cell, has a shape factor of approximately 0.5 
(Figure S5-3).   
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Flow cytometry 
Cells were collected from T25 flasks after 24 and 48 h of drug exposure, washed once with 
1x PBS, pH 7.4, and then re-suspended in 500µL of FxCycle™ PI/RNase Staining Solution 
(Thermo Fisher Scientific). Flow cytometry was performed on FACS BD LSRII and FACS BD 
Fortessa flow cytometers (BD Biosciences). DNA content analysis was by FlowJo software.  
Statistical analysis 
Chi-square tests of independence were performed on contingency tables assessing the 
observed cell fate counts per inhibitor dosage for significant association relative to expected counts 
in each drug treatment panel with a 95% confidence interval (Prism 6, GraphPad, Inc.). Dose 
response curve-fitting was performed using the curve fitting toolbox in MATLAB (MathWorks). 
Two-sample Kolmogorov-Smirnov (KS) tests were performed between bipolar cell division versus 
prolonged mitotic arrest and cell death fate distributions for each drug treatment panel in 
MATLAB with a 95% confidence interval. One-way ANOVA with unbalanced sample groups 
was performed on duration of mitosis datasets between cell fate groups in MATLAB with a 95% 
confidence interval. Statistical significance required p < 0.05. 
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A B 
Supplementary Figure S5-1 Mean phase-shift and shape factor thresholds 
A) Mean phase-shift and shape factor values for flat and mitotic HeLa cells. Thresholds set at 140
for mean phase- shift and 0.7 for shape factor. B) Mean phase-shift and shape factor values for flat
and mitotic M202 cells. Same thresholds also apply to these cells.
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HeLa carcinoma cells M202 melanoma cells 
Supplementary Figure S5-2 Flow cytometry analysis of QPI-defined endocycling cells 
A) DNA content profile of HeLa cells in media control condition. B) DNA content profile of HeLa cells
in DMSO (0.1%) control condition. C) DNA content profile of HeLa cells in 300nM of VX-680, 24 h.
D) DNA content profile of HeLa cells in 600nM of VX-680, 24 h. E) DNA content profile of HeLa
cells in 300nM of VX-680, 48 h. F) DNA content profile of HeLa cells in 300nM of VX-680, 24 h. G)
DNA content profile of M202 cells in media control condition. H) DNA content profile of M202 cells
in DMSO (0.1%) control condition. I) DNA content profile of M202 cells in 300nM of VX-680, 24 h.
J) DNA content profile of M202 cells in 600nM of VX-680, 24 h. K) DNA content profile of M202
cells in 300nM of VX-680, 48 h. L) DNA content profile of M202 cells in 300nM of VX-680, 24 h.
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Supplementary Figure S5-3 EC50 Values from Live Cell Counting After 24-hour Drug 
Treatments  
Data points indicate average cell counts across three technical replicates. Error bars indicate standard 
deviation of the three technical replicates. A) Live cell counting assay for HeLa cells after 24 hours 
of paclitaxel treatment. B) Live cell counting assay for M202 cells after 24 hours of paclitaxel 
treatment. C) Live cell counting assay for HeLa cells after 24 hours of colchicine treatment. D) Live 
cell counting assay for M202 cells after 24 hours of colchicine treatment. E) Live cell counting assay 
for HeLa cells after 24 hours of VX-680 treatment. F) Live cell counting assay for M202 cells after 
24 hours of VX-680 treatment. 
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Supplementary Figure S5-4 Multi-day Cell Counting Assays 
Data points indicate average cell counts across three technical replicates. Error bars 
indicate standard deviation of the three technical replicates. A) Multi-day cell counting 
assay for HeLa cells under paclitaxel treatment. B) Multi-day cell counting assay for 
M202 cells under paclitaxel treatment. C) Multi-day cell counting assay for HeLa cells 
under colchicine treatment. D) Multi-day cell counting assay for M202 cells under 
colchicine treatment. E) Multi-day cell counting assay for HeLa cells under VX-680 
treatment. F) Multi-day cell counting assay for M202 cells under VX-680 treatment. 
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Supplementary Figure S5-5 M202 cells division time visualization 
A) Time spent in mitosis for M202 single cells with colchicine exposure. The length of each
color bar indicates the amount of time spent in mitosis for that individual cell. The color of the
bar corresponds to its cell fate outcome. (B) Time spent in mitosis for M202 single cells with
palitaxel exposure. (C) Time spent in mitosis for M202 single cells with VX-680 exposure.
(D) Box plot of time spent in mitosis for five cell fate outcomes. One-way ANOVA with
unbalanced sample groups performed in MatLab provide a p-value of 2.30E-4.
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Supplementary Table S5-1 Drug response curve fitting, EC50 values and Kolmogorov-Smirnov test 
p-values
Data Group EC50 (nM) 95% Confidence Bounds (nM) R-square DEC50 (nM) KS Test p-value 
HeLa_Colchicine_Division_Rate EC50,Growth = 6.53 (2.67, 15.96) 0.9791 
2.25 0.00075491 
HeLa_Colchicine_Death/Arrest_Rate EC50,Death = 8.78 (2.53, 30.48) 0.9492 
HeLa_Paclitaxel_Division_Rate EC50,Growth = 7.32 (4.33, 12.39) 0.9784 
8.31 0.0369 
HeLa_Paclitaxel_Death/Arrest_Rate EC50,Death = 15.63 (7.17, 34.12) 0.9239 
HeLa_VX-680_Division_Rate EC50,Growth = 8.37 (1.92, 36.31) 0.9855 
927.04 2.9256E-30 
HeLa_VX-680_Death/Arrest_Rate EC50,Death = 935.41 (695.02, 1256.03) 0.961 
M202_Colchicine_Division_Rate EC50,Growth = 7.4 (2.59, 21.18) 0.854 
5.34 0.0129 
M202_Colchicine_Death/Arrest_Rate EC50,Death = 12.74 (5.50, 29.51) 0.8791 
M202_Paclitaxel_Division_Rate EC50,Growth = 1.51 (1.20, 1.90) 0.9788 
2.96 0.0524 
M202_Paclitaxel_Death/Arrest_Rate EC50,Death = 4.47 (1.96, 10.19) 0.7976 
M202_VX-680_Division_Rate EC50,Growth = 46.77 (17.86, 122.18) 0.8327 
808.30 2.5882E-16 
M202_VX-680_Death/Arrest_Rate EC50,Death = 855.07 (480.84, 1524.05) 0.8799 
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Table Analyzed 
HeLa 
(Colchicine) 
HeLa 
(Paclitaxel) 
HeLa 
(VX-680) 
M202 
(Colchicine) 
M202 
(Paclitaxel) 
M202 
(VX-680) 
Chi-square 607.7 302 381.9 543.5 502 517 
df 20 16 9 20 24 15 
p-value < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
p-value summary **** **** **** **** **** **** 
One- or two-tailed NA NA NA NA NA NA 
Statistically significant? (alpha<0.05) Yes Yes Yes Yes Yes Yes 
Number of rows (Concs.) 6 5 4 6 7 6 
Number of columns (Fates) 5 5 4 5 5 4 
Supplementary Table S5-2 Chi-square test results for cell fate distribution (Prism 6, Graphpad) 
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Chapter 6  
TOPOLOGICAL ARRANGEMENT OF CARDIAC 
FIBROBLASTS REGULATES CELLULAR 
PLASTICITY 
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Cardiac fibroblasts develop from epithelial–mesenchymaltransition of epicardial cells during cardiac development.1 
After adoption of the mesenchymal phenotype, they migrate into 
the developing myocardium and as the myocardium compacts, 
they get trapped between the myocyte interstitium to become res-
ident cardiac fibroblasts. This topological arrangement of fibr -
blasts and myocytes persists throughout postnatal life. However, 
this spatial relationship is disrupted after acute myocardial ne-
crosis, when fibroblasts are recruited to, proliferate and aggre-
gate in the region of injury, resulting in a much higher density of 
fibroblasts in the region of necrosis.2 Aggregating fibroblasts in 
the region of injury are known to express gap junctions that fa-
cilitate intercellular communication between physically apposed 
fibroblasts 3 Tumor cells and cancer cell lines, when cultured in 
3-dimensional (3D) conditions to promote aggregation exhibit 
altered phenotypic features such as migration, proliferation, and 
chemo resistance associated with changes in gene expression 
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Cellular Biology
Topological Arrangement of Cardiac Fibroblasts Regulates 
Cellular Plasticity
Jingyi Yu,* Marcus M. Seldin,* Kai Fu,* Shen Li, Larry Lam, Ping Wang, Yijie Wang,  
Dian Huang, Thang L. Nguyen, Bowen Wei, Rajan P. Kulkarni, Dino Di Carlo, Michael Teitell, 
Matteo Pellegrini, Aldons J. Lusis, Arjun Deb
Rationale: Cardiac fibroblasts do not form a syncytium but reside in the interstitium between myocytes. This topological
relationship between fibroblasts and myocytes is maintained throughout postnatal life until an acute myocardial injury 
occurs, when fibroblasts are recruited to, proliferate and aggregate in the region of myocyte necrosis. The accumulation 
or aggregation of fibroblasts in the area of injury thus represents a unique event in the life cycle of the fibroblast, but little 
is known about how changes in the topological arrangement of fibroblasts after cardiac injury affect fibroblast function.
Objective: The objective of the study was to investigate how changes in topological states of cardiac fibroblasts
(such as after cardiac injury) affect cellular phenotype.
Methods and Results: Using 2 and 3-dimensional (2D versus 3D) culture conditions, we show that simple
aggregation of cardiac fibroblasts is sufficient by itself to induce genome-wide changes in gene expression and 
chromatin remodeling. Remarkably, gene expression changes are reversible after the transition from a 3D back 
to 2D state demonstrating a topological regulation of cellular plasticity. Genes induced by fibroblast aggregation 
are strongly associated and predictive of adverse cardiac outcomes and remodeling in mouse models of cardiac 
hypertrophy and failure. Using solvent-based tissue clearing techniques to create optically transparent cardiac scar 
tissue, we show that fibroblasts in the region of dense scar tissue express markers that are induced by fibroblasts 
in the 3D conformation. Finally, using live cell interferometry, a quantitative phase microscopy technique to detect 
absolute changes in single cell biomass, we demonstrate that conditioned medium collected from fibroblasts in 3D 
conformation compared with that from a 2D state significantly increases cardiomyocyte cell hypertrophy.
Conclusions: Taken together, these findings demonstrate that simple topological changes in cardiac fibroblast
organization are sufficient to induce chromatin remodeling and global changes in gene expression with potential 
functional consequences for the healing heart.  (Circ Res. 2018;123:73-85. DOI: 10.1161/CIRCRESAHA.118.312589.)
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profiles 4 However, little is known about how spatial rearrange-
ment of fibroblasts such as that occurs after acute myocardial 
injury affects the cellular and genetic outputs of the fibroblas  
and the cardiac wound healing response.
Methods
All data and supporting materials are within the article and in the 
Online Data Supplement. In addition, RNA-seq and assay for trans-
posase accessible chromatin (ATAC-seq) data for the study are 
available in National Center for Biotechnology Information’s Gene 
Expression Omnibus and have been made publicly available through 
GEO series accession number GSE113277 at https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE113277.
Cardiac fibroblasts were isolated from adult wild-type mice 
(both male and female) as well as Col1a2CreERT:R26Rtdtomato and 
TCF21MerCreMer:R26Rtdtomato as described.5 Isolated cardiac fibr -
blasts (<3 passages) were grown on standard polystyrene coated 
tissue culture plates (2D; plates not coated with collagen or other ma-
trix proteins) or seeded onto ultra-low attachment plates (not coated 
with any extracellular matrix protein), whereby they formed spheres 
within 24 hours of seeding (3D). Subsequently, the cardiac fibroblasts
were again transferred back to regular tissue culture plates, on which 
the spheres attached and fibroblasts migrated out of the spheres to 
form monolayers within 4 to 5 days (3D-2D). Reseeding of the   -
broblasts onto ultra-low attachment plates again resulted in forma-
tion of spheres within 24 hours (3D-2D-3D). Fibroblasts in 2D or 
3D maintained for 5 days served as temporally adjusted controls 
for 3D-2D states. 3D-2D fibroblasts trypsinized and reseeded onto 
2D states served as additional controls for 3D-2D-3D states. RNA-
seq and ATAC-seq were performed at each topological state of the 
cardiac fibroblast and on temporally adjusted controls for each time 
point. Transcripts upregulated in 3D states were correlated to clini-
cal traits across a mouse population (Hybrid Mouse Diversity Panel 
[HMDP]) after isoproterenol infusion.6 Cardiac fibroblasts were also 
seeded onto tissue culture plates of varying stiffness (0.5 kPa, 8 kPa, 
and 64 kPa elastic moduli) to determine whether 2D-3D gene expres-
sion changes were recapitulated by modulating substrate stiffness. 
Optical transparency of the heart was performed with solvent-based 
tissue clearing7 and imaging performed with a Nikon C2+ confocal 
microscope. Immunofluorescent staining was performed using stan-
dard methods.5 Conditioned medium was collected from 2D or 3D 
cardiac fibroblasts exactly 24 hours after initial seeding. Live cell 
interferometry was performed to track changes in cell biomass of 
single neonatal rat ventricular cardiomyocytes (NRVM) with 2D or 
3D conditioned medium.
Results
To determine whether aggregation of cardiac fibroblasts af-
fects the cellular phenotype, we first created a scaffold-free 
3D system using ultra-low attachment tissue culture dishes 
where a covalently bonded hydrogel layer on the surface of 
the dish prevents cell attachment.8 Cardiac fibroblasts were 
isolated from adult mice, and cells that had not undergone >3 
passages were used for experiments. Seeding of primary adult 
mouse cardiac fibroblasts onto ultra-low attachment dishes 
resulted in fibroblasts aggregating together within 24 hours 
to form 3D spherical clusters (Figure 1A and 1B). To con-
firm that cardiac fibroblasts alone were capable of forming 
these spherical clusters, we next isolated cardiac fibroblast  
from uninjured hearts of TCF21MerCreMer:R26RtdTomato and 
Col1a2CreERT:R26RtdTomato mice.5,9,10 We and others have 
shown that the inducible Cre drivers are specific for genetic 
Nonstandard Abbreviations and Acronyms
Acta2 alpha-smooth muscle actin 2
ADAMTS15 metallopeptidase with thrombospondin motif 15
ATAC 
Cnn2 
CTGF 
CTNNB1 
GPNMB 
HMDP 
MITF 
MMP 
NRVM 
PC 
SRF 
assay for transposase accessible chromatin
calponin 2
connective tissue growth factor
beta-catenin
glycoprotein nonmetastatic B
Hybrid Mouse Diversity Panel
microphthalmia-associated transcription factor
matrix metalloproteinase
neonatal rat ventricular cardiomyocytes
principle component
serum response factor
Novelty and Significance
What Is Known?
• Unlike cardiac myocytes, cardiac fibroblasts do not form a syncytium
but reside in the interstitium among myocytes.
• This topological relationship is altered after heart injury when fibro-
blasts are recruited to an aggregate at the area of injury.
• Aggregation of fibroblasts after injury thus represents a unique event
in the life cycle of the cardiac fibroblast but whether such topological
rearrangement affects fibroblast function is not clear.
What New Information Does This Article Contribute?
• Aggregation of cardiac fibroblasts leads to global changes in gene ex-
pression and chromatin reorganization.
• Changes in the transcriptome are reversible on aggregation, disag-
gregation, and reaggregation of cardiac fibroblasts.
• Genes induced by fibroblast aggregation are expressed in the injured
heart and correlate with poor cardiac outcomes in mouse models of
hypertrophy and heart failure.
• The secretome of aggregated cardiac fibroblasts can induce hypertro-
phy of cardiac myocytes.
Cardiac fibroblasts reside in the interstitium of the heart and do 
not form a syncytium. After the injury, they, however, are recruited 
to aggregate in the area of injury, but the physiological signifi-
cance of fibroblast aggregation remains unknown. Here, we dem-
onstrate that simple aggregation of cardiac fibroblasts induces 
widespread changes in gene expression and chromatic reorga-
nization. Such transcriptional changes are reversible when car-
diac fibroblasts are disaggregated or subsequently reaggregated. 
Genes upregulated in the aggregated state are expressed in the 
region of injury and correlate with indices of adverse cardiac re-
modeling in murine models of cardiac hypertrophy and failure. 
Finally, we demonstrate that the secretome of aggregated cardiac 
fibroblasts induces hypertrophy of cardiac myocytes. Taken to-
gether these observations demonstrate that topological changes 
in the spatial organization of cardiac fibroblasts drives chromatin 
reorganization, gene expression patterns and has functional con-
sequences for cardiac wound healing.
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Figure 1. Cardiac fibroblasts exhibit dynamic changes in gene expression in different topological states. A, Schematic of how fibroblasts 
were transitioned from a 2-dimensional (2D) to 3D state and then back to 2D and 3D, respectively. For each topological state, fibroblasts were 
harvested for RNA-seq. B, Bright phase image of cardiac fibroblasts in 2D and 3D (scale bar: 50 µm). C, Pure population of genetically labeled 
(tdTomato) fibroblasts isolated by flow cytometry from hearts of TCF21MerCreMer:R26Rtdtomato or Col1a2CreERT:R26Rtdtomato mice were subjected to 
sphere formation (3D) and spheres stained with wheat germ agglutinin (WGA), that stains cell membranes (scale bar: 20 µm). D, Cardiac fibroblasts 
in 2D or 3D states dissociated and subjected to image flow cytometry showing representative image of fibroblast from 2D or 3D state (3000 cells 
imaged in each group, scale bar: 10 µm) and corresponding mean diameter and surface area of fibroblasts in 2D or 3D states (*P<0.001, mean±SEM, 
n=3). E, Heat map demonstrating clustering of sample correlations of fibroblasts (shown by Z scores) in different topological states. F and G, 
Heat map comparing (F) expression of the most upregulated 3D genes in different topological states and (G) 3D downregulated genes in different 
topological states (H) gene ontology analysis showing cellular pathways most affected by genes upregulated or downregulated in 2D/3D states.
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labeling of cardiac fibroblasts after tamoxifen administration. 
Similar to cardiac fibroblasts from wild-type animals, geneti-
cally labeled cardiac fibroblasts within 24 hours of seeding 
onto ultra-low attachment plates also formed spherical clus-
ters confirming the ability of cardiac fibroblasts to form 3D 
spherical aggregates under defined conditions (Figure 1C). 
Imaging Flow cytometry11 demonstrated that aggregation 
into a 3D state resulted in significantly smaller small cell 
size (cell diameter: 22.45±0.30 um in 2D versus 18.41±0.26; 
mean±SEM; P<0.001) and surface area (449.85±3.05 μm2 in 
3D versus 297.97±8 μm2; mean±SEM; P<0.001; Figure 1D) 
suggestive of cellular remodeling as fibroblasts adopt the 
3D state. To determine whether a switch from a 2D to a 3D 
state changes fibroblast phenotype, we first compared global 
gene expression changes by RNA-seq between cardiac   -
broblasts cultured under standard 2D conditions on regular 
tissue culture dishes and 3D conditions as mentioned above 
(Figure 1A). For this purpose, cardiac fibroblasts were seeded 
onto standard tissue culture plates or ultra-low attachment 
plates with similar seeding density and identical cell culture 
medium and cells were harvested 24 hours later for gene 
expression analysis. To ask whether observed changes were 
reversible, we transferred 3D cardiac fibroblasts to regular 
tissue culture plates to put them back in 2D conditions (group 
termed 3D-2D; Figure 1A). Spherical clusters of 3D fibr -
blasts attached to regular tissue culture plates and the fibr -
blasts migrated from spherical cluster to a monolayer within 
4 to 5 days. We again determined gene expression of 3D-2D 
fibroblasts (after transition from 3D to a monolayer) to deter-
mine whether the gene expression pattern reverted to that of 
the 2D state (Figure 1A). Finally, cardiac fibroblasts which 
had been grown under 3D conditions and then transferred to 
2D conditions (3D-2D) were put back under 3D conditions 
(group termed 3D-2D-3D). Sphere formation occurred with-
in 24 hours of reseeding on ultra-low attachment plates, and 
RNA-seq was performed to determine whether readoption of 
the 3D state was associated with gene expression signatures 
flipping back to the 3D state (Figure 1A). These experiments 
would thus determine whether changes in topological states 
or spatial arrangement of cardiac fibroblasts are associated 
with reversible and dynamic changes in gene expression. 
RNA-seq was performed for all the different topological 
states of the cardiac fibroblast and clustering of sample corre-
lations demonstrated a grouping of all 2D fibroblast states and 
a separate grouping of 3D fibroblast states (Figure 1E). The 
gene expression profile of 2D cardiac fibroblasts was like that 
of the 3D-2D fibroblast group, whereas the gene expression 
profile of 3D fibroblasts was like that of the 3D-2D-3D group 
(Figure 1E). We observed a remarkable dynamic and revers-
ible plasticity between the 2D and 3D states (Online Table I; 
Figure 1F and 1G). Out of 997 genes that were upregulated in 
3D fibroblasts, expression of 996 genes reverted back when 
the 3D fibroblasts were transitioned back to the 2D state (3D-
2D group) and reinduced after transition to 3D (3D-2D-3D 
group; Figure 1F). Similarly, genes downregulated in 3D 
state exhibited increased expression after transition to the 
2D state (3D-2D group) and silencing on transitioning back 
to 3D (3D-2D-3D group; Figure 1G). To adjust for potential 
temporal changes in gene expression, the gene expression 
pattern of the 3D-2D group was also compared with that of 
2D and 3D fibroblasts cultured for 5 days. A cluster analysis 
demonstrated distinct clustering of 2D and 3D states (Online 
Figure IA). In addition, for the 3D-2D-3D group, temporally 
adjusted controls of 3D-2D cells lifted and reseeded back 
onto 2D instead of 3D conditions was also used (Online 
Figure IB). Again, cluster analysis demonstrated distinct 2D 
and 3D states making it unlikely that differential gene expres-
sion was simply secondary to temporal dependent changes in 
gene expression of cardiac fibroblasts in culture
We next examined whether dynamic changes in gene 
expression in different topological states can be simply ex-
plained by sudden changes in substrate stiffness as the fibr -
blasts transition from a 2D adherent state to a 3D spherical 
nonadherent state. To answer this question, we seeded cardiac 
fibroblasts onto tissue culture plates coated with biocompat-
ible silicone controlled elastic moduli recapitulating environ-
ments similar to tissue.12 We seeded cardiac fibroblasts on 
tissue culture plates with stiffness of 0.8 kPa, 8 kPa, and 64 
kPa (Online Figure IIA) and following 24 hours of seeding, 
harvested the cells to compare changes in gene expression to 
that of 2D and 3D topological states. Analysis of global gene 
expression demonstrated a clustering of 2D states with that of 
cells seeded at different substrate stiffness (0.5, 8, and 64 kPa) 
and were distinct from gene expression signature of cardiac 
fibroblasts in 3D states (Online Figure IIB). We specifically
examined the set of genes that displayed the highest degree 
of differential expression between 2D and 3D states and ob-
served that the expression pattern of such genes was similar 
between cells seeded at 0.8, 8, and 64 kPa and 2D states and 
distinct from that seen in 3D states (Online Figure IIC and 
IID). Taken together, these observations suggest that topologi-
cal changes in cardiac fibroblasts drive gene expression pat-
terns and changes in substrate stiffness are unlikely to underlie 
differences in gene expression between 2D and 3D states. We 
next examined the pool of genes that were the most upregu-
lated (Figure 1F) or downregulated (Figure 1G) in 3D versus 
2D fibroblast states. Gene ontology analysis demonstrated 
that genes downregulated in the 3D state mainly comprised 
cell cycle processes such as DNA replication, chromosom-
al condensation/segregation, and cytokinesis (Figure 1H). 
Transcripts differentially upregulated in the 3D state involved 
pathways regulating extracellular matrix metabolism/prote-
olysis, surface proteins, chemotaxis, and immune response. 
(Figure 1H; Online Table II). We next specifically examined 
several genes which were highly differentially expressed be-
tween 3D versus 2D fibroblasts and that are also known to 
regulate extracellular matrix such as metalloproteinases/me-
tallopeptidases, (MMP11, MMP2 [matrix metalloproteinases 
11 and 2], ADAMTS15 [metallopeptidase with thrombospon-
din motif 15]), CTGF (connective tissue growth factor) and 
fibroblast contractility, Acta2 (alpha-smooth muscle actin 2), 
Cnn2 (calponin 2) and modulators of inflammatory response 
(GPNMB [glycoprotein nonmetastatic B]). Based on RNA-
seq patterns, expression of these genes was reversible and 
highly dependent on the topological state of the fibroblast
(Figure 2). For instance, MMP11 and MMP2 were highly in-
duced after aggregation and sphere formation of fibroblasts,
but expressions declined to 2D levels when the 3D fibroblasts
107 
Yu et al Topological States Regulate Fibroblast Plasticity 
were allowed to attach and grow out as a monolayer for a 
few days (Figure 2A and 2B). However, reseeding the cells 
back to a 3D conformation led to rapid reinduction of MMP2/
MMP11 expression illustrating the dynamic plasticity of the 
system (Figure 2A and 2B). Gene expression of Acta2, Cnn2, 
ADAMTS15, GPNMB, and CTGF, which are thought to play 
a role in fibroblast contractility and regulation of inflamm -
tion and extracellular matrix, demonstrated similar patterns of 
changes of gene expression dependent on the topological state 
(Figure 2C through 2G).
To determine whether such gene expression changes are 
associated with changes in phenotype, we first determined 
changes in cardiac fibroblast proliferation in the 3D versus 
2D state. For this purpose, cardiac fibroblasts either in the 2D 
or 3D state were treated with EdU for 4 hours followed by 
determination of EdU uptake by fl w cytometry. Consistent 
with decreased expression of cell cycle genes in the 3D state, 
we observed that 5.47±1.4% of cardiac fibroblasts in the 
2D state were cycling (EdU uptake) versus 0.15±0.05% in 
the 3D state (P<0.05; Figure 3A). Similarly, the fraction of 
Figure 2. Dynamic changes in 
expression of myofibroblast and 
extracellular matrix genes between 
2-dimensional (2D) and 3D cardiac
fibroblast states. A and B, Normalized
gene counts on RNA-seq demonstrating
rapid changes in gene expression of (A)
MMP11 (matrix metalloproteinase 11), (B)
MMP2 (matrix metalloproteinase 2), (C)
Acta2 (alpha-smooth muscle actin 2), (D)
Cnn2 (calponin 2), (E) CTGF (connective
tissue growth factor), (F) ADAMTS15
(metallopeptidase with thrombospondin
motif 15), and (G) GPNMB (glycoprotein
nonmetastatic B) in cardiac fibroblasts in
different topological states.
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cells expressing Ki67 (marker of proliferation) significan -
ly decreased from 10.94±3.0% of cardiac fibroblasts in the 
2D state to 1.0±0.08% in the 3D state (P<0.05; Figure 3B). 
Western blotting with quantitative densitometry demonstrated 
that fibroblasts in the 3D state exhibit decreased expression 
of contractile proteins alpha-smooth muscle actin (88±6% 
decrease in 3D versus 2D; P<0.001) and calponin (54±6% 
decrease in 3D versus 2D; P<0.001; Figure 3C), consistent 
with gene expression data demonstrating decreased expres-
sion of myofibroblast proteins. Differentially expressed genes 
between the 2D and 3D states included genes affecting ex-
tracellular matrix catabolism. Collagen is the most common 
abundant extracellular matrix protein secreted by cardiac   -
broblasts, and we next determined how adoption of the 3D 
state affects collagen production. We measured total collagen 
using the Sircoll assay in 2D and 3D fibroblasts and observed 
Figure 3. Changes in fibroblast phenotype in 3-dimensional (3D) vs 2D topological state. A and B, Flow cytometry to determine 
fraction of proliferating fibroblasts in 2D and 3D states by (A) EdU uptake (5.48±1.4% in 2D vs 0.15±0.05% in 3D, mean±SEM, P<0.05, 
n=3) or (B) Ki67 expression (10.14±3.0% in 2D vs 1.02±0.01% in 3D, mean±SEM, P<0.05, n=3). C, Western blotting and quantitative 
densitometry of expression of alpha-smooth muscle actin and calponin expression by cardiac fibroblasts in 2D or 3D states (mean±SEM, 
*P<0.001, n=3). D, Estimation of total collagen content of cardiac fibroblasts in 2D or 3D state (8.40±2.8 μg/106 cells in 3D vs
1.32±0.71/106 cells in 2D, mean±SEM, *P<0.05, n=3). E, Heat map demonstrating expression of members of the frizzled, Vangl, and
Celsr family in different topological states of cardiac fibroblasts. F, Flow cytometry demonstrating Fzd1 (frizzled 1) expression in 3D vs 2D
cardiac fibroblasts (2.07±0.33% in 2D vs 5.63±0.24% in 3D, mean±SEM, P<0.05, n=3).
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that the total cellular collagen content significantly decreased 
from 8.40±2.8 μg/106 cells in 3D states to 1.32±0.71/106 cells 
in 2D states (P<0.05; Figure 3D). Cardiac fibroblasts secrete 
extracellular matrix proteins but are also known to express 
matrix-degrading enzymes and can undergo dedifferentiation 
as well.13 These data suggest that a transition from a 2D to 
a 3D state leads to a switch of cardiac fibroblast phenotype 
from a matrix synthetic to a nonsynthetic dedifferentiated 
state. Recent evidence suggests that aggregation of cardiac 
fibroblasts in the area of myocardial injury is associated with 
fibroblasts exhibiting evidence of polarization.14 Polarization 
or alignment of cardiac fibroblasts is thought to play a critical 
role in appropriate cardiac wound healing.15 We thus exam-
ined whether 3D cardiac fibroblasts exhibited any evidence 
of polarization compared with 2D fibroblasts. To address this 
question, we examined expression of genes that are members 
of the Frizzled (Fzd), Van Gogh (Vangl in vertebrates), and 
Flamingo (Celsr in vertebrates; Figure 3E). These families of 
genes initially identified in Drosophila are now known to play 
a critical role in planar cell polarity and cellular orientation 
in epithelial and mesenchymal cells of vertebrates as well.16 
Within this subset of genes known to regulate cellular polarity, 
we observed that Fzd1 (frizzled 1) expression was significan -
ly higher in 3D compared with 2D states (Figure 3E). Fzd1 is 
a cell surface receptor and we performed fl w cytometry to 
demonstrate that Fzd1 expression was significantly upregulat-
ed in 3D fibroblasts (Figure 3F) consistent with gene expres-
sion changes. Members of the frizzled family are known to be 
expressed in fibroblasts in the area of injury after myocardial 
injury and thought to contribute to cardiac remodeling and 
have been considered as therapeutic targets for augmenting 
cardiac repair.14,17,18 In this regard, cardiac fibroblasts in 3D 
states recapitulate to a certain extent the expression of polarity 
genes known to be important for wound healing in vivo. Taken 
together, these observations demonstrate that aggregation and 
changes in spatial arrangement of cardiac fibroblasts can drive 
rapid, dynamic, and reversible expression of genes affecting 
a panoply of processes regulating wound healing such as   -
broblast proliferation, activation, collagen content, and cell 
polarity.
We next investigated the mechanistic basis of such rapid 
and reversible changes in gene expression. We hypothesized 
that dynamic changes in chromatin structure may contribute at 
least in part to the rapid changes in gene expression seen after 
the transition of fibroblasts from a 2D to 3D state. Therefore, 
changes in chromatin organization and DNA accessibility 
(open and closed chromatin) were examined between cardiac 
fibroblasts in 2D versus 3D states by performing an ATAC-
seq.19 ATAC-seq enables identification of open and closed re-
gions of chromatin across the genome and provides insights 
about regions of the genome that are more (open) or less ac-
cessible (closed) to transcription factors.19 We observed that 
there were significant changes in global chromatin organiza-
tion (Figure 4A). Approximately 23% of the genes differen-
tially upregulated in fibroblast 3D states and 18% of the genes 
downregulated in fibroblast 3D state (ie, upregulated in 2D 
states) underwent significant changes in chromatin accessibil-
ity (Figure 4A) with remarkable concordance with their RNA-
seq profiles.Both these values were significantlyenriched over 
background levels as we observed that only 10% of all genes 
had differential ATAC-seq peaks on transition from a 2D to 
3D state (Figure 4A). We next examined differential ATAC-
seq peaks for specific genes such as MMP2 and CTGF that 
demonstrated significant induction and silencing of gene ex-
pression respectively in the 3D state and observed significant
differences in ATAC-seq peaks in their respective genomic 
loci, correlating with changes in gene expression (Figure 4B 
and 4C). These observations suggest that fibroblast aggrega-
tion and changes in spatial arrangement of cardiac fibroblasts
are sufficient to induce changes in chromatin structure or or-
ganization that contributes to the global changes in genes ex-
pression between the 2D and 3D state.
Having demonstrated that changes in fibroblast aggrega-
tion and spatial arrangement are associated with concordant 
changes in the epigenome and gene expression, we next inves-
tigated the functional connotations of such global changes in 
gene expression for cardiac wound healing. Like humans, ge-
netically diverse strains of mice differ in the degree of fibrosis
or cardiac remodeling after pathological cardiac stressors and 
offer the advantage of tissue availability and experimental ma-
nipulation. The HMDP is a collection of genetically diverse 
mouse strains and allows sufficient power for genome-wide 
association analysis to determine how genetic architecture im-
pacts phenotypic traits.20–23 A single pathological stressor can 
be thus applied across all strains within the HMDP to perform 
genome-wide association studies and determine how genetic 
and environmental interactions contribute to global gene ex-
pression and clinical phenotypes.24 In these studies, 96 strains 
of mice were administered a 3-week continuous infusion of 
isoproterenol via an osmotic pump.6 Throughout the study, 
various physiological characteristics including cardiac func-
tional indices (eg, ejection fraction, left ventricular internal 
dimensions in end systole and diastole), metabolic parameters 
and tissue weights (61 traits in all) were measured (Online 
Table III) and the left ventricle of each mouse strain was sub-
jected to global expression arrays.6,24 In this study, the mice 
responded dramatically to isoproterenol, as nearly every indi-
vidual showed increased left ventricular mass after treatment. 
This data set enabled us to assess whether differentially ex-
pressed genes between 3D and 2D states of cardiac fibroblasts
could inform phenotypic traits known to predict outcomes or 
disease severity in isoproterenol-induced cardiac hypertrophy 
and failure.
Initially, we asked whether significantly upregulated tran-
scripts in all 3D fibroblast states (compared with 2D) were 
correlated with heart failure traits in the HMDP. By simply 
correlating individual 3D upregulated genes from our RNA-
sequencing experiment across clinical traits in the mouse pop-
ulation (Online Figure III), we observed striking patterns of 
significance (Figure 5A). Because these patterns are difficult
to interpret on a gene-by-gene basis, we used a data reduction 
method to establish vectors which represent 3D-specific gene 
signatures. Principle component (PC) approaches provide a 
means of data reduction whereby variation across any number 
of dimensions can be aggregated into single or multiple vectors. 
Similar approaches utilizing a PC to represent large gene sets 
are commonly utilized in population-based studies.6,25 These 
produce a series of vectors which represent a given pattern of 
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variation, referred to as eigenvectors. Here, we applied this 
approach to gene expression, where the genes identified from 
the 2D versus 3D analysis were analyzed across a mouse pop-
ulation. We generated PC eigengenes which captured 14.4% 
(PC1) and 6.8% (PC2) of the variation of all 3D-upregulated 
transcripts within the HMDP expression arrays (Figure 5B). 
It is worth mentioning that these values are fairly typical 
when performing PC analysis on population-wide data (here, 
we use ≈600 genes within ≈100 strains of mice), especially 
given the significant variation observed in gene expression 
profiles. Using these eigengenes (PC1 and PC2) as signatures 
of 3D fibroblast genes, we plotted the position of each strain 
against various cardiac and noncardiac clinical traits. Cardiac 
fibroblasts are known to affect cardiac hypertrophy and play 
a major role in adverse cardiac remodeling and dilatation of 
the cardiac chambers, clinically determined by the left ven-
tricular dimensions in end systole and diastole. Consistent 
with this notion, we observed highly significant positive cor-
relations between 3D fibroblast-der ved gene signatures and 
left ventricular dimensions in both end diastole (Figure 5C 
and 5D) and end systole (Figure 5E and 5F) as well as car-
diac mass (Figure 5G and 5H). Notably, these 3D fibroblast
eigengene signatures did not correlate with either heart rate 
(Figure 5I and 5J) or noncardiac traits such as plasma glu-
cose (Figure 5K and 5L) demonstrating specificity of these ei-
gengene signatures to cardiac remodeling traits. Collectively, 
these data show that 3D fibroblast-enriched transcripts show 
striking patterns of correlation with adverse cardiac indices 
such as cardiac hypertrophy and chamber dilatation across the 
murine population after isoproterenol infusion.
To date, our data demonstrate that cardiac fibroblasts ex-
hibit a high degree of dynamic plasticity with induction and 
silencing of genes after transition from a 2D to 3D state. Genes 
induced in the 3D state significantly correlated with clinical 
indices of adverse ventricular remodeling. Therefore, we next 
determined whether genes differentially expressed in the 3D 
state were also upregulated in regions of fibroblast aggregation 
in vivo at the time of wound healing. For this purpose, we per-
formed cryoinjury on hearts of Col1a2CreERT:R26Rtdtomato and 
TCF21MerCreMer:R26Rtdtomato mice after tamoxifen-mediated 
Figure 4. Chromatin 
changes underlie altered 
gene expression of 
fibroblasts in 3-dimensional 
(3D) vs 2D states. A, ATAC-
seq (assay for transposase 
accessible chromatin) 
performed to demonstrate 
a fraction of genes 
demonstrating differential 
ATAC-seq peaks in either 
2D or 3D cardiac fibroblast 
states. B and C, ATAC-seq 
peaks and RNA-seq showing 
expression of (B) MMP2 
(matrix metalloproteinase 2), 
and (C) CTGF (connective 
tissue growth factor) in 2D 
and 3D states demonstrating 
differential ATAC-seq peaks 
in loci of MMP2 and CTGF 
genes (numbers listed refer to 
scales of enrichment).
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labeling of cardiac fibroblasts. Tamoxifen was administered 
for 10 days to label the cardiac fibroblasts and stopped 5 days
before cryoinjury. We chose cryoinjury as cryoinjury unlike 
ischemic myocardial injury creates a highly well-defined
compact transmural scar on the left ventricle and the tdTo-
mato labeling of cardiac fibroblasts can easily identify regions 
of compact scarring. Hearts were harvested at 7 days after 
cryoinjury and immunofluorescent staining performed to de-
termine whether genes highly upregulated in 3D fibroblasts
in vitro were expressed by labeled cardiac fibroblasts or ex-
pressed in abundance in the region of fibroblast aggregation. 
We observed abundant expression of MMP11 by tdTomato-
labeled cardiac fibroblasts but minimal MMP11 expression 
in uninjured regions (Figure 6A through 6D). ADAMTS15, a 
Figure 5. Genes enriched in 3-dimensional (3D) fibroblast states show significant correlation with indices of adverse ventricular 
modeling in HMDP (Hybrid Mouse Diversity Panel) studies after isoproterenol infusion. A, Correlation heat map (yellow: positive and 
blue: negative correlation) of top 15 differentially upregulated genes in 3D/2D states vs clinical traits of left ventricular dimensions, heart 
mass, plasma glucose and heart rate after infusion of isoproterenol. B, Individual gene contribution to eigengene signatures principle 
component (PC1 and PC2) using transcripts enriched in 3D states. C–H, Correlation of both eigengene signatures against cardiac and 
noncardiac traits with significant correlation between both eigengenes and (C and D) left ventricular internal diameter (LVID) at end 
diastole (E and F) LVID at end systole and (G and H) total heart mass with no significant correlation between either eigengene and (I and 
J) heart rate and K and L) plasma glucose. bicor indicates bicorrelation coefficient.
112 
Circulation Research June 22, 2018
secreted protein that regulates extracellular matrix, is expressed 
in the developing heart and highly induced in the 3D fibroblast
state (Online Table I), was also found to be abundantly present 
in the injured region and expressed by tdTomato-labeled   -
broblasts (Figure 6E through 6H). To study the expression of 
3D enriched transcripts in aggregating fibroblasts in regions 
Figure 6. Genes enriched in 3-dimensional (3D) fibroblasts are expressed in vivo in regions of fibroblast aggregation after 
heart injury and affect cardiomyocyte hypertrophy. A–D, Immunofluorescent staining for MMP11 (matrix metalloproteinase 11) 
on uninjured and cryoinjured hearts of (A and B) TCF21MerCreMer:R26Rtdtomato and (C and D) Col1a2CreERT:R26Rtdtomato mice (B 
and D) area of injury shown in higher magnification demonstrating tdTomato-labeled fibroblasts expressing MMP11 (arrows). E–H, 
Immunofluorescent staining for ADAMTS15 (metallopeptidase with thrombospondin motif 15) on uninjured and cryoinjured hearts 
of (E and F) TCF21MerCreMer:R26Rtdtomato and (G and H) area of injury shown in higher magnification demonstrating tdTomato-labeled 
fibroblasts expressing ADAMTS15 (arrows; scale bars: 20 µm). I and J, Cryoinjured heart of Col1a2CreERT:R26Rtdtomato mouse (I) 
before and (J) after optical clearing (arrowhead points to suture for identifying injured region, arrow points to green dye to identify 
area adjacent to injury; note the wire mesh on which the heart lies is now visible through the transparent heart; red arrow). K, 
tdTomato fluorescence observed on cryoinjured Col1a2CreERT:R26Rtdtomato heart and (L) confocal image through an area of injury 
showing intense tdTomato fluorescence (scale bar: 500 µm). M, Immunofluorescent staining for GPNMB (glycoprotein nonmetastatic 
B) on optically cle ed Col1a2CreERT:R26Rtdtomato heart after injury. The entire depth of the scar was imaged with a confocal
microscope and sequential Z stack images are demonstrating the distribution of tdTomato (red), GPNMB (green) and merged (yellow)
image demonstrating distribution of fluorophores across the depth of the scar (asterisk corresponds to position of suture). (Continued )
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of injury in greater detail, we subjected the harvested heart 
to solvent-based tissue clearing techniques to make the heart 
optically transparent.7 This allows the entire 3D structure of 
the scar to be visualized in detail without having to extrapo-
late and reconstruct a 3D structure from conventional analysis 
of histological sections. We again performed cryoinjury on 
Col1a2CreERT:R26Rtdtomato mice after fibroblast labeling. We 
harvested the heart 7 days after cryoinjury and made them op-
tically transparent and a nonabsorbable suture (placed at the 
time of injury) was used to identify an area of cryoinjury in the 
heart after tissue clearing (Figure 6I through 6K). The region 
of injury could be identified easily as an area with accumula-
tion of tdTomato-labeled cardiac fibroblasts (Figure 6L). On 
the optically cleared heart, we performed immunostaining for 
another marker GPNMB, a gene upregulated in the 3D state, 
involved with immune response pathways and that strongly 
correlated with adverse cardiac remodeling indices in our mu-
rine model of isoproterenol-induced heart failure. Analysis 
of Z stacked confocal images taken sequentially through the 
whole depth of the scar demonstrated expression of GPNMB 
by tdTomato-labeled fibroblasts throughout the depth of the 
scar (Figure 6M). These observations demonstrate that genes 
expressed by aggregating fibroblasts in the region of injury at 
least partially recapitulate the gene expression signatures of 
3D fibroblasts
Fibroblasts are known to affect cardiac hypertrophy26 and 
the gene expression signatures of 3D fibroblasts strongly cor-
related with clinical indices of heart mass and remodeling 
across mouse strains. We next investigated whether fibroblasts
in 3D exert prohypertrophic effects on cardiomyocytes com-
pared with fibroblasts cultured in 2D. For this purpose, we 
collected conditioned medium from fibroblasts grown in 3D 
or 2D conditions for 24 hours. We treated neonatal rat cardio-
myocytes with 3D or 2D conditioned medium to determine 
effects on cardiomyocyte hypertrophy over the next 48 hours. 
Live cell interferometry, a validated version of quantitative 
phase microscopy27,28 is an extremely sensitive tool for deter-
mining changes in total cellular biomass. Live cell interfer-
ometry is based on the principle that light slows as it interacts 
with matter. As light traverses through a cell that has greater 
biomass (ie, hypertrophied), the light slows and its waveform 
shifts in phase compared with light not passing through the 
cell29 (Figure 6N). The change in phase shift over time is di-
rectly related to the change in biomass of the cell over time, 
and this quantitative phase shift has been used to precisely 
and reproducibly determine the dry biomass of cells including 
T cells, stem cells, cancer cells, and fibroblasts 27,28 NRVM 
were treated with conditioned medium as above, and each 
cardiomyocyte was subjected to repeated measurements by 
live cell interferometry to obtain a growth rate. We observed 
that 2D conditioned medium significantly increased the rate 
of cardiomyocyte biomass accumulation compared with non-
conditioned medium (0.4 picogram/h for 2D compared with 
−0.12 picogram/h for growth medium; P=0.04; Figure 6O).
However, treatment with 3D conditioned medium tripled the
rate of growth versus treatment with 2D conditioned me-
dium (1.25 pg/h for 3D versus 0.4 pg/h for 2D; P=0.0001;
Figure 6O). As cardiomyocytes after isolation can exhibit a
significant difference in cell size, we normalized the growth
rate of each cardiomyocyte to initial cell biomass. Again, we
observed a significant 34% increase in cell biomass of NRVM
after treatment with 2D conditioned medium compared
with nonconditioned growth medium (0.34% for 2D versus
−0.01% for growth medium; P=0.02; Figure 6P). However,
3D fibroblast conditioned medium significantly increased the
cell biomass accumulation rate of NRVM by a further 88%
compared with NRVM treated with 2D conditioned medium
(0.64% for 3D versus 0.34% for 2D; P=0.002; Figure 6P).
These observations demonstrate that the secretome of fibr -
blasts in 3D is sufficient to induce cardiomyocyte hypertrophy
and are broadly consistent with the genome-wide association
data shown earlier demonstrating a high correlation between
Figure 6 Continued. N, Set up of live cell interferometry with phase shift of light being a read out for changes in cell biomass (O) absolute 
and (P) normalized single cell cardiomyocyte (neonatal rat ventricular cardiomyocytes [NRVM]) biomass accumulation rates determined by 
serial measurements with interference microscopy >48 h after treatment of NRVM with growth medium (nonconditioned) or conditioned 
medium from fibroblasts in 2D or 3D state (each circle represents a single cardiomyocyte; number of single cardiomyocytes tracked: 103 
for growth medium, 142 for 2D medium, and 231 for 3D medium).
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genes induced in the 3D state and indices of cardiac hypertro-
phy and remodeling after isoproterenol infusion. Our observa-
tions also suggest that the gene expression signatures adopted 
by aggregating fibroblasts may have a direct causal effect on a 
hypertrophic response after cardiac injury.
We next analyzed our RNA-seq data to obtain insight 
into transcription factors or transcriptional regulators that 
could be contributing to changes in gene expression between 
the 2D and 3D states and affecting myocyte hypertrophy. 
Genes differentially upregulated in the 3D versus 2D state 
were assayed for enrichment of upstream transcriptional fac-
tors or regulators using TRRUSTv2.30 This analysis queries 
hundreds of published Chip-Seq and open chromatin data to 
infer regulatory elements from gene expression patterns. The 
3D upregulated genes were used to identify enrichment of 
regulation by specific transcription factors or DNA binding 
elements known to regulate expression. We observed a signi  -
cant representation of several transcription factors predicted 
to regulate 3D-specific genes (Online Figure IV) and some of 
these are also known to regulate or be associated with the car-
diac hypertrophic response such as MITF (microphthalmia-
associated transcription factor), CTNNB1 (beta-catenin), and 
SRF (serum response factor).31–33 Next, to obtain insight into 
secreted factors present in 3D conditioned medium that in-
duced or contributed to myocyte hypertrophy, we filtered the 
differentially upregulated genes in the 3D state for secreted 
factors and observed expression of proteins known to affect 
the myocyte hypertrophic response such as angiotensinogen, 
pyrophosphatases affecting purinergic signaling (ENPP3 
[ectonucleotide pyrophosphatase/phosphodiesterase 3]) and 
members of the Wnt signaling family (Dkk3 [dickkopf-related 
protein 3]; Online Table IV).34–36
Discussion
Cardiac fibroblasts are known to be highly plastic, and our 
study suggests that simple aggregation of fibroblasts may be 
sufficient to induce genome-wide changes in chromatin reor-
ganization and gene expression. We show that gene expression 
signatures adopted by aggregating cardiac fibroblasts at least 
in part recapitulate changes in gene expression in the injured 
region in vivo and that such altered genetic outputs may have 
functional consequences for cardiac wound healing and re-
modeling. Cardiac fibroblasts are the principal contributors 
toward deposition of extracellular matrix but are also known 
to secrete metalloproteinases, and extracellular proteases that 
lead to degradation of extracellular matrix.37 Acute myocar-
dial injury is associated with significant upregulation in me-
talloproteinase activity38 and MMP expression significantly
increased in 3D cardiac fibroblasts mirroring such in vivo 
changes. A balance between the synthetic and proteolytic phe-
notype of the fibroblasts determines extracellular matrix con-
tent or burden of scar tissue in pathological states. Augmented 
matrix synthetic and matrix-degrading properties of cardiac 
fibroblasts can lead to high turnover of extracellular matrix, as 
seen in heart failure. Such fibroblast phenotypes with opposing 
effects on matrix synthesis and degradation, as seen in our 2D 
and 3D model could determine the burden of scar after acute 
and chronic injury and serve as a model for obtaining further 
mechanistic insight.39 Although little is known about signaling 
mechanisms that regulate resolution of fibrosis, dedifferentia-
tion of contractile elements of fibroblasts with decreased ex-
pression of alpha-smooth muscle actin is thought to represent 
a key event for fibrosis resolution.40 In this regard, our model 
of fibroblast aggregation with decreased expression of smooth 
muscle actin and induction of various matrix-degrading en-
zymes demonstrates phenotypic features consistent with 
myofibroblast dedifferentiation and a proteolytic rather than a 
synthetic phenotype. The expression of alpha-smooth muscle 
actin and other contractile proteins in fibroblasts in the injury 
region allows for wound contraction in vivo, a mechanism that 
enables a reduction in the area of injury. Conversely, impaired 
expression of fibroblast contractile proteins or defects in fibr -
blast polarization in vivo can cause impaired wound contrac-
tion, dysregulated wound healing and lead to an expansion of 
the infarcted region, a dreaded complication after myocardial 
infarction. Our model that demonstrates a rapid and reversible 
expression of contractile proteins in fibroblasts could ser e as 
a platform for investigating the molecular events that abruptly 
can switch a cardiac fibroblast from a synthetic and contrac-
tile phenotype to a proteolytic and dedifferentiated phenotype. 
Hypertrophy of surviving cardiac myocytes at the edges of the 
injured region occurs after myocardial infarction, and the 3D 
fibroblasts can serve as a platform for interrogating the para-
crine effects of cardiac fibroblasts on myocyte hypertrophy. 
Given the global changes in gene expression and substantial 
changes in the 3D cardiac fibroblast secretome, it is likely that 
rather than a single driver, the activity of multiple transcrip-
tion factors and secreted proteins synergistically affect gene 
expression changes and the myocyte hypertrophic response.
Study of cells in spheroids have been performed for cancer 
cells and cells with progenitor potential. Our study suggests 
that studying fibroblasts in a 3D state in contrast to the con-
ventional analysis of 2D fibroblasts may be more informative 
of cellular changes in the injury region in vivo. Potentially, our 
model could also be used as a tool or a primary screening sys-
tem to determine how drugs or small molecules affect changes 
in expression of specific genes that are upregulated in the 3D 
state or affect phenotypic transitions between matrix synthetic 
(2D) and matrix-degrading (3D) states of a cardiac fibroblast
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Supplementary Methods 
Animal care and use 
All experimental procedures involving animals in this study were approved by the Institutional Animal 
Care and Use Committee (IACUC) of University of California at Los Angeles (UCLA). All animals were 
maintained at the UCLA vivarium according to the policies instituted by the American Association for 
Accreditation of Laboratory Animal Care. 
Isolation of cardiac fibroblasts 
Cardiac fibroblasts were isolated as described(1, 2). Briefly, cardiac fibroblasts were isolated from 
explanted hearts of uninjured wild type or Col1a2CreERT:R26RtdTomato and 
TCF21MerCreMer:R26RtdTomato mice which previously injected with tamoxifen for 10 days. The hearts 
were explanted and washed three times with 1× HBSS (GIBCO) then minced into approximately 1mm2 
sized pieces and digested using 12.5 ml Liberase TH (SIGMA, CAT# 5401151001) digestion buffer 
[prepared by adding 5mg of liberase TH to 50ml Tyrodes buffer (136mM NaCl, 5.4mM KCl, 0.33mM 
NaH2PO4, 1.0mM MgCl2, 10mM HEPES with 1.8mg/L Glucose) to a final concentration of 0.1ug/ml]. 
Two sequential digestions were performed at 37°C. The cells were collected and passed through a 40μm 
strainer and plated in F12K medium (CORNING) with 1% penicillin/streptomycin, 20% Fetal Bovine 
Serum (FBS) (GIBCO) for 2 h at 37°C in a 5% CO2 incubator. After incubation for 2 hours, the medium 
was changed to F12K medium (GIBCO) supplemented with 20% FBS, 1% penicillin/streptomycin, 1,000 
U/ml leukemia inhibitory factor (LIF) (Millipore) and 10 ng/ml basic fibroblast growth factor (bFGF) 
(Millipore). Cells were maintained under these conditions until they became confluent and used. All the 
cardiac fibroblast that had not undergone more than 3 passages were used for experiments 
Cardiac fibroblast 2D/3D culture 
For cardiac fibroblast sphere formation, the primary outgrowth of confluent monolayer cardiac fibroblasts 
from C57BL/6J, Col1a2CreERT:R26RtdTomato or TCF21MerCreMer:R26RtdTomato mice were harvested 
(0.25% trypsin-EDTA) and re-plated onto regular tissue culture dish (2D) (CORNING) or ultra-low 
attachment dish (3D) (CORNING) (CAT# 3261) at a density of 1-1.2 × 105 cells/cm2. Both 2D and 3D 
cardiac fibroblasts were treated with identical cell culture medium [35% IMDM, 65% F12K, 3.5% FBS, 
1% penicillin-streptomycin, 200mmol/L L-glutamine, 20ng/ml bFGF, 25ng/ml EGF (PEPROTECH), 
1,000 U/ml LIF, 0.1mM 2-Mercaptoethanol (SIGMA)](3, 4). Under these conditions, cardiac fibroblasts 
seeded onto ultra -low attachment plates formed spherical clusters within 24 hours of seeding. After 24 h, 
the 3D spheres were collected and plated back onto a regular cell culture dish at 37°C 5%CO2 for 5 days, 
with cell culture medium being changed every two days. The spherical clusters of cardiac fibroblasts 
attached and fibroblasts migrated out to form a monolayer by 5 days (3D-2D). Fibroblasts in 2D or 3D 
states maintained for 5 days served as controls. These cells were subsequently trypsinized and reseeded 
onto ultra-low attachment plates, where they again formed spherical clusters (3D-2D-3D) within 24 
hours. Cells identically trypsinized but reseeded onto 2D conditions served as controls. Cardiac 
fibroblasts at different topological states were used for RNA-seq and ATAC-seq experiments. For WGS 
staining, cardiac fibroblasts isolated from Col1a2CreERT:R26RtdTomato and TCF21MerCreMer: 
R26RtdTomato were fixed in 2% paraformaldehyde for 15 min at 37˚C, then stained with 1:200 diluted 
Wheat Germ Agglutinin Conjugates (WGA) stock solution 1.0mg/mL (Invitrogen) in HBSS for 10 min at 
room temperature (5). The cells were subsequently washed twice with HBSS and then permeabilized with 
0.2% Triton X-1000 for 15min. Finally, the cells were mounted in slow fade gold anti-fade reagent with 
DAPI. Labeled cells were imaged with a confocal microscope (PROMO C2, NIKON). 
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To determine changes in gene expression of cardiac fibroblasts seeded onto substrates with varying elastic 
moduli (stiffness), cardiac fibroblasts (5x105 cells) were cultured on 6-well plates with various rigidities 
(0.5, 8, 64 kPa) at 37˚C, 5%CO2 for 24 hours according to the manufacturer’s instruction (Advanced 
BioMatrix, CAT# 5145) (5, 6). All wells were pre-coated with type I collagen according to 
manufacturer’s instructions (100μg/ml collagen Type I).  Cardiac fibroblasts seeded onto regular tissue 
culture dishes precoated with type I collagen and at a similar seeding density served as controls. Cardiac 
fibroblasts seeded onto ultra-low attachment plates were used to create 3D fibroblast states for analyzing 
gene expression changes within the different groups. Following 24 hours of seeding, cells were harvested 
for RNA-seq.  
RNA-seq and ATAC-seq 
RNA was isolated from cardiac fibroblasts in different topological states, temporally adjusted controls as 
well as from cardiac fibroblasts seeded onto substrates of varying elastic moduli (0.5, 8, 64 kPa). RNA 
isolation was performed using PROMEGA RNA Isolation Kit (PROMEGA) and reverse transcription 
using Reverse Transcription System (PROMEGA). Libraries were constructed using standard Illumina 
RNA-seq library construction protocols and were sequenced on Illumina HiSeq 3000. For analysis of 
gene expression changes, we first mapped RNA-Seq reads of each sample to its corresponding genomic 
coordinates (mm10 genome version) with Tophat software (default parameters)(7). Next, we quantified 
the expression of each gene, i.e. the number of reads falling into each gene, with HTSeq-count 
software(8). We then performed the normalization and differential expressed genes (DEGs) analysis with 
DESeq2 software(9). The identified DEGs required a FDR value smaller than 0.01 and a log2 fold change 
larger than 1. Marker set enrichment analysis (MSEA) was performed on the DESeq2 output from RNA-
sequencing, based on normalized fold-change expression in 3D/2D (3D up-regulated) and 2D/3D (3D 
down-regulated) conditions as well as for fibroblasts on substrates of varying stiffness. For pathway 
analysis, genes in each condition were weighted based on their fold-change, merged into modules based 
on Gene Ontology Terms and permuted 2000 times against transcripts detected across all RNA-seq 
samples to generate corresponding p-values(9, 10). 
ATAC-seq was performed as described previously(11) using approximately 50,000 cells/sample. Cardiac 
fibroblasts harvested from all topological states (2D, 3D) were subjected to ATAC-seq. Samples were 
lysed with cold lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2 and 0.1% IGEPAL 
CA-630). Immediately following the nuclei preparation, the pellets were re-suspended in the transposase 
reaction mix (25μl 2×TD buffer, 2.5μl transposase (Illumina) and 22.5μl nuclease-free water). The 
transposition reaction was carried out for 30 min at 37°C. Directly following transposition, the samples 
were purified using a Qiagen MinElute kit. Following purification, the libraries were amplified using 
1×NEB next PCR master mix and 1.25μM of custom Nextera PCR primers 1 and 2 (Table 1), using the 
following PCR conditions: 72°C for 5min; 98°C for 30 s; and thermocycling at 98°C for 10 s, 63°C for 30 
s and 72°C for 1 min. Libraries were purified using a Qiagen PCR cleanup kit yielding a final library 
concentration of ∼30nM in 20μl to remove primer dimers. Libraries were amplified for a total of 10–12 
cycles. For analysis of ATAC-seq data, we first mapped ATAC-Seq reads of each sample to its 
corresponding genomic coordinates with Bowtie2 software, requiring no more than two mismatches(12). 
The uniquely mapped reads were then used for further analyses. We used MACS2 software to identify the 
enriched signal regions of ATAC-Seq peaks with default q-value cutoff(13). To compare the ATAC-Seq 
signals between different samples, we used MACS2 bdg diff function, requiring the identified differential 
regions were having a log10 likelihood of more than 5. 
Expression overlay with hybrid mouse diversity panel 
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Differentially expressed transcripts from 2D vs 3D spheres were used for population-based analysis 
within the HMDP. We utilized gene expression arrays from left ventricle (GEO accession: GSE48760) 
among HMDP strains subjected to isoproterenol treatment. ALZET Model 1004 minipumps (Cupertino, 
CA, USA) were implanted intra-peritoneally to administered ISO, at a dose of 30 mg/kg body weight/day 
for 21 days. At the end of the protocol, mice were sacrificed by giving a sub-lethal dosage of inhaled 
isoflurane followed by cervical dislocation. LV tissues were collected and frozen immediately in liquid 
nitrogen. Data from HMDP populations administered isoproterenol were analyzed from the following 
studies(14, 15).  From these arrays, all probes corresponding to the same genes were aggregated to a 
single gene by strain measurement. This gene-by-strain matrix was used for further analyses. Initially, 
individual differentially expressed genes were correlated with clinical traits from the corresponding 
isoproterenol study. For a larger sample size and consistency, we chose to measure echocardiogram traits 
following 14 days of isoproterenol infusion. Biweight midcorrelation values (bicor) were calculated using 
pairwise strains (70-96, depending on the trait assessed) in the R package WGCNA(16). From the matrix 
of gene-by-trait, biweight midcorrelation coefficients student p-values were calculated using the 
corresponding sample sizes. Following individual gene x trait correlations, the gene -by-strain matrix 
from HMDP study was used for eigengene construction. First, the matrix was narrowed down to genes 
only upregulated under 3D conditions by overlaying gene symbol of aggregated probes with the output 
from DESeq2 analysis on 3D fibroblast spheres. Next principal component analysis was performed on the 
remaining gene set (R package, prcomp) and score contributions for components were extracted for each 
strain. The score matrices for each PC and strain were then correlated against traits also using WGNCA as 
described above. 
Flow cytometry analysis 
Cultured Cardiac fibroblasts at different topological states were dissociated using 0.25% trypsin-EDTA 
solution (SIGMA), stained in FACS buffer (0.1%BSA PBS) with APC-conjugated anti-Frizzled-1 
antibody (Miltenyi Biotec Inc. cat#130-112-398) or FITC conjugated anti-Ki67 antibody (eBioscience, 
cat#11-5698-82) for 30min at 4°C. After washing with FACS buffer twice, stained cells were analyzed on 
a flow cytometer. Unstained control cells were run first to establish gates followed by the cells stained 
with the primary antibody conjugated to the fluorophore. For EdU analysis, EdU was added to the cell 
culture medium at a final concentration of 10mM. After 4 hours incubation, the cells were dissociated 
with 0.25% trypsin-EDTA solution; cells were then fixed and permeabilized with 1x Click-iT saponin-
based permeabilization and wash regent for 15min according to the manufacturing instruction of Click-
iT™ Plus EdU Alexa Fluor™ 488 Flow Cytometry Assay Kit (Life technologies, cat#C10632). 
Subsequently Click-iT reaction cocktail was added to the cells and incubated for an additional 30 minutes 
at room temperature. After washing with1x Click-iT saponin-based permeabilization and wash regent 
twice, cells were analyzed on a flow cytometer.   
Cell Cycle analysis using ImageStream 
Cultured Cardiac fibroblasts at different topological states were dissociated as described above and fixed 
with 1% PFA on ice for 20min. Cells were washed twice with PBS/2%FBS twice, and then passed 
through a 70μm nylon mesh strainer. At least 1 million cells in 50μl were used for flowcytometry 
analyzing on the ImageStream system with bright field at 40x magnification (Amnis). Parameters 
including cell image, cell diameter, cell surface area were analyzed (n=3000 cells used for analysis) using 
the IDEAS™ post-acquisition analysis software (Amnis) (17, 18).  
Immunoblotting analysis 
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Cultured Cardiac fibroblasts at different topological states were washed twice with ice-cold PBS and 
harvested in RIPA Lysis and Extraction Buffer (life technologies) plus Halt Protease Inhibitor Cocktail 
(life technologies) and Halt™ Phosphatase Inhibitor Cocktail (life technologies). Pierce™ BCA Protein 
Assay Kit was used for the colorimetric detection and quantitation of total protein (Life Technologies). 
Total 25μg protein was separated on 4-12% Tris-Glycine Mini Gels (Life Technologies) and transferred 
onto PVDF membranes (Merck Millipore). The membranes were probed with antibodies to alpha smooth 
muscle Actin (α SMA, 1:1000) (Abcam, cat# ab5694), calponin(1:1000)( Abcam, cat# ab46794), 
GAPDH(1:5000) (MilliporeSigma, cat# ABS16). Protein signals were detected using horseradish 
peroxidase (HRP)-conjugated secondary antibodies and enhanced chemiluminescence (ECL) western 
blotting detection regents (Thermo Fisher Scientific, MA, USA).  
Sircol assay for determining collagen amounts 
The Sircol collagen assay kit (Biocolor Ltd.,Newtownabbey, UK, CAT# CLRS4000) was used to 
quantify total collagen amounts in cardiac fibroblasts in 2D or 3D states according to the manufacturer’s 
instructions. Collagen was measured only in 2D or 3D fibroblasts following harvest and collagen secreted 
from the cells onto the surface of the dish was thus not measured in this assay. In brief, collagen was 
extracted and digested overnight with 0.1 mg/ml pepsin in 5 M acetic acid. Soluble and insoluble collagen 
was measured according to the manufacturer’s instructions using a standard curve of known 
concentrations of purified rat tail collagen to estimate total collagen content (19, 20). 
Genetic labeling of cardiac fibroblasts 
Col1a2CreERT:R26RtdTomato and TCF21MerCreMer:R26RtdTomato mice lines were obtained by crossing 
Collagen1a2CreERT and TCF21MerCreMer mice with the lineage reporter R26R tdTomato mice(1). 
Tamoxifen (1mg) (Sigma) was injected intraperitoneally for 10 days to induce Cre-mediated 
recombination in Col1a2CreERT:R26RtdTomato and TCF21MerCreMer:R26RtdTomato mice (8-10 weeks old). 
Five days following cessation of tamoxifen, animals were subjected to cardiac fibroblasts isolation or 
cardiac injury (myocardial cryoinjury). All mice were maintained on a C57BL/6 background. For 
isolation of tdTomato labeled cardiac fibroblasts, cultured cardiac fibroblasts isolated from non-transgenic 
mice were first run through the flow cytometer to establish gates. Next population of cultured cardiac 
fibroblasts isolated from Col1a2CreERT:R26RtdTomato or TCF21MerCreMer:R26RtdTomato mice hearts were 
run through the same gates to identify tdTomato labeled cells. All the tdTomato labeled cardiac fibroblast 
were sorted and collected for further culture and assays. 
Murine Cardiac Cryo-injury 
Mice (both male and female), 8–10 weeks old, were subjected to sham or myocardial cryoinjury as 
described(1). For cryoinjury, mice were initially anaesthetized with 3% isoflurane, maintained at 2% 
isoflurane, and intubated using a Harvard Rodent Volume-Cycled ventilator. A left thoracotomy was 
performed at the level of 2nd intercostal space and cardiac cryo-injury was performed by gently pressing 
a steel rod of 1mm diameter pre-cooled in dry ice against the exposed beating heart for 10 seconds. 
Freezing of cardiac tissue was confirmed by the rapid discoloration of the tissue. Seven days after injury, 
the hearts were harvested and processed for histological analysis. 
Immunofluorescent staining and confocal microscopy 
For harvesting the heart, the left ventricle was perfused with 5 ml PBS followed by 2 ml of 4% 
120 
paraformaldehyde (PFA). The hearts were post fixed in 4% PFA for additional 4 h and cryo-protected 
using 25% sucrose and embedded in OCT compound (TISSUE-TEK) (1). Immunofluorescent staining 
was performed on 7 mm frozen sections against markers that were upregulated in 3D spheres. Sections 
were washed and blocked using 10% normal donkey serum for 1 h and then stained with primary 
antibodies against MMP11 (ABCAM, AB119284), ADAMTS15 (R&D STSTEMS, AF5149) overnight at 
4°C. After washing three times with PBS, sections were incubated in secondary antibodies for 1 h 
followed by washing an additional three times with PBS. Finally, the sections were mounted in slow fade 
gold anti-fade reagent with DAPI (LIFT TECHNOLOGIES, S36938). Labeled sections were imaged 
using a PROMO C2 inverted Laser Scanning Confocal Microscope (NIKON). For each sample, eight 
independent images within 100mm radius of the cryo injured region were used for quantitative analysis. 
Mouse Heart Clearing using simplified CLARITY method (SCM) and Immunofluorescence Labeling 
A simplified CLARITY method was used to perform cardiac tissue clearing as described(21). Mouse 
hearts were rinsed thoroughly with 1x Phosphate Buffered Saline (PBS) immediately following 
harvesting to remove residual blood from cardiac chambers. The hearts were subsequently fixed in 4% 
paraformaldehyde (PFA) overnight at 4°C. Following fixation, samples were rinsed with 1x PBS and then 
immersed in a solution of 4% acrylamide monomer (Bio-Rad) along with 0.625% w/v of the 
photoinitiator 2,2’-Azobis[2-(2-imidazolin-2-yl) propane] dihydrochloride (VA-044, Wako Chemicals 
USA). The tissues were then incubated overnight at 4°C. The following day, the tubes containing the 
hearts were incubated at 37°C for 3-4 hours, until the acrylamide solution became viscous. After 
polymerization, the tissues were rinsed with 1x PBS and then placed into a clearing solution comprised of 
8% w/v sodium dodecyl sulfate (SDS, Sigma Aldrich) and 1.25% w/v boric acid (Fischer) (Ph8.4). 
Samples were incubated at 37°C until the desired transparency was reached, usually two weeks. 
Following incubation in clearing solution, the heart samples were washed with 1x PBS for one day and 
then blocked with bovine serum albumin (1x PBS, 1% BSA, 0.05% Tween-20) overnight prior to 
immunofluorescence applications. For immunofluorescence studies, the heart samples were incubated 
with GPNMB (R&D Systems, AF2550) primary antibody at 1:100 dilution for 24 hours. Samples were 
then rinsed with PBS for one day prior to the application of the appropriate Alexa 488-conjugated 
secondary antibody (Cell Signaling) for 24 hours at 1:100 dilution. To amplify the endogenous tdTomato 
signal when present, anti-td-Tomato primary antibody (Rockland) and appropriate Alexa 555-conjugated 
secondary antibody (Cell Signaling) were applied as described above. Following immunofluorescence 
labeling, the heart samples were placed in Refractive Index Matching Solution (RIMS) prior to imaging. 
To make 30 mL RIMS, 40 grams of Histodenz (Sigma-Aldrich) was dissolved in 1X PBS (Sigma) with 
0.05% w/v sodium azide (Sigma) and syringe filtered through a 0.2 μm filter. 
2D/3D conditioned medium experiments on neonatal rat ventricular myocytes 
NRVMs were isolated from P1-P3 day old Sprague-Dawley rat pups of mixed gender as described 
previously (22) and plated with 700ul plating medium (DMEM, supplemented with 10% FBS and 1% 
penicillin/streptomycin) in a µ–Slide 4 well Ph+ (Phase contrast plus) (IBIDI) coated with 0.1% gelatin 
(104 cells /well). After resting overnight in plating medium, medium was changed to 700ul serum-free 
DMEM medium supplemented with 1% insulin-transferrin-selenium (ITS) (BD BIOSCIENCE) and 1% 
penicillin/streptomycin. Cells were incubated at 37°C, 5% CO2. The medium was then replaced with 
conditioned medium obtained from 2D or 3D cardiac fibroblast cultures and myocyte mass measured over 
the next 48 hours. 
Live cell Interferometry (LCI) 
Cells were imaged every 30 min for up to 48 hours at 20x magnification using a 0.40 numerical aperture 
objective on an Axio Observer.A1 inverted microscope (Zeiss) in a temperature and CO2 regulated stage-
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top cell incubation chamber. Quantitative phase microscopy (QPM) data was captured with a quadriwave 
lateral shearing interferometry (QWLSI) camera (SID4BIO, Phasics)(23). Illumination was provided by a 
660nm center wavelength collimated LED (Thorlabs). In each experiment, QPM data was collected from 
32 distinct locations for automated image processing and biomass segmentation analysis. 
Quantitative phase microscopy (QPM) image analysis 
All images were processed with custom MATLAB (MathWorks) scripts. Cells were identified and 
segmented using a local adaptive threshold based on Otsu’s method (24) and tracked using particle 
tracking code based on Grier et al (25). 
Biomass accumulation rate calculation 
QPM biomass data was summed over the projected area of each cell to obtain total cell biomass at each 
collection time point. Biomass accumulation rates were calculated by fitting a first-order polynomial to 
each biomass versus time plot using MATLAB Polyfit (Math Works). Individual cell growth tracks were 
quality filtered using an upper cutoff of ± 5% uncertainty (s.d. of residuals) in the calculated growth rate, 
as determined by linear fitting the biomass versus time data. 
Statistics 
All data are presented as mean standard error of the mean (S.E.M.). The value of n stated in the figure 
legends stands for independent biological replicates. Statistical analysis was performed using Graph Pad 
(Prizm) using student’s t-test (two tailed). A P value <0.05 was considered significant and individual p 
values are mentioned in the figure/figure legend. 
All computational procedures were carried out using R statistical software.  For analysis of the Hybrid 
Mouse Diversity Panel (HMDP) and correlation of phenotypic traits with 3D upregulated genes, all 
computational procedures were carried out using R statistical software. The HMDP expression arrays 
were aggregated to average expression of each gene across multiple probes and used for correlation or 
principal component analysis.  Correlations and associated p-values were calculated with the biweight 
midcorrelation, which is robust to outliers and associated pvalue (16).  Principle component vectors were 
assigned using the R base function “prcomp” where strain position on corresponding vectors were used 
for correlation analysis also using WGCNA.  Transcriptional Regulatory Relationships Unraveled by 
Sentence-based Text mining (TRRUSTv2) were interrogated for literature-based transcription factor 
(TF)-target interactions which persist in mice, focused on significance (FDR < 0.1) of TFs enriched 
among interactions with the set of 3D-enriched genes. Single comparisons between two groups were 
performed using two-tailed Student's t tests with 95% confidence intervals.  To retrieve and overlay 
annotated secreted proteins, we used the list deposited in the Universal Protein resource (UniProt) as 
“secreted” localization annotations [SL-0243] for overlapping HUGO symbol in Mus musculus (Mouse) 
[10090]. 
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Table 1: Oligo designs. A list of ATAC-seq oligos used for PCR. 
Ad1_noMX: AATGATACGGCGACCACCGAGATCTACACTCGTCGGCAGCGTCAGAT
GTG 
Ad2.1_TAAGGCGA CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTCTCGTGGGCTCGG
AGATGT 
Ad2.2_CGTACTAG CAAGCAGAAGACGGCATACGAGATCTAGTACGGTCTCGTGGGCTCGG
AGATGT 
Ad2.3_AGGCAGAA CAAGCAGAAGACGGCATACGAGATTTCTGCCTGTCTCGTGGGCTCGG
AGATGT 
Ad2.4_TCCTGAGC CAAGCAGAAGACGGCATACGAGATGCTCAGGAGTCTCGTGGGCTCGG
AGATGT 
Ad2.5_GGACTCCT CAAGCAGAAGACGGCATACGAGATAGGAGTCCGTCTCGTGGGCTCGG
AGATGT 
Ad2.6_TAGGCATG CAAGCAGAAGACGGCATACGAGATCATGCCTAGTCTCGTGGGCTCGG
AGATGT 
Ad2.7_CTCTCTAC CAAGCAGAAGACGGCATACGAGATGTAGAGAGGTCTCGTGGGCTCG
GAGATGT 
Ad2.8_CAGAGAGG CAAGCAGAAGACGGCATACGAGATCCTCTCTGGTCTCGTGGGCTCGG
AGATGT 
Ad2.9_GCTACGCT CAAGCAGAAGACGGCATACGAGATAGCGTAGCGTCTCGTGGGCTCGG
AGATGT 
Ad2.10_CGAGGCTG CAAGCAGAAGACGGCATACGAGATCAGCCTCGGTCTCGTGGGCTCGG
AGATGT 
Ad2.11_AAGAGGCA CAAGCAGAAGACGGCATACGAGATTGCCTCTTGTCTCGTGGGCTCGG
AGATGT 
Ad2.12_GTAGAGGA CAAGCAGAAGACGGCATACGAGATTCCTCTACGTCTCGTGGGCTCGG
AGATGT 
Ad2.13_GTCGTGAT CAAGCAGAAGACGGCATACGAGATATCACGACGTCTCGTGGGCTCGG
AGATGT 
Ad2.14_ACCACTGT CAAGCAGAAGACGGCATACGAGATACAGTGGTGTCTCGTGGGCTCGG
AGATGT 
Ad2.15_TGGATCTG CAAGCAGAAGACGGCATACGAGATCAGATCCAGTCTCGTGGGCTCGG
AGATGT 
Ad2.16_CCGTTTGT CAAGCAGAAGACGGCATACGAGATACAAACGGGTCTCGTGGGCTCG
GAGATGT 
Ad2.17_TGCTGGGT CAAGCAGAAGACGGCATACGAGATACCCAGCAGTCTCGTGGGCTCGG
AGATGT 
Ad2.18_GAGGGGTT CAAGCAGAAGACGGCATACGAGATAACCCCTCGTCTCGTGGGCTCGG
AGATGT 
Ad2.19_AGGTTGGG CAAGCAGAAGACGGCATACGAGATCCCAACCTGTCTCGTGGGCTCGG
AGATGT 
Ad2.20_GTGTGGTG CAAGCAGAAGACGGCATACGAGATCACCACACGTCTCGTGGGCTCGG
AGATGT 
Ad2.21_TGGGTTTC CAAGCAGAAGACGGCATACGAGATGAAACCCAGTCTCGTGGGCTCGG
AGATGT 
Ad2.22_TGGTCACA CAAGCAGAAGACGGCATACGAGATTGTGACCAGTCTCGTGGGCTCGG
AGATGT 
Ad2.23_TTGACCCT CAAGCAGAAGACGGCATACGAGATAGGGTCAAGTCTCGTGGGCTCGG
AGATGT 
Ad2.24_CCACTCCT CAAGCAGAAGACGGCATACGAGATAGGAGTGGGTCTCGTGGGCTCG
GAGATGT 
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Online Figure I. Dendrogram demonstrating relationship of gene expression patterns of 3D-2D and 
3D-2D-3D cardiac fibroblasts with temporally adjusted controls. (A) 3D-2D cardiac fibroblasts were generat-
ed by transferring the 3D cardiac fibroblasts to 2D conditions and maintaining the cells for 5 days (allowing the 
cells to migrate out from spheroids to a monolayer). For this purpose, additional temporally adjusted controls of 
2D fibroblasts and 3D fibroblasts maintained in culture for 5 days (2D-5d; 3D-5d) and then subsequently harvest-
ed for RNA-seq were used. RNA-seq and gene expression analysis to construct dendrograms shows clustering of 
3D-2D groups with 2D and 2D-5 day groups and are distinct from that of 3D or 3D-5 day groups. (B) Similarly, 
3D-2D-3D fibroblasts were generated by transferring 3D-2D fibroblasts to an ultra-low attachment dish and 
harvesting the cells at 24 hours after initial seeding. A temporally adjusted control was generated by transferring 
the 3D-2D cells to a regular tissue culture dish and harvested 24 hours after seeding (3D-2D-2D). Dendrogram 
again shows clustering of the 3D-2D-3D gene expression pattern with that of the 3D and distinct from the 2D or 
3D-2D-2D groups.
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Online Figure II. Gene expression changes following seeding of cardiac fibroblasts onto tissue culture plates with 
stiffness of 0.5,8 and 64kPa. (A) Cardiac fibroblasts were seeded onto control (regular tissue culture plate or 2D group) or 
plates of 0.5kPA, 8kPa and 64kPa stiffness or ultra-low attachment plate (3D group) and cells harvested after 24 hours and RNA-
seq performed. (B) Gene expression analysis and dendrogram demonstrates that the gene expression patterns of cardiac 
fibroblasts under different stiffness cluster together with that of the 2D group and are distinct from that of the 3D group. (C,D)
Heat map demonstrating expression of the most highly (C) upregulated and (D) downregulated genes between the 3D and 2D 
groups across all the groups.
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Online Figure III. Heat map of all 3D upregulated genes plotted against all cardiac and non-cardiac 
traits measured following infusion of isoproterenol in 96 strains of mice. Correlation heat map (yellow: 
positive and blue: negative correlation) of all differentially upregulated genes in 3D/2D states versus all 
cardiac and non-cardiac traits following infusion of isoproterenol.
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Online Figure IV. Predicted transcriptional regulators of 3D specific genes. Genes upregulated in 3D cardiac 
fibroblasts were assayed for enrichment of upstream transcriptional factors using TRRUSTv2. Significantly represented
transcriptional components are plotted with corresponding p value enrichment among 3D genes.
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3D down-regulated pathways
MODULE FDR GENE LOCUS VALUE Descrip?on
GO:0006281 0.00% Pif1 Pif1 28.39 DNA repair
GO:0006281 0.00% Exo1 Exo1 17.72 DNA repair
GO:0006281 0.00% Neil3 Neil3 15.45 DNA repair
GO:0006281 0.00% Clspn Clspn 14.42 DNA repair
GO:0006281 0.00% Polq Polq 13.91 DNA repair
GO:0007059 0.00% Ska1 Ska1 31.16 chromosome segreg??on
GO:0007059 0.00% Kif2c Kif2c 27.23 chromosome segreg??on
GO:0007059 0.00% Cenpf Cenpf 26.66 chromosome segreg??on
GO:0007059 0.00% Nek2 Nek2 22.36 chromosome segreg??on
GO:0007059 0.00% Cenpe Cenpe 19.4 chromosome segreg??on
GO:0000776 0.00% Ska1 Ska1 31.16 kinetochore
GO:0000776 0.00% Kif2c Kif2c 27.23 kinetochore
GO:0000776 0.00% Cenpf Cenpf 26.66 kinetochore
GO:0000776 0.00% Nek2 Nek2 22.36 kinetochore
GO:0000776 0.00% Plk1 Plk1 20.1 kinetochore
GO:0006260 0.00% Pif1 Pif1 28.39 DNA repli???on
GO:0006260 0.00% Dscc1 Dscc1 17.22 DNA repli???on
GO:0006260 0.00% Rrm2 Rrm2 14.56 DNA repli???on
GO:0006260 0.00% Polq Polq 13.91 DNA repli???on
GO:0006260 0.00% Ticrr Ticrr 12.63 DNA repli???on
GO:0005694 0.00% Ska1 Ska1 31.16 chromosome
GO:0005694 0.00% Kif2c Kif2c 27.23 chromosome
GO:0005694 0.00% Kif4 Kif4 24.66 chromosome
GO:0005694 0.00% Nek2 Nek2 22.36 chromosome
GO:0005694 0.00% Plk1 Plk1 20.1 chromosome
GO:0051301 0.00% Anln Anln 36.4 cell division
GO:0051301 0.00% Ska1 Ska1 31.16 cell division
GO:0051301 0.00% Kif2c Kif2c 27.23 cell division
GO:0051301 0.00% Aspm Aspm 27.05 cell division
GO:0051301 0.00% Cdc20 Cdc20 26.59 cell division
3D upregulated pathways
MODULE FDR GENE LOCUS VALUE Descrip?on
GO:0009986 2.88% Adamts15 Adamts15 173.38 cell surface
GO:0009986 2.88% Cd36 Cd36 19.93 cell surface
GO:0009986 2.88% Ciita Ciita 8.01 cell surface
GO:0009986 2.88% Apoe Apoe 6.74 cell surface
GO:0009986 2.88% Adgrv1 Adgrv1 6.71 cell surface
GO:0007166 2.48% Agt Agt 44.71 cell surface receptor signaling pathway
GO:0007166 2.48% Cd36 Cd36 19.93 cell surface receptor signaling pathway
GO:0007166 2.48% Adgrf4 Adgrf4 9.34 cell surface receptor signaling pathway
GO:0007166 2.48% Adgrg1 Adgrg1 9.16 cell surface receptor signaling pathway
GO:0007166 2.48% Cd22 Cd22 7.5 cell surface receptor signaling pathway
Online Table II
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GO:0004950 2.19% Ccr1 Ccr1 5.68 chemokine receptor activity
GO:0004950 2.19% Ccr3 Ccr3 4.67 chemokine receptor activity
GO:0004950 2.19% Ccr5 Ccr5 4.64 chemokine receptor activity
GO:0004950 2.19% Ackr2 Ackr2 4.34 chemokine receptor activity
GO:0004950 2.19% Ccrl2 Ccrl2 3.66 chemokine receptor activity
GO:0004930 1.42% Adra1a Adra1a 18.01 G-protein coupled receptor activity
GO:0004930 1.42% Ackr1 Ackr1 13.01 G-protein coupled receptor activity
GO:0004930 1.42% Adgrf4 Adgrf4 9.34 G-protein coupled receptor activity
GO:0004930 1.42% Adgrg1 Adgrg1 9.16 G-protein coupled receptor activity
GO:0004930 1.42% Adgrv1 Adgrv1 6.71 G-protein coupled receptor activity
GO:0070098 1.36% Ccl6 Ccl6 30.3 chemokine-mediated signaling pathway
GO:0070098 1.36% Ccl8 Ccl8 14.23 chemokine-mediated signaling pathway
GO:0070098 1.36% Ackr1 Ackr1 13.01 chemokine-mediated signaling pathway
GO:0070098 1.36% Ccl19 Ccl19 6.62 chemokine-mediated signaling pathway
GO:0070098 1.36% Ccr1 Ccr1 5.68 chemokine-mediated signaling pathway
GO:0002376 1.11% C2 C2 8.87 immune system process
GO:0002376 1.11% Cd7 Cd7 7.01 immune system process
GO:0002376 1.11% Cd24a Cd24a 6.4 immune system process
GO:0002376 1.11% Cd1d1 Cd1d1 6.23 immune system process
GO:0002376 1.11% Clec4d Clec4d 5.63 immune system process
GO:0048020 0.49% Ccl6 Ccl6 30.3 CCR chemokine receptor binding
GO:0048020 0.49% Ccl8 Ccl8 14.23 CCR chemokine receptor binding
GO:0048020 0.49% Ccl19 Ccl19 6.62 CCR chemokine receptor binding
GO:0048020 0.49% Ccl3 Ccl3 5.46 CCR chemokine receptor binding
GO:0048020 0.49% Ccl9 Ccl9 4.88 CCR chemokine receptor binding
GO:0005615 0.35% Adamts15 Adamts15 173.38 extracellular space
GO:0005615 0.35% Ahsg Ahsg 143.77 extracellular space
GO:0005615 0.35% Cilp Cilp 101.07 extracellular space
GO:0005615 0.35% Agt Agt 44.71 extracellular space
GO:0005615 0.35% Ccl6 Ccl6 30.3 extracellular space
GO:0006955 0.35% Ccl6 Ccl6 30.3 immune response
GO:0006955 0.35% Cd36 Cd36 19.93 immune response
GO:0006955 0.35% Ccl8 Ccl8 14.23 immune response
GO:0006955 0.35% Ccr1 Ccr1 5.68 immune response
GO:0006955 0.35% Ccl3 Ccl3 5.46 immune response
GO:0006935 0.34% Ccl6 Ccl6 30.3 chemotaxis
GO:0006935 0.34% Ccl8 Ccl8 14.23 chemotaxis
GO:0006935 0.34% Ccr1 Ccr1 5.68 chemotaxis
GO:0006935 0.34% Ccl3 Ccl3 5.46 chemotaxis
GO:0006935 0.34% Ccl9 Ccl9 4.88 chemotaxis
GO:0005576 0.03% Adamts15 Adamts15 173.38 extracellular region
GO:0005576 0.03% Ahsg Ahsg 143.77 extracellular region
GO:0005576 0.03% Cilp Cilp 101.07 extracellular region
GO:0005576 0.03% Angptl7 Angptl7 35.5 extracellular region
GO:0005576 0.03% Ccl6 Ccl6 30.3 extracellular region
GO:0009897 0.01% Cd36 Cd36 19.93 external side of plasma membrane
GO:0009897 0.01% Anpep Anpep 14.75 external side of plasma membrane
131 
GO:0009897 0.01% Abcg1 Abcg1 12.08 external side of plasma membrane
GO:0009897 0.01% Cd22 Cd22 7.5 external side of plasma membrane
GO:0009897 0.01% Ace Ace 7.03 external side of plasma membrane
Online Table II. Gene Ontology (GO) enrichment of differentially expressed genes in 3D/2D fibroblast states using marker 
set enrichment analysis. Genes weighted by differential expression in 3D vs 2D conditions were used for pathway enrichment. 
The top 5 genes in each module (GO Term) are shown, as well as enrichment parameters used for marker set enrichment 
analysis. 
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Cardiac Traits PC1 bicor PC1 pvalue PC2 bicor PC2 pvalue
LVID at end diastole 0.307153722 0.003061476 0.323570986 0.00175629
LVID at end systole 0.335373707 0.001155294 0.31977809 0.00200237
total heart mass 0.401094007 8.15E-05 0.382985671 0.00017906
Heart rate -0.096279289 0.363951754 0.012565032 0.90590092
 atrium mass -0.207355374 0.04858779 -0.194756892 0.06432276
 atrium mass/body weight 0.234401802 0.02532589 -0.126156765 0.23342204
Mitral in?ow E to A velocity o 0.206913009 0.049080681 -0.181414515 0.08525588
Mitral in?ow E velocity 0.142027866 0.179288492 0.027156442 0.79832003
right atrium mass 0.141874927 0.17976205 -0.213481134 0.0421724
right ventricle mass 0.248416495 0.017580812 -0.136692434 0.19635339
PW thickening -0.141602933 0.180606502 -0.027406706 0.79650139
IVS at end diastole 0.118263577 0.264212253 0.047024272 0.65803569
Fr onal shortening -0.117997784 0.265294858 0.069023215 0.51561902
Eje on on -0.116547941 0.271253069 0.069464983 0.51292866
IVS to PW o at end systole 0.110277742 0.298052867 0.140994675 0.18250542
Mitral in?ow A to E velocity -0.105389119 0.320114602 0.097216285 0.35927989
Velocity of circumfe l shorteni -0.092840053 0.381417667 0.020914209 0.84400568
Aor valve ejec on me -0.041190146 0.698266367 -0.006581397 0.95063029
right atrium mass/body weight -0.031229221 0.768863947 -0.162622492 0.12352472
ve wall thickness at end diasto 0.021042494 0.843061023 0.004800975 0.96397537
Non-Cardiac Traits PC1 bicor PC1 pvalue PC2 bicor PC2 pvalue
glucose 0.071762413 0.49905418 0.079651552 0.45294327
liver mass 0.419959472 3.41E-05 -0.204154599 0.05224801
body weight 0.356474817 0.000523921 -0.217214 0.03862046
adrenal mass/body weight 0.017261024 0.870994403 -0.068477455 0.5189526
lung mass 0.314333443 0.002410094 -0.191032842 0.06969477
lung mass/body weight 0.028022775 0.792029117 -0.148271069 0.16072745
free y acids 0.261513514 0.012282178 -0.349471421 0.00068532
unesteri?ed cholesterol -0.001138736 0.991452678 -0.215058364 0.0406398
total cholesterol 0.058346891 0.582752968 -0.338164028 0.00104384
HDL 0.204694279 0.051615441 -0.340203757 0.00096866
trigycerides 0.197385148 0.060737614 -0.103279085 0.32995308
adrenal mass 0.159128625 0.131907152 -0.101031122 0.3406441
liver mass/body weight 0.237248848 0.023552203 -0.168058428 0.1113036
Online Table III. Traits measured in the HMDP following infusion of isoproterenol and their correlation with principal 
components based on genes upregulated in 3D fibroblasts. Individual cardiac and non-cardiac traits were plotted against 
the strain position on each component axis (as illustrated in Figure 3C-L).  From these correlations, bicorrelation coefficients 
and corresponding p-values were calculated for each PC x trait relationship.  Traits illustrated in Figure 3 are highlighted with a 
grey background.
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Gene adjusted pvalue
Adamts15
Ahsg
Cilp
Wfdc3
Ptgds
Ctrb1
Fndc5
Agt
Angptl7
Dkk3
Fam180a
Ig?p5
Mmp11
Htra3
Penk
Emid1
Fbln7
Plin4
Ccl8
Mmp2
Mamdc2
Sparcl1
Fam198a
Tg?i
Fgl2
Il1rn
Epor
Pik3ip1
Enpp3
Enpp2
C2
Col9a2
Lpl
Mfap2
Fbln1
Pamr1
Lgi4
Smoc2
Sepp1
Adamtsl2
C1ql1
Sned1
Apoe
Iglon5
Vash1
Clu
6.26E-07
2.05E-21
4.22E-06
1.96E-25
4.14E-13
5.63E-05
2.46E-07
2.79E-16
1.16E-07
5.87E-27
4.03E-12
1.62E-28
2.03E-228
1.39E-07
0.008313927
0.005125138
8.73E-23
1.19E-06
0.000140485
3.15E-26
5.10E-38
1.66E-05
2.13E-05
2.13E-32
8.79E-09
0.009482538
0.001064303
4.01E-10
1.77E-25
7.36E-05
0.0008716
0.001275955
0.002443402
9.54E-11
0.000326378
0.000697679
1.64E-09
3.10E-05
5.53E-19
2.79E-11
0.000609573
1.21E-05
0.001412247
4.34E-11
0.005782713
0.00605853
Online Table IV
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Dpt 0.008989791
Pla2g2e 0.000201816
Serpine2 4.13E-10
Dpp7 7.48E-19
Ssc5d 1.21E-06
Cpz 0.002400706
Islr 6.52E-06
Psap 0.008066424
Matn4 2.40E-09
Creg1 0.002226995
Ephb6 1.32E-08
Matn2 1.81E-05
Fam19a5 0.000596104
Sorl1 0.003374037
Slc17a5 0.000125364
Ctsl 3.23E-05
Hsd17b11 4.15E-18
Sord 2.79E-06
I?30 0.009015165
Sdc1 0.002285504
Tcn2 0.001758118
Gnptg 0.00861747
Grn 0.004461313
Txndc16 6.76E-07
Scpep1 3.31E-17
Mmp19 0.002352839
Glb1l 4.94E-05
Online Table IV. Genes upregulated in 3D cardiac fibroblasts filtered for secreted factors. Genes upregulated in the 3D cardiac 
fibroblast state were filtered for secreted factors by overlaying the gene symbol of 3D specific transcripts with deposited data of known 
secreted factors within the Universal Protein Resource (UniProt) using the following accessions: location:"Secreted [SL-0243]" 
type:component AND organism:"Mus musculus (Mouse) [10090].  The p values listed were generated from differential expression 
analysis of 3D vs 2D transcripts using a 10% FDR.
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Chapter 7  
CONCLUSIONS AND FUTURE DIRECTIONS 
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Summary of Work Presented 
Developments of LCI and HSLCI technologies have enabled precise measurements of live 
single cell mass, morphology and motion over time. The characterization of biophysical properties 
on both small single cell and large population scales addressed many questions in studies of cancer 
biology, cardiac biology and basic fundamental biology research. The work presented in this thesis 
showcased several significant accomplishments of LCI and HSLCI in these fields of study, which 
demonstrated the platform’s versatility of handling a wide variety of experimental setup and 
biological sample types. LCI and HSLCI are capable of imaging single cells, cell clusters and large 
colonies, both in adherence or in suspension. These samples range from immortalized cancer cell 
lines, to primary cells from animal models and patient samples. Furthermore, LCI and HSLCI 
quantification of melanoma heterogeneity and drug responses to front line therapies on the single 
cell level showcased that these imaging platforms are capable of the resolution, precision, speed 
and throughput required for clinical applications. The study of cancer cell fate response to mitotic 
inhibitors further validated the clinical and industrial utility of LCI in drug screening, development 
and dose selection. Finally, the work in cardiac hypertrophy and wound healing linked genomic 
expressions and molecular phenotypes to biophysical properties, demonstrating the advantages of 
using LCI in correlative molecular and genomic studies in basic research. In short, this thesis 
presented the development, implementation, and validation of LCI and HSLCI as capable tools in 
both bench and bedside applications. 
Future Directions 
Imaging tumor organoids using HSLCI 
Traditional two-dimensional cell culture is the most widely used tissue culture setup in 
basic research and drug development. Even though almost all breakthroughs in biological sciences 
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came from 2D cultures in the past century, microenvironments of in vivo conditions became 
increasingly important in studies of cancer and regenerative medicine in the past few decades, 
propelling development of novel solutions in 3D tissue culture.1-3 The most important missing 
factors in 2D culture is the diversity of cell types, such as stromal cells and infiltrating immune 
cells, and the diffusion of small signaling molecules from these cell types. In addition to the lack 
of cell type diversity, 2D cultures are often conducted on hard plastics with stagnant cell culture 
fluid, which does not mimic in vivo physical properties of cell surroundings. This stagnant 
environment can induce changes in genotypes and phenotypes that alter cell growths, divisions, 
differentiations and drug responses.4 Recent developments in culturing 3D spheroids and 
organoids aim to address the issues stated above and to provide better models for studies in basic 
research and drug developments.5, 6 
Last year, Dr. Alice Soragni and her team developed a high throughput approach of 
culturing and studying patient sample derived tumor organoids, and have started collaborative 
studies with the Teitell lab to investigate organoid biology using HSLCI.7 Although the organoid 
culture setup can be greatly improved to allow optimal quantitative phase imaging, LCI captured 
quantitative phase maps of small pancreatic adenocarcinoma organoids (Figure 7-1). However, a 
number of issues still need to be resolved to use this technique for organoid studies. One concern 
of employing quantitative phase imaging in this setup is that small tissue organoids have inherent 
spherical geometries that can act as lenses to distort sample illumination light. This distortion is 
likely to introduce errors in quantitative phase information and produce inaccurate biomass density 
maps of the organoids. A solution to this issue is to mathematically model optical light paths 
through organoid scale spherical lenses and to derive the correlation between resulting HSLCI 
image and actual phase shift of illumination light. Another technical concern in this study is the 
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issue of phase-wrapping in dense organoids, as seen in Figure 7-1. Images of the organoids will 
require additional phase-unwrapping processing for better accuracy. To conduct correlative studies 
on organoids with florescence imaging, additional complexity to existing imaging setup is needed 
to achieve florescence image acquisition at different focal planes. Lastly, the quantitative phase 
imaging setup, specifically the sample illumination setup, can be altered to perform 3D quantitative 
phase imaging that provides enhanced vertical resolution in phase.8, 9   
Patient tumor sample studies using HSLCI 
A natural progression of HSLCI work in characterizing melanoma heterogeneity and drug 
resistance is the large-scale patient tumor sample screening for optimal drug cocktails. Previous 
studies have shown correlation between in vitro biomass decline with patient response to drug 
treatments on a small scale.10 Rapidly and accurately quantifying large scale primary patient tumor 
sample response to panels of drug cocktails before selecting optimal therapeutics strategies will 
allow correlation between HSLCI outcomes to actual patient outcomes in clinical trials and 
Figure 7-10 Example quantitative phase images of small pancreatic adenocarcinoma organoids 
Organoids are cultured and embedded in 3D Matrigel. 
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types that are frequently biopsied for diagnosis, such as melanoma, breast cancer and blood 
cancers. Primary patient samples cannot survive long outside of the human body. Therefore, the 
high speed and throughput of HSLCI maximizes the utility of precious patient samples in 
diagnostics and therapeutics screening. Additionally, patient samples can be cultured in 3D using 
methods mentioned in the previous section, allowing parallel studies with 2D culture to gain 
additional data that better simulates tumor response in vivo.  
Tumor heterogeneity and drug resistance study 
While previous studies uncovered single cell growth rate heterogeneity with and without 
drug treatments, the results only reflected cell responses in a single melanoma cell line and co-
culture conditions with two patient tumor-derived cell lines. Future studies should investigate 
heterogeneity and drug response in co-cultures consisting of three or more melanoma cell lines, 
which better simulates heterogeneity in patient tumors. Previous studies showed that cells can 
acquire drug resistance through genetic and epigenetic modifications.11-13 Cells that acquired 
upregulated RTK signaling can possibly influence the drug response and adaptation of cells that 
acquired specific genetic lesions through epigenetic alterations in co-cultures. Correlative studies 
of co-culturing effect on evolution of drug resistance in cell lines with unique molecular 
mechanisms for resistance, can provide a model for novel therapeutic strategies. Furthermore, LCI 
can quantify intercellular effects and interactions between different cell types. Co-culture drug 
response studies of tumor cells with stromal and immune cells can yield additional evidence for 
outcome prediction in vivo and shed light on the systemic effects of chemotherapeutics. For 
example, chemotherapeutic agents have known immunomodulatory effects on tumor 
microenvironment and cancer immunotherapy.13-15 Therefore, LCI can be utilized to investigate 
the change in killing efficiency, cell mass, growth rates, motility and other biophysical properties 
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of tumor infiltrating lymphocytes in co-culture with cancer cells being treated with chemotherapy. 
Lastly, the long term culture and imaging ability of HSLCI permits extended correlative studies of 
cancer cells, allow investigation into the  acquisition of resistance mechanisms in response to 
single or multiple therapeutic agents. For example, it was observed that knocking down tumor 
suppressor genes SIRT2 significantly accelerates tumor resistance adaptation in M249 parental cell 
line. HSLCI can be used to continuously quantify cell mass, growth rates and other biophysical 
properties of M249 cells in response to long-term drug exposure. Subsequently, molecular and 
genomic analysis can be performed on isolated single cells or colonies of interests to elucidate the 
mechanisms of action used during this adaptation process. 
Cell fate and mitotic inhibitor response study 
The study presented in this thesis characterized single cell fate responses to individual 
mitotic inhibitors, and showed varying degrees of mitotic slippage and aberrant cell fate events. 
As stated in a previous chapter, investigating the effects of combinatorial drug treatments, such as 
a mitotic inhibitor with a chemotherapeutic agent, can provide additional insights that aid novel 
therapeutic development.16 Additionally, LCI can be used to quantify cell growth and cell fate 
responses to inhibitors that target different stages of the cell cycle (e.g. Intraconazole, Baicalein 
and Daidzein for G1 or G2), enabling correlative studies of cell cycle and growth regulation with 
further molecular dissections. Lastly, deep learning can be employed in conjunction with LCI 
imaging to deliver rapid and robust quantification of cell fates in cell cycle studies. This integration 
can replace previously laborious semi-manual data analysis and cell fate identification, and can be 
applied to previously mentioned studies of tumor heterogeneity and drug responses of mixed-cell-
type co-cultures.  
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Conclusion 
LCI and HSLCI are powerful QPI tools with remarkable consistency, flexibility, versatility 
and applicability in characterizing biophysical properties for basic and translational research. 
Previous works in tumor heterogeneity and drug response, cell cycle regulation and cardiac 
biology showcased the importance and advantage of quantifying biophysical properties, and paved 
ways for future studies in fundamental biology and medicine. The utility of HSLCI is constantly 
expanding through incorporation of novel analytical tools and technologies, such as microfluidics 
and deep learning. With future software and hardware developments, HSLCI not only has great 
promise to link biophysical properties to genomic and molecular studies for a complete 
appreciation of cellular processes, but also has immense capabilities to provide valuable clinical 
insights in precision medicine.  
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Appendix-I 
APOPTOSIS STUDY 
145 
Introduction 
LCI and other quantitative phase imaging techniques have quantified single cell and colony 
biomass change during normal cell growth, differentiation and cell death in response to drug 
treatments.1-3 While most interests in quantifying biomass change have focused on cell growth and 
cell cycle related inquries, biomass change during cell death has remained mostly uncharacterized. 
Biomass and the decline of mass accumulation rate have typically been associated with cell death, 
which was demonstrated in previous QPI studies.2, 4 However, biomass loss patterns and dynamics 
during specific mechanisms of cell death are still unclear. Biomass dynamic profiles for specific 
mass loss mechanisms, such as autophagy, apoptosis and necrosis can serve as powerful tools in 
future studies of single cell response to physical and chemical stimuli. This study aims to link 
changes in a biophysical property to well define molecular pathways and processes within a cell.  
To characterize loss of biomass and link it to a specific set of pathways, a well define mass 
loss mechanism was chosen for this study. Actinomycin d is a transcription inhibitor that binds 
to DNA at the transcription initiation complex and prevents elongation of RNA chain by RNA 
polymerase. Treatments of actinomycin d induces apoptosis, a form of programmed cell death that 
entails blebbing, nuclear fragmentation, chromatin condensation, cell shrinkage and death.5-8 In 
this study, death by apoptosis in M202 cells in response to actinomycin d was first confirmed by 
immunofluorescence (IF) staining and flow cytometry. Single cell and population mass loss 
characteristics during apoptosis were then quantified and analyzed using LCI.  
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Results and Discussion 
To study cell mass change during apoptosis, we first confirmed that M202 cells underwent 
apoptosis in response to actinomycin d treatment using IF staining and flow cytometry. Cells were 
stained for nucleus, cytochrome c and tom20 and imaged under confocal microscopy. Cytochrome 
c is released during early apoptosis from mitochondria to cytoplasm, and is a common molecular 
Figure 8-11 Analysis of biomass change during apoptosis 
a) Confocal images of IF staining in M202 cells under normal cell culture media, 0.1% DMSO and
20 µM actinomycin d treatment. Apoptotic cells in actinomycin d treatment showed dispersed patters 
of cytochrome c, where cells in control conditions showed punctate patterns of cytochrome c that co-
localized with tom20, a mitochondria marker. Flow cytometry analysis of Annexin V/SYTOX 
staining results showed apoptotic percentages of 4.43%, 2.84% and 9.27% in media, DMSO and 6 h 
of actinomycin d treatment respectively. b) Biomass over time tracks of a single M202 cell in media 
control condition and a single M202 cell under 20 µM actinomycin d treatment. Biomass of apoptotic 
blebs were also tracked during cell death. c) Images of the specific apoptotic cell tracked in b). 
Segmentation of apoptotic bodies is shown in the last frame. d) Population average normalized 
biomass over time in apoptotic M202 cells. Cell biomass were binned by every 4 minutes and 
normalized to the point of mass decline at the beginning of the blebbing process. Red line indicates 
the average values and whiskers indicate the standard deviations.
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marker for apoptosis. Tom20 is a mitochondria marker that is routinely used alongside cytochrome 
c to visualize co-localization of the two in the mitochondria networks inside the cell. Cells under 
normal control condition should exhibit punctate patterns in both cytochrome c and tom20, and 
the two stains should overlap. This was seen in M202 cells in media and DMSO controls (Figure 
8-1a). These M202 cells also showed rounded and healthy-looking nuclei, in contrast to the
apoptotic cells after 6 h of 20 µM actinomycin d treatment that exhibited shriveled and irregular 
shaped nuclei. Cytochrome c and tom20 stains were dispersed in apoptotic cells under drug 
treatment, indicating the release of cytochrome c into the cytoplasm. 
Flow cytometry was also utilized to confirm apoptosis as the mode of cell death in 
actinomycin d treated M202 cells. An Annexin V/SYTOX staining kit was used to detect the 
externalization of phosphatidylserine in apoptotic cells. Flow analysis showed that 4.43%, 2.84% 
and 9.27% of cells were apoptotic in media, DMSO and 6 h of 20 µM actinomycin d treatment 
respectively (Figure 8-1a). Data also revealed that 0.36%, 0.27% and 0.62% of the population 
were in early apoptosis, where phosphatidylserine was detected but the cell membrane has not 
been permeabilized (Figure 8-1a). Together, IF and flow cytometry confirmed that M202 cell 
deaths in response to actinomycin d are apoptotic.  
M202 cells were then imaged using Bruker-Michelson phase shifting interferometry setup 
under conditions stated above. Figure 8-1b demonstrates a comparison of biomass-over-time track 
between a normal cell in media and an apoptotic cell in response to 20 µM of actinomycin d 
treatment. The healthy cell continuously accumulated biomass over time, where the biomass of the 
apoptotic cell plateaued at around 250 mins after imaging began and slowly decayed over the next 
300 mins until eventually massively declined due to blebbing. Images of the apoptotic cell and its 
apoptotic blebs are shown in Figure 8-1c. As the biomass of the apoptotic cell massively declined, 
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the apoptotic bodies quickly gained then lost biomass as seen in Figure 8-1b. This was probably 
due to the instability of apoptotic bodies and their permeable membranes. Many biomass-over-
time tracks similar to the apoptotic example were collected and normalized to the time and biomass 
at which the blebbing process begins. The population average was plotted over time, binned by 
every 4 minutes. The overall trend of fast decay at blebbing point holds true for most cells, 
however, further mathematic modeling and statistical analysis is required to characterize the 
specific patterns.  
Future studies using a range of actinomycin d concentrations and a variety of other 
apoptotic agents can provide insights into biomass decay characteristics for specific apoptotic 
pathways and specific drug thresholds. Other cell death patterns, i.e. necrosis and autophagy, 
should also be studied using chemical or physical stimuli. Furthermore, this study required 
laborious manual image and data analysis with a low throughput imaging system. This study can 
be repeated using HSLCI and deep learning to rapidly profile cell death characteristics with 
additional parameters from other biophysical properties such as morphology, motion and 
membrane elasticity.  
Methods 
Cells and cell culture 
M202 human melanoma cells were a gift from Dr. Owen Witte (UCLA). M202 cells were 
maintained in RPMI 1640 media (Thermo Fisher Scientific), with each media supplemented by 
10% FBS (Omega Scientific), 100 U/mL penicillin (Corning), 100 µg/mL streptomycin (Corning) 
and 2 mmol/l-glutamine (Thermo Fisher Scientific). 
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Flow cytometry 
Cells were collected using EDTA after 6 h of control or drug exposure, washed three times 
with 1x PBS, pH 7.4, the re-suspended in annexin binding buffer made with Anexin V/SYTOX 
kit (Invitrogen). Pacific BlueTM annexin V and SYTOX stain working solution were added to the 
cells and incubated at room temperature for 30 minutes. 1x annexin binding buffer was then added 
and the sample was kept on ice before analysis. Flow cytometry was performed on FACS BD 
LSRII and FACS BD Fortessa flow cytometers (BD Biosciences). Apoptosis analysis was by 
FlowJo software.  
Immunofluorescence staining 
Cells were seeded onto chambered coverglass slides and allowed to adhere overnight, then 
treated with control or 6 h of drug treatment the next day. Cells were fixed with 70% formaldehyde 
in 1 x PBS, pH 7.4, and permeablized in 0.1% Triton-X. Samples were then incubated with tom20 
rabbit antibodies and cytochrome c mouse antibodies over night at 4oC. Secondary antibodies of 
anti-rabbit Alexa red 568 and anti-mouse Alexa 488 were then introduced at room temperature for 
1 h. Coverglass slides were then mounted onto imaging glass slides using mounting solution 
containing DAPI and sealed with nail polish. Confocal images were taken with a Zeiss LSM 780 
CCD camera using Zen 2010 software. 
Interferometer 
The live cell interferometer setup and workflow has been previously published.1, 2, 4, 9 A 
modified Bruker NT9300 optical profiler (Bruker; Tucson, AZ) with a 20X 0.28NA Michelson 
interference objective was used to perform phase shifting interferometry on M202 cells. 
Quantitative phase images of cells were acquired and processed through phase-unwrapping, 
background correction, image segmentation and particle tracking algorithms in MatLab 
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(Mathworks Inc., Natick, MA). Manual phase-unwrapping and image segmentations were required 
for this study.  
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Abstract
Polynucleotide phosphorylase (PNPase) is an essential mitochondria-localized exoribonu-
clease implicated in multiple biological processes and human disorders. To reveal role(s) for
PNPase in mitochondria, we established PNPase knockout (PKO) systems by first shifting
culture conditions to enable cell growth with defective respiration. Interestingly, PKO estab-
lished in mouse embryonic fibroblasts (MEFs) resulted in the loss of mitochondrial DNA
(mtDNA). The transcriptional profile of PKO cells was similar to rho0 mtDNA deleted cells,
with perturbations in cholesterol (FDR = 6.35 x 10−13), lipid (FDR = 3.21 x 10−11), and sec-
ondary alcohol (FDR = 1.04x10-12) metabolic pathway gene expression compared to wild
type parental (TM6) MEFs. Transcriptome analysis indicates processes related to axono-
genesis (FDR = 4.49 x 10−3), axon development (FDR = 4.74 x 10−3), and axonal guidance
(FDR = 4.74 x 10−3) were overrepresented in PKO cells, consistent with previous studies
detailing causative PNPase mutations in delayed myelination, hearing loss, encephalomyo-
pathy, and chorioretinal defects in humans. Overrepresentation analysis revealed alter-
ations in metabolic pathways in both PKO and rho0 cells. Therefore, we assessed the
correlation of genes implicated in cell cycle progression and total metabolism and observed
a strong positive correlation between PKO cells and rho0 MEFs compared to TM6 MEFs.
We quantified the normalized biomass accumulation rate of PKO clones at 1.7% (SD ±
2.0%) and 2.4% (SD ± 1.6%) per hour, which was lower than TM6 cells at 3.3% (SD ± 3.5%)
per hour. Furthermore, PKO in mouse inner ear hair cells caused progressive hearing loss
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that parallels human familial hearing loss previously linked to mutations in PNPase. Com-
bined, our study reports that knockout of a mitochondrial nuclease results in mtDNA loss
and suggests that mtDNA maintenance could provide a unifying connection for the large
number of biological activities reported for PNPase.
Introduction
Polynucleotide phosphorylase (PNPase) is a conserved 3’-5’ exoribonuclease that bacteria and
most eukarya express, but is absent in archae [1, 2]. In addition to phosphorolytic RNA
degrading activity, bacterial PNPase catalyzes template independent polymerization of RNA
[3, 4]. The enzymatic features of bacterial PNPase have been well studied [4–10] and recent
discoveries reveal bacterial PNPase involvement in modulating levels of multiple mRNAs and
sRNAs [4, 11–13], an etiology in cold-shock [14–16] and oxidative stress responses [17], bio-
film formation [18–20], virulence [21], and even DNA recombination, repair and mutagenesis
[22–25].
Similar to its bacterial counterpart, mammalian PNPase has several roles in RNA homeosta-
sis, and it has also been found to function within mitochondria. Constitutive PNPase knockout
(PKO) in mice is lethal at embryonic day 8, because PNPase is essential for maintaining mito-
chondrial homeostasis in all cell types [26, 27]. Mammalian PNPase exhibits enzymatic features
that are similar to bacterial PNPase with a different optimal phosphate concentration for RNA
degradation [28, 29]. PNPase localizes to both the intermembrane space (IMS) and matrix com-
partments of mitochondria, as revealed in several model systems and by multiple localization
methods [26, 27, 30, 31]. Knockdown studies have shown variable effects on the processing and
polyadenylation of mitochondrial RNA (mtRNA) that is transcribed from mitochondrial DNA
(mtDNA) [32–34]. In addition to RNASET2, which is a mitochondrial RNA degrading enzyme
[35], recent studies have established that PNPase and the hSUV3 RNA helicase form a mtRNA
degrading complex and degrade mirror-mtRNAs, which are noncoding mtRNAs that are anti-
sense and complementary to coding mtRNAs [31, 34, 36].
Also similar to bacterial PNPase, mammalian PNPase participates in many physiologic
pathways beyond mtRNA regulation. One study suggests that PNPase regulates c-Myc levels
possibly through interactions with EGFR [37], whereas another study suggests PNPase con-
trols an interferon-β (IFNβ)-induced reduction of c-Myc mRNA [38]. PNPase modulates an
IFNβ-induced decrease of mir-221 levels that results in growth inhibition in melanoma cells
[39] and it regulates nucleus encoded small non-coding RNA import into mitochondria [27,
40]. PNPase is a type-I IFN induced gene [41] and over-expression at supra-physiologic levels
affects reactive oxygen species (ROS) generation and NF-κB activation [42]. Recently, PNPase
was linked to metabolism control during somatic cell reprogramming to induced pluripotent
stem cells [43, 44]. In humans, PNPase mutations genetically link to hereditary hearing loss,
encephalomyopathy, and axonal and auditory neuropathy, gut disturbances, chorioretinal
defects, Leigh syndrome, and delayed myelination [45–50]. Combined, PNPase affects many
essential cellular processes and pathways that regulate organism physiology and pathology
without a unifying theme or underlying mechanism, which requires further investigation.
Almost all investigations to date elevate PNPase to supra-physiologic levels in gain-of-func-
tion studies or use knockdown approaches with incomplete loss of PNPase in loss-of-function
work to gain insight into mammalian PNPase activities. A few studies examined changes in
gene expression profiles with gain and loss of PNPase function using these approaches to help
PNPase knockout results in mtDNA loss
PLOS ONE | https://doi.org/10.1371/journal.pone.0200925 
July 19, 2018
155 
PLOS ONE | https://doi.org/10.1371/journal.pone.0200925 
July 19, 2018
explain the plethora of impacted physiologic systems [51, 52]. However, no study eliminated
PNPase completely to evaluate the impact on global gene expression and cell function, likely
due to the essential role of PNPase for cell growth and survival under usual conditions in vivo
and in culture. Given its mitochondrial localization, roles in mtRNA regulation, and its activity
in small nucleus-encoded RNA import into mitochondria to control respiration, we reasoned
that reducing the dependence of cells on mitochondrial function first could generate a suitable
internal cell environment for stable knockout of PNPase. Here, we established complete PKO
cells by first reducing immortalized mouse embryonic fibroblast (MEF) dependence on respi-
ration. The resulting PKO cell lines enabled studies of changes in gene expression and cell
function directly due to PNPase loss. We also examined the effect of PNPase loss-of-function
in inner ear hair cells in mice, as homozygous PNPase mutation or loss links with familial
hearing loss in humans [45].
Results
PNPase knockout results in loss of mtDNA and inability to respire
Our previous attempts to generate a PKO MEF line failed because deletion of the PNPase-
encoding gene, Pnpt1, ultimately caused cell death [27]. Given its essential role in maintaining
mitochondrial homeostasis and its mitochondrial localization, we considered that PKO might
disrupt mitochondrial functions required for survival [26]. To test this idea, and because cell
lines are known to rely on mitochondria to varying extents, we sought to establish PKO MEFs
using a two-step approach. First, we generated a cell line that lacked mtDNA (rho0) using
Pnpt1fl/flMEFs isolated from our Pnpt1fl/flmouse colony. SV-40 large T-antigen immortalized
Pnpt1fl/flMEFs, designated TM6, were incubated in media containing ditercalinium chloride
and uridine for 3 weeks to eliminate the mtDNA [53]. PCR validated, respiration defective
rho0 Pnpt1fl/flMEFs were then infected with an adenovirus expressing Cre recombinase to
delete the loxP-flanked portion of exon 2 in Pnpt1, generating non-functional PNPase-encod-
ing alleles that translate out-of-frame with multiple stop codons in exons 3, 4, and 6 [27].
Using this strategy, we obtained numerous independent rho0 PKO MEF clones, indicating
that eliminating mtDNA first provides a permissive internal cell environment for the complete
loss of PNPase (data not shown).
rho0 mammalian cells are pyrimidine auxotrophs that require uridine media supplementa-
tion to grow due to an inactive dihydroorotate dehydrogenase enzyme in the mitochondrial
inner membrane, resulting from a non-functional electron transport chain (ETC) [54].
Encouraged by the generation of a PKO in rho0 MEFs, we considered whether a simple pre-
conditioning of mtDNA-containing MEFs with rho0 permissive, uridine-supplemented
media, rather than by chemical removal of mtDNA, would result in PKO MEF lines. There-
fore, we incubated Pnpt1fl/flTM6 MEFs in uridine-containing media for 3 weeks, followed by
infection with an adenovirus expressing Cre recombinase. Multiple individual PKO MEF
clones emerged from a background of dead and dying cells; these clones were isolated,
expanded, and 5 clones were PCR verified for complete loss of loxP-flanked exon 2 in the
Pnpt1 gene, as performed previously using internal and external PCR primer sets (Fig 1A)
[27]. We selected 3 PKO MEF clones, designated PKO-1, PKO-4, and PKO-6, for additional
analyses. Immunoblotting revealed undetectable PNPase protein in these 3 PKO clone lines, in
contrast with strong PNPase expression from Pnpt1fl/flTM6 and rho0 MEFs (Fig 1B). Thus,
mtDNA-containing MEFs conditioned to grow in uridine-supplemented media tolerate PKO,
whereas MEFs in standard growth media are non-permissive for PNPase loss.
To examine the impact of PKO on cell function, we first determined the effects on mtDNA
content because chemically induced loss of mtDNA enabled subsequent PKO. Surprisingly,
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Fig 1. PKO results in loss of mtDNA. (A) PCR to evaluate Pnpt1 (encoding PNPase) exon 2 deletion in the parental MEF line, TM6, and 5 
independent PKO lines (n = 5). Three primer sets include one to examine Pnpt1 exon 2 (in exon 2), a flanking set to capture deletion of exon 2 
(span exon 2), and a control set that amplified the 3’ end of Pnpt1 (PNPase 3’ end). (B) Representative immunoblot for PNPase protein in TM6, 
rho0 and 3 PKO clones. Total protein lysates were separated by SDS-PAGE and analyzed using polyclonal antibodies that target PNPase and β-
actin. (C) TaqMan quantitative PCR (qPCR) analysis of a control nucleus encoded Tfrc gene and the mtDNA encoded Rnr1, Nd3, and Cox3 
genes in TM6 and 3 PKO cell lines. This experiment was performed in biological triplicates (n = 3, ± SD). (D-F) Respiration analysis using a 
Seahorse XFe96 Extracellular Flux Analyzer on the cell lines in (B). These experiments were performed in biological quintuplicates, normalized 
to cell number per 103 cells. (D) Oxygen consumption rate (OCR) during mitochondrial stress, (E) basal extracellular acidification rate (basal 
ECAR), and (F) basal OCR/ECAR ratios are shown (n = 5, ± SD).
https://doi.org/10.1371/journal.pone.0200925.g001
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the TaqMan qPCR assay using probes specific to Rnr1, Nd3 and Cox1 showed no signal for all
3 PKO clones, identical to the lack of mtDNA in rho0 MEFs (Fig 1C). This result suggested
that PKO MEFs lost mtDNA. Additionally, PicoGreen double-stranded DNA dye staining
using fluorescence microscopy also suggested that mtDNA was not present in PKO cells (S1
Fig). Whereas the TM6 MEF cells displayed green puncta in the cytosol marking abundant
mtDNA, rho0 and PKO MEFs lacked green cytosolic puncta, confirming the loss of mtDNA.
All 3 PKO clones and rho0 MEFs showed no mitochondrial respiration, which contrasted with
TM6 MEFs, as measured by a Seahorse XFe96 extracellular flux analyzer (Fig 1D). This result
was consistent with loss of mtDNA and resultant failure of the ETC (Fig 1C). Rather, these
PKO cells manufacture energy by substantially increasing glycolysis and show an elevated
basal extracellular acidification rate (ECAR) relative to TM6 MEFs (P value = 0.0079 for PKO-
1, PKO-6, and rho0 to TM6 comparisons, P value = 0.0159 for PKO-4 to TM6 comparison)
(Fig 1E). In cells with low or absent respiration, ECAR is a good approximation of glycolysis
and lactate excretion. A plot of the ratio of basal OCR/ECAR provides a remarkable graphic
display for the metabolic alteration caused by PKO (P value< 0.0079 for all PKO and rho0 to
TM6 comparisons) (Fig 1F). Combined, these genetic, protein, and functional data indicate
that MEFs that lose PNPase cannot respire or maintain the mitochondrial genome.
Transcriptional, growth and cell cycle profiles are similar for PKO and
rho0 cells
To determine the effect of PNPase loss on gene expression and the potential to alter cell physi-
ology, we performed RNA-Seq analyses on TM6 MEFs, rho0 cells derived from TM6 MEFs
and PKO-1 and PKO-6 MEFs. PKO-4 cells were excluded from analysis because of aneuploidy
detected by cell cycle profiling (data not shown). Principal components analysis (PCA), used
to determine sample covariance with respect to their transcriptomic features, indicated exten-
sive transcriptional variance, denoted by the first principal component (PC1), between TM6
MEF cells and the remaining cell lines (Fig 2A). Isolated PKO cells clustered away from the
parental TM6 cell line and showed variability in inter-clone gene expression with little intra-
clone variation (Fig 2A). However, PKO-1 and PKO-6 MEFs displayed similar expression sig-
natures to rho0 TM6 MEFs (Fig 2A). A rank-rank hypergeometric overlap (RRHO) analysis
calculating the significance between overlaps of averaged PKO and rho0 expression changes
with respect to TM6 indicates strong correlative overlap in expression profiles between PKO
and rho0 cells (maximum–log10(P value) > 4500) (Fig 2B). We identified a significant overlap
in up- and down-regulated transcripts within PKO and rho0 signatures and additionally
sought to identify differentially expressed genes (DEGs) in both expression profiles. Our analy-
sis identified 1,629 DEGs between rho0 and TM6 MEFs, with a false discovery rate (FDR)
adjusted P value below 0.01 and an absolute log2 fold-change above 0.5, and 1,527 DEGs
between PKO and TM6 MEFs using the same thresholds (Fig 2C). Of the DEGs expressed by
rho0 and PKO MEFs, 886 genes were in common, as anticipated due to significant overlaps in
RRHO analysis and similar cellular physiology with the loss of mtDNA (Fig 2C).
We performed Gene Ontology (GO) gene set overrepresentation analysis (ORA) for each
area represented in the Venn diagram (Fig 2C) and examined DEGs that are specific to rho0
MEFs (cluster 1) and PKO MEFs (cluster 3) and those DEGs shared between rho0 and PKO
MEFs (cluster 2). GO terms overrepresented in cluster 1 identified processes including regula-
tion of cell morphogenesis (FDR = 4.45 x 10−4), cell-cell junction assembly (FDR = 8.70 x
10−3), mitochondrial DNA replication (FDR = 0.014), and regulation of protein stability
(FDR = 0.026) (Fig 2D). Genes whose expression associates with mtDNA replication are ele-
vated in rho0 and reduced in TM6 MEFs (S2 Fig). These genes include a subunit of
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Fig 2. PKO cell gene expression patterns converge and diverge with rho0 MEFs. (A) Principal Components Analysis (PCA) of TM6, rho0, 
PKO-1, and PKO-6 MEFs (n = 3 biological replicates per line; 12 replicates total). Expression profiles for each sample were plotted for their PC1 
and PC2 scores, providing primary and secondary sources of variance, respectively. Samples were color-coded based on cell type. (B) Rank-rank 
hypergeometric overlap (RRHO) maps of the log2 fold-change expression profiles between PKO and rho0 MEFs with respect to TM6 MEFs. 
Color coding represents–log10 transformed hypergeometric P values, with higher values indicating strength of overlapping enrichment between 
PKO and rho0 gene lists. (C) Venn diagram of differentially expressed genes (DEGs) between rho0 MEFs (left) and PKO clones (right) with 
respect to TM6 MEFs. DEGs were identified in each comparison using an absolute log2 fold-change threshold above 0.5 and a false discovery rate 
(FDR) adjusted Wald P value below 0.01. Clusters indicate rho0 specific (cluster 1), PKO specific (cluster 3), and shared DEGs (cluster 2).(D) 
Dotplot of Gene Ontology (GO) overrepresentation analysis (ORA) of the rho0 specific, shared, and PKO specific DEG clusters. Dot size 
indicates the ratio of genes from the selected ontology set in the DEG cluster, color indicates significance of gene set overrepresentation in the 
cluster (FDR adjusted P value) following hypergeometric significance testing.
https://doi.org/10.1371/journal.pone.0200925.g002
PNPase knockout results in mtDNA loss
159 
PLOS ONE | https://doi.org/10.1371/journal.pone.0200925 
July 19, 2018
ribonucleotide reductase that regulates cytosolic nucleotide pools (Rrm2b), an RNase that
removes an RNA primer in replicating mtDNA (Rnaseh1), and a pyrimidine transporter
(Slc25a33) (S2 Fig).
Amongst pathways overrepresented by PKO and rho0 MEF DEGs (cluster 2) are cholesterol
metabolic processes (FDR = 6.35 x 10−13), sterol metabolic processes (FDR = 6.35 x 10−13),
lipid biosynthetic processes (FDR = 3.21 x 10−11), and secondary alcohol synthesis
(FDR = 1.04 x 10−12), which were all reduced in both cell types (S2 Fig). Cholesterol and sterol
biosynthetic process repression is consistent with data from PNPase shRNA knockdown in
melanoma cell lines, reported previously [52].
Pathways pertaining to neuronal function are overrepresented in PKO specific cluster 3
and include axonogenesis (FDR = 4.49 x 10−3), axon development (FDR = 4.74 x 10−3), and
axon guidance (FDR = 4.74 x 10−3) (Fig 2D). We extracted specific genes belonging to the axo-
nogenesis, axon development and axon guidance pathways identified in the ORA for analysis
(Fig 3A and S1 Table). Among this list are genes involved in survival of neural cells such as
Bcl2 and Artn [55, 56], cell junction or adhesion such as Vcl and Agrn [57, 58], and cell migra-
tion such as Reln, Robo3, Sema4d, Sema5, Wnt5a, Dag1, Robo1, and Fgfr2 [59–66]. Although
this study uses MEFs, it is interesting to note that the change in these particular genes correlate
with the lack of PNPase expression relative to their TM6 and rho0 MEF counterparts, since
PNPase mutations are linked to delayed myelination, hearing loss, encephalomyopathy, gut
disturbances, and chorioretinal defects in humans [45–50]. Axonogenesis (FDR = 1.14 x 10−3)
and axon development (FDR = 2.00 x 10−4) pathways are also overrepresented in genes shared
between rho0 and PKO MEF DEGs (cluster 2). However, these axonogenesis and axon devel-
opment pathway overrepresented genes (cluster 2) differ from genes in PKO MEF-specific
cluster 3 for the same ontologies. Thus, both loss of PNPase and loss of mtDNA may contrib-
ute uniquely to neurologic pathologies in patients with PNPase mutations.
Because of the concordance in gene expression profiles between PKO and rho0 MEFs (Fig
2B), we examined cell growth, cell cycle progression, and metabolic features in these cell types.
Genes implicated in mitotic progression (KEGG: MMU04110) show a strong positive correla-
tion for rho0 and PKO relative to TM6 MEFs (Pearson Correlation Coefficient (PCC) = 0.86, P
value < 2.2 x 10−16) (Fig 4A). Furthermore, given the importance of metabolism in cell growth
and a key role for cholesterol biosynthesis in cell cycle progression, we assessed the correlation
of metabolic gene expression between PKO and rho0 MEFs [67, 68]. Total metabolic gene sets
(KEGG: MMU01100) showed similar positive correlations for PKO and rho0 expression pro-
files relative to TM6 (PCC = 0.79, P value < 2.2 x 10−16) (S3 and S4 Figs). We next assessed
whether these correlated expression profiles show phenotypic similarity by measuring growth,
or biomass accumulation, rates for TM6, rho0, and PKO MEFs using a quantitative phase
microscopy (QPM) technique called live cell interferometry (LCI) [69]. As anticipated, rho0
MEFs grew much slower than TM6 MEFs, and PKO clones accumulated biomass as slowly as
rho0 MEFs (Fig 4B). LCI quantification revealed a mean growth rate for TM6 and rho0 MEFs
of 3.3% (SD ± 3.5%) and 1.7% (SD ± 2.7%) of normalized cell biomass per hour, respectively,
with a P value of 4.7 x 10−10 (Fig 4B). PKO-1 and PKO-6 showed a mean growth rate of 1.7%
(SD ± 2.0%) and 2.4% (SD ± 1.6%) of normalized cell biomass per hour, respectively, and with
P values compared to the TM6 growth rate of 6.49 x 10−12 and 5.54 x 10−5, respectively (Fig
4B). Furthermore, cell proliferation studies supported LCI quantified growth rate profiling
data in that rho0, PKO-1 and PKO-6 cells replicated much slower than TM6 MEFs (Kruskal
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Wallis P value = 0.0137) (Fig 4C). Finally, cell cycle analysis by flow cytometry revealed a trend
in which PKO and rho0 MEFs have a lower proportion of cells in S phase compared to TM6
MEFs (Fig 4D). The mean percentage of the cell population in S phase is 51.6% (SD ± 1.36%)
for TM6 MEFs, 47.3% for rho0 MEFs (SD ± 6.80%), 43.1% (SD ± 1.25%) for PKO-1 cells, and
44.3% (SD ± 7.84%) for PKO-6 cells. The proportion of cells in S phase is significantly reduced
in the PKO-1 clone relative to TM6 (P value = 0.05) and trending towards a decrease between
PKO-6 clone and TM6 (P value = 0.10), supporting a decrease in S phase for PKO cells (Fig
4D). The difference in cell cycling characteristics is easier to appreciate in the flow cytometry
Fig 3. Heatmap of overrepresented neuronal function pathways in DEG cluster 3. Axonogenesis (GO:0007409),
axon guidance (GO:0007411), and axon development (GO:0061564) genes overrepresented in cluster 3. Heatmap is
hierarchically clustered based on Euclidean distance and Ward linkage. Heatmap values are plotted as the variance
stabilized transform (VST) subtracted by the gene row average mean of samples. (n = 3 biological replicates, 12 total).
https://doi.org/10.1371/journal.pone.0200925.g003
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Fig 4. PKO and rho0 MEFs have similar cell growth, cell cycle and metabolic gene expression prof iles. (A) Scatterplot of mitotic gene 
expression changes between PKO (y-axis) and rho0 (x-axis) MEFs with respect to TM6 MEFs (calculated as log2 fold-change) (n = 3 biological 
replicates per line, 12 total). Linear regression lines were fit and Pearson (top value) and Spearman (bottom value) correlation coefficients were 
calculated with accompanying P values calculated using two-tailed t significance tests. Gene sets were derived from KEGG database cell cycle ID 
MMU04110. (B) Growth (biomass accumulation) rates for TM6, rho0, PKO-1, and PKO-6 cells were quantified by live cell interferometry 
(TM6 n = 308, rho0: n = 233, PKO-1: n = 303 PKO-6: n = 364). (Median = red stripe, 95% confidence interval = pink region ± SD = purple 
region. (C) Proliferation of TM6, rho0, PKO-1 and PKO-6 MEFs by manual cell counting (n = 3, ± SD). (D) Stacked barplots of phases of the 
cell cycle in percentage distributions for TM6, rho0, PKO-1, and PKO-6 MEFs (n = 3, ± SD). (E) Representative flow cytometry profiles for 
TM6, rho0, PKO-1, and PKO-6 MEFs. DNA was stained with propidium iodide.
https://doi.org/10.1371/journal.pone.0200925.g004
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profiles of PKO-1 and PKO-6 MEFs, which resemble rho0 MEFs, whereas the TM6 MEF flow
profile has a distinct shape from the others (Fig 4E). Thus, integrated RNA-Seq, QPM, prolif-
eration, and cell cycle analyses clearly show that PKO MEFs resemble rho0 MEFs that do not
respire.
PKO in inner ear hair cells causes progressive hearing loss
The PNPase E475G mutation results in hereditary hearing loss [45]. We therefore examined
PKO for physiological relevance by examining auditory effects in vivo using Pnpt1fl/fl x
Atoh1-Cre expressing mice (Atoh1-Cre PKO mice). Atoh1 encodes a transcription factor of the
basic helix-loop-helix family involved in hair cell differentiation, and Atoh1-Cre expression in
Pnpt1fl/flmice results in knockout of PNPase in the inner ear hair cells [70]. Auditory brain-
stem recordings of Atoh1-Cre PKO mice showed progressive hearing loss especially at higher
frequencies. Up until 4 weeks of age both control and Atoh1-Cre PKO mice showed similar
hearing capacities between 4 kHz and 16 kHz (S5 Fig). However, even at 3 weeks of age, the
hearing capacity of Atoh1-Cre PKO mice above 16 kHz was reduced compared to control
mice (S5 Fig). By week 4, the lowest level of hearing for 4 weeks of age Atoh1-Cre PKO mice in
the high frequency range at 32 kHz was above 78 db in contrast to 39 db for 3 weeks of age
control mice (P value = 0.0238) (S5 Fig). Scanning electron microscopy (SEM) images of inner
ear hair cell stereocilia show loss of cilia (yellow arrow) and stereocilia fusions (red arrow) in
the middle turn and base of the cochlea that are responsible for hearing in the middle and high
frequencies, respectively (S5 Fig). Overall, hearing impairment observed in Atoh1-Cre PKO
mice recapitulates the hearing loss observed in PNPase mutation harboring patients and
emphasizes the association of PNPase with sensorineural defects.
Discussion
We report that loss of PNPase, an RNA degrading enzyme that localizes in mitochondria,
results in unanticipated depletion of the mitochondrial genome. Transcriptome profiling of
PKO MEFs correlates significantly with rho0 MEFs and exhibits reduced expression of choles-
terol and lipid biosynthesis genes compared to control wild-type TM6 MEFs. Cell growth, pro-
liferation, and cell cycle features are similar between PKO and rho0 MEFs, suggesting a role for
PNPase in maintaining mtDNA. We speculate that PNPase loss-related changes in gene
expression programs pertaining to axon function could suggest a link with reported mutant
PNPase neuronal disease phenotypes in humans, including familial hearing loss. Modeling
PNPase loss in mouse inner ear hair cells leads to progressive auditory loss, reinforcing a
potential connection uncovered from mining gene expression profiling data presented here.
Since PNPase does not belong to any of the previously identified classes of genes associated
with mtDNA maintenance defects, it seems surprising that PKO results in mtDNA loss. Dele-
tions and mutations of genes involved in mtDNA replication and repair (POLG, TWNK,
TFAM, RNASEH1, LIG3 and MGME1), cytosolic and mitochondrial nucleotide pool regulating
and import genes (TK2, DGUOK, SUCLA2, SUCLG1, ABAT, TYMP, RRM2B, AGK, and
MPV17), along with mitochondrial dynamics genes (OPA1 and FBXL4), all result in mtDNA
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loss [71, 72]. Thus, it is intriguing to speculate on how PNPase may regulate the maintenance
of mtDNA in a cell.
We hypothesize several potential reasons why lack of PNPase results in loss of mtDNA.
Impaired import of small non-coding RNAs from the cytosol may reduce levels of nucleus-
encoded MRP RNA that is required for mtDNA replication. Accumulation of mirror mtRNAs
occurs in PNPase knockdown cells and in cells expressing dominant negative hSUV3, the
binding partner of PNPase. Therefore, it is also possible that accumulation of mirror mtRNAs
may somehow inhibit replication of mtDNA. Furthering this idea are studies that report that
loss of hSUV3 in human cells and mSUV3 +/- haploinsufficiency in mice result in decreased
mtDNA copy numbers and increased mtDNA mutations [31, 36, 73, 74]. PNPase functions in
DNA repair in bacterial systems [24] and mammalian PNPase may have a similar function in
mitochondria. We also cannot exclude that the loss of mtDNA may be a result of long-term
dysregulated mtRNA metabolism. Although the mechanism(s) for how PNPase maintains
mtDNA warrants further investigation, it nevertheless is interesting that PKO causes cells to
functionally assume a rho0 phenotype.
We note that individuals with different mutations in PNPT1 display a reduction in ETC
function in specific tissues, yet their mtDNA is mostly retained [46, 47, 75, 76]. In particular,
patient fibroblasts with heterozygous PNPT1 c.227G>A; p.Gly76Asp and c.574C>T; p.
Arg192 mutations [49] showed decreased oxygen consumption, and c.760C>A; p.Gln254Lys
and c.1528G>C; p.Ala510Pro mutations have been linked to a decrease in MT-CO1 and
MT-CO2 encoded Complex IV protein levels [46]. Homozygous mutations of c.1160A>G; p.
Gly387Arg also result in decreased Complex III and Complex IV activities in liver homoge-
nates [47]. While these patients do present with severe respiratory chain defects, these observa-
tions do not compare with the abolishment of respiration in our PKO system (Fig 1D), where
complete loss of mtDNA likely abrogates any capacity to establish a functional ETC for sup-
porting cell respiration. Additionally, the minimal yet present levels of ETC protein and ATP
production in several patients indirectly suggests that these patients still possess mtDNA [46,
76]. Unfortunately, only one study amongst the reported PNPase mutant patient analyses pro-
vide mtDNA level measurements. In homozygous PNPT1 c.1160A>G; p.Gly387Arg patient
derived fibroblasts, the mtDNA levels were decreased by 58% relative to the control, but this
extent of decrease is not considered significant due to the large variability in control mtDNA
levels [47]. PNPase protein expression levels vary amongst different PNPase mutations
expressed in assessed patient tissues [45–48, 75, 76]. We suggest that even the minimal pres-
ence of mutant PNPase in these various patients may allow for a low amount of PNPase activ-
ity that can support the maintenance of mtDNA at reduced but functional levels. Therefore,
the extent of mtDNA loss and ETC activity decrease is much more severe in the PKO MEF sys-
tem compared to mutant PNPase patients, likely due to the complete loss of PNPase protein
levels in PKO MEFs.
PNPase regulates oxidative phosphorylation during reprogramming of somatic cells to
induced pluripotent stem cells and is an essential factor for maintaining mitochondrial
homeostasis [26, 43, 44]. Understanding the specific functions of PNPase may reveal how
RNA regulation may affect cellular metabolism. Here, we established PKO MEF lines utilizing
uridine supplemented media and show that PKO cells lose their mtDNA. This brings a new
perspective to PNPase activity and suggests that mtDNA levels are important to consider when
dissecting PNPase functionality. Lastly, PNPase loss impairs neuron-relevant gene expression
even in non-neuronal cell types and the Atoh1-Cre PKO mice show reduced hearing through
auditory brainstem recording analysis. Altogether, our study describes an additional unsus-
pected function for PNPase in mtDNA maintenance, which could provide an underlying or
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unifying connection for its large number of reported activities in multiple biological systems
and contexts.
Materials and methods
Cell culture and mice
Pnpt1fl/flMEFs, named TM6 [27], were grown at 37˚C and 5% CO2 in Dulbecco’s Modified
Eagle Medium supplemented with 10% Hyclone Fetal Bovine Serum (Thermo Scientific), 1X
penicillin-streptomycin solution (Cellgro, Corning), and 50 μg/mL uridine (Sigma-Aldrich).
MEF rho0 cells were established by culturing with 750 ng/mL ditercalinium dichloride dihy-
drochloride (NCI DCTD Developmental Therapeutics Program, NSC 335153, NIH), for 3
weeks followed by single cell colony isolation. PKO MEF lines were established by transduc-
tion of TM6 MEFs with a Cre-recombinase expressing adenovirus (SignaGen Laboratories cat
# SL100707) in uridine- supplemented media, followed by isolation of single cell colonies.
Atoh1-Cre PKO mice were established by crossing Pnpt1fl/flC57BL/6J mice with Atoh1-Cre
transgenic C57BL/6J mice [70, 77]. All mice were housed in a pathogen-free animal facility at
IUPUI, and the study was approved by the University of Minnesota Institutional Animal Care
and Use Committee. Mouse experiments were designed and performed according to Animal
Research: Reporting In Vivo Experiments (ARRIVE) guidelines, developed by the National
Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs)
guidelines.
Characterization of PKO MEFs
Western blots were performed using standard molecular biology practices. PNPT 3370 anti-
body (Koehler/Teitell Labs) and β-tubulin MMS-410P (Covance) were used for immunoblot-
ting. Assessments of mtDNA quantity were performed by TaqMan qPCR assay using mouse
Rnr1 probe (Thermo Scientific Mm04260177_s1), mouse Nd3 probe (Thermo Scientific
Mm04225292_g1), mouse Cox1 probe (Thermo Scientific 4448484), mouse Tfrc probe
(Thermo Scientific 4458366) and Amplitaq Gold 360 Master Mix (Thermo Scientific
4398881). DNA was extracted from proteinase K digested and RNase A treated samples
through aqueous phase separation using phenol/chloroform/isoamyl alcohol. The resulting
DNA was suspended in TE buffer, normalized to 20 ng/μL across samples, pooled, and serially
diluted for standard curve generation in comparison to a no-template control. Biological tripli-
cates of each sample were split into technical triplicates, and subsequently loaded on a Roche
LightCycler 480 II (Roche 050152278001), with one preincubation cycle at 95˚C for 10 min,
followed by 45 amplification cycles at 95˚C for 15s, to 60˚C for 1 min. Raw cycle threshold
(Ct) values were extracted for each well, averaged across technical replicates, and ΔCt values
calculated for each experimental (Rnr1, Nd3, Cox3) and housekeeping gene (Tfrc). ΔΔCt values
were calculated for each pairwise condition replicate and 2ΔΔCt transformed to generate an
expression fold change relative to Tfrc. Expression fold changes per comparison were averaged
and plotted using GraphPad Prism 6 (GraphPad Software, Inc.). Fluorescence microscopy
images were obtained from cells treated with Mitotracker Red CMXRos (Thermo Scientific)
and PicoGreen dye (Thermo Scientific). OCR and ECAR measurements were performed as
previously described [78]. The following primers were used to check for the presence of Pnpt1
exon 2 in the genome DNA: forward primer: TATCCTCTGGGAAACTGGCA, reverse
primer: ATTCGTACTGCCCCAACAGG. The following primers were used to check for the dele-
tion of exon 2 in Pnpt1 that spans the exon 2 region: forward primer: TCGGGCACTCAGCT
ATTTGC, reverse primer: CACCAACGGCATGAATTGGG. The following primers were used to
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check for the presence of the 3’ end of Pnpt1: forward primer: ACCGCGACAATAACTGAAATC,
reverse primer: GCAGCACTGCAGTCATGTTT.
Seahorse extracellular flux analysis
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured
as previously described [78]. We plated 20,000 cells/well in a XFe96 microplate (Seahorse Bio-
science). Oligomycin (ATP synthase inhibitor) was injected at 1.5μM, FCCP (uncoupling
agent) was injected at 0.5μM followed by a secondary injection of 0.9μM, and Antimycin A
plus Rotenone (inhibitors of Complex III and I, respectively) were injected at 2μM each.
Results were normalized per 103 cells per well using the Operetta High Content Imaging Sys-
tem (PerkinElmer, Inc.).
RNA extraction
TM6, rho0 MEFs, and PKO clones were grown in biological triplicates to 70–80% confluence
and purified using TriZol Reagent (Life Technologies) or RNeasy Mini Kit (Qiagen). All sam-
ples used showed a A260/280 ratio > 2.00 (Nanodrop; Thermo Scientific). Prior to library
preparation, RNA quality control was performed using the Advanced Analytical Technologies
Fragment Analyzer (Advanced Analytical, Inc.) and PROSize 2.0.0.51 software. RNA Quality
Numbers (RQNs) were computed per sample with a final score of 10.0 indicating fully intact
total RNA per sample prior to library preparation.
RNA-Seq library preparation
Strand-specific ribosomal RNA (rRNA) depleted RNA-Seq libraries were prepared from 1 μg
of total RNA using the KAPA Stranded RNA-Seq Kit with Ribo-Erase (Kapa Biosystems,
Roche). Briefly, rRNA was depleted from total RNA samples, the remaining RNA was heat
fragmented, and strand-specific cDNA was synthesized using a first strand random priming
and second strand dUTP incorporation approach. Fragments were then A-tailed, adapters
were ligated, and libraries were amplified using high-fidelity PCR. All libraries were prepared
in technical duplicates per sample (n = 12 samples, 24 libraries total), and resulting raw
sequencing reads merged for downstream alignment and analysis. Libraries were paired-end
sequenced at 2x125bp on an Illumina HiSeq.
RNA-Seq pre-processing
PKO clones 1 and 6, rho0, and TM6 MEFs were each sequenced in biological triplicates (n = 3,
12 total samples). Raw sequencing reads were converted into fastq files and filtered for low
quality reads and Illumina sequencing adapter contamination using bcl2fastq (Illumina).
Trimmed reads were then aligned to the Mus musculus transcriptome, generated using the
NCBI mm10 (NCBI/mm10/GRCm38, December 2011) genome and RefSeq gene annotation,
using RSEM 1.2.25 prepare-reference (command parameters—bowtie—bowtie2—gtf
$(BUILD)/genes.gtf $(GENOME).fa $(RSEM)) [79]. Transcript counts were estimated using
RSEM 1.2.25 calculate-expression, and collapsed to gene level counts using RSEM 1.2.25
tbam2gbam [79]. Gene-level transcript counts were extracted from the results output using
custom R/3.4.1 scripts.
Differential gene expression analysis
The resulting sample gene count matrix was size factor normalized and analyzed for pairwise
differential gene expression using R/3.4.2 Bioconductor 3.6 package DESeq2 v1.18.1.
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Expression changes were estimated using an empirical Bayes procedure to generate moderated
fold change values [80, 81]. Significance testing was performed using the Wald test, and result-
ing P values were adjusted for multiple testing using the Benjamini-Hochberg procedure [82].
DEGs were filtered using an adjusted false discovery rate (FDR) q value < 0.01 and an absolute
log2 transformed fold-change > 0.5. Variance stabilized transform (VST) values in the gene
count matrix were calculated and plotted for principal component analysis (PCA) using
DESeq2 [80, 81]. Scatterplots of gene expression fold-changes between TM6, rho0 and PKO
MEFs were performed and Pearson/Spearman correlation coefficients calculated using R/3.4.1
package ggpubr v0.1.6 (https://cran.r-project.org/web/packages/ggpubr/index.html). Genes of
interest were extracted and heat maps were prepared using R Bioconductor packages pheat-
map v1.0.8 and gplots v3.0.1 [83, 84].
Gene set overrepresentation analysis (ORA)
DEGs were extracted and analyzed for pathway/gene ontology (GO) term overrepresentation
using the R/3.4.1 Bioconductor 3.6 package clusterProfiler v3.6.0 and ReactomePA v1.22.0,
using a background gene set of all genes expressed with at least one read count in the sample
gene count matrix [85, 86]. Overrepresented Reactome/KEGG pathways and GO terms were
identified using significance testing cutoffs of P< 0.05, and an adjusted FDR< 0.25.
Rank-rank hypergeometric overlap analysis (RRHO)
To determine overlapping significance between PKO and rho0 expression patterns relative to
TM6, rank-rank hypergeometric overlap was performed using the online web server (http://
systems.crump.ucla.edu/rankrank/rankranksimple.php)) [87]. Separate gene ranking lists
were constructed according to the signed log10 transformed Wald test q value in fold change
comparisons between PKO/TM6 and rho0/TM6. Hypergeometric testing was then performed
to determine the significance of overlap between ranks in both datasets. Heat map values were
plotted as the signed log10 transformed hypergeometric P value of overlap between ranks at the
identified pixel; high values indicate enrichment of overlap, low values indicate reduced
enrichment of overlap.
Live cell interferometry (LCI)
Cells were plated into each well of an Ibidi 4 well Ph+ μ-slide (Ibidi, USA) at a density of 6
x103 cells/cm2. 24 hours later, Ibidi anti-evaporation oil (Ibidi, USA) was added to seal the liq-
uid opening of each well and loaded onto the LCI stage. All 4 wells were imaged continuously,
every 10 minutes for 24 hours with 15–20 locations per well. The LCI set up consists of a Zeiss
Axio Observer Z1 inverted microscope, an on-stage incubation chamber (Zeiss) with tempera-
ture, CO2 and humidity modulations. QPM images were captured by a SID4BIO (Phasics)
quadriwave lateral shearing interferometry camera. All cells were imaged using a 20x 0.4NA
objective and a 660nm collimated LED (Thorlabs) light source.
Cell cycle flow cytometric analysis
Cells (~5 x 105) were collected, washed once with 500 μl FACS buffer and resuspended in
200 μl hypotonic propidium iodide staining solution containing 10 mg/ml RNAse, 10% Triton
X-100, 85 mg/ml trisodium citrate and 2 mg/ml PI (Roche). Data was obtained on FACS BD
LSRII and FACS BD Fortessa flow cytometers (BD Biosciences). Cell cycle analysis was per-
formed with FlowJo 10 software using the univariate model.
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Auditory brainstem response (ABR)
ABR waveforms were collected for frequencies between 4 kHz and 32 kHz at half-octave inter-
vals, starting at supra-threshold levels and decreasing in 5 dB steps to a sub-threshold level. A
Tucker-Davis Technologies System 3 was used to generate symmetrically shaped tone bursts 1
ms in duration with 300 μs raised cosine ramps that were delivered to a calibrated magnetic
speaker. For this assay, n = 3 heterozygous control mice at 3 weeks (1 female, 2 male), n = 2
Atoh1-Cre PKO mice at 3 weeks (2 females) and n = 2 Atoh1-Cre PKO mice at 4 weeks (2
females) were analyzed. Mice were anesthetized with Avertin and scalp potentials were
recorded with subdermal electrodes, with signals amplified 20,000 times, bandpass filtered
between 0.03 and 10 kHz, digitized using a 20,000 kHz sampling rate and subjected to artifact
rejection. Stacked waveforms were compared and the lowest level of stimulation that evoked
an unambiguous ABR waveform was designated as the threshold.
Scanning electron microscopy (SEM)
Mouse cochlea were dissected and fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate
buffer with 1 mM CaCl2 by perfusing dissected cochlea through the round and oval windows
followed by incubation in the same solution at RT for 4 h. Following decalcification in 170
mM EDTA at 4˚C for 16 h, the organ of Corti was dissected and processed for SEM as
described [88]. Briefly, tissues were successively incubated in 2% each arginine, glycine, glu-
tamic acid and sucrose in water, 2% each tannic acid and guanidine-HCl in water and then 1%
osmium tetroxide. Samples were critical point dried from CO2 and sputter coated with plati-
num before viewing on a cold field emission SEM (Hitachi S4700). SEM images were taken
using 1 male Pnpt fl/+ Cre- mouse at 6 weeks of age, and 2 female Atoh1-Cre PKO mice at 6
weeks of age. Mice were anesthetized with Avertin and euthanized via cervical dislocation.
Statistical analysis
Statistical analysis performed for live cell interferometry and sequencing experiments are
described in the above specified methods and figure legends. All other experiments were ana-
lyzed using GraphPad Prism 6.07 (GraphPad Software Inc.), reporting mean ± standard devia-
tion (SD) for all conditions. P values reported for cell growth and ABR assays were calculated
using a non-parametric Kruskal-Wallis ANOVA test. Pairwise P values reported for Seahorse
extracellular flux and cell cycle distribution analyses were calculated using the non-parametric
Mann-Whitney test. All significance testing was performed with a significance cutoff of P
value < 0.05.
Accession numbers
All raw RNA-Seq reads and processed gene count matrices were submitted to the NCBI Short
Read Archive (SRA) and Gene Expression Omnibus (GEO), respectively, under GEO Acces-
sion number GSE111668.
Supporting information
S1 Fig. Immunofluorescence images of PKO cells show loss of mtDNA (related to Fig 1).
Fluorescence microscopy of TM6, rho0, and representative PKO (PKO-4) MEF cell lines with
PicoGreen staining for double-stranded DNA (left), MitoTracker Red (center), and an overlay
(right).
(TIF)
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S2 Fig. Heatmaps of select overrepresented pathways in DEG clusters (related to Fig 2D).
(A) Heat map of mtDNA replication genes (GO:0006264) overrepresented in cluster 1. (B)
Cholesterol metabolic (GO:0008203), sterol metabolic (GO:0016125), lipid biosynthetic
(GO:0008610), and secondary alcohol synthetic (GO:1902652) processes overrepresented in
cluster 2.
(TIF)
S3 Fig. PKO and rho0 MEFs show highly correlated metabolic gene expression profiles
(related to Fig 4). Metabolic gene expression changes between PKO (y-axis) and rho0 (x-axis)
MEFs with respect to TM6 MEFs (calculated as log2 fold-change) (n = 3 biological replicates
per line, 12 total). Linear regression lines were fit and Pearson (top value) and Spearman (bot-
tom value) correlation coefficients were calculated with accompanying P values calculated
using two-tailed t significance tests. Gene sets were derived from KEGG database metabolic ID
MMU00100.
(TIF)
S4 Fig. PKO and rho0 MEFs show highly correlated gene expression profiles within specific
metabolic pathways (related to Figs 3 and 4). Scatterplot of metabolic gene expression values
between PKO (y-axis) and rho0 (x-axis) MEFs with respect to TM6 MEFs (calculated as log2
fold-change) (n = 3 biological replicates per line, 12 total). Linear regression lines were fit and
Pearson (top value) and Spearman (bottom value) correlation coefficients were calculated with
accompanying significance P values calculated using two-tailed t significance tests. Gene sets
were derived from the KEGG database under the identification numbers indicated above each
plot.
(TIF)
S5 Fig. Loss of PNPase results in hearing loss. (A) Auditory brainstem response test for WT
(black) (n = 3) and Atoh1-Cre PKO mice (red) at 3 weeks (n = 2) and 4 weeks (n = 2), error
bars denotes standard error of mean. (B) SEM analysis of hair cell stereocilia (n = 2). Yellow
arrows indicate regions that lack cilia, and red arrows indicate regions of stereocilia fusion.
(TIF)
S1 Table. List of DEGs and overrepresented gene ontologies (related to Figs 2, 3, 4A, S2, S3
and S4). (A) List of DEGs identified between rho0 and TM6 MEFs. (B) List of DEGs identified
between PKO and TM6 MEFs. (C) List of PKO-specific DEGs, shared DEGs, and rho0-specific
DEGs. (D) Results of GO overrepresentation analysis (ORA) performed on DEG clusters in
(C).
(XLSX)
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LETTER TO THE EDITOR
Mitochondrial metabolism and glutamine are essential for
mesoderm differentiation of human pluripotent stem cells
Cell Research (2019) 0:1–3; https://doi.org/10.1038/s41422-019-0191-2
and Gln, such as facilitating cell fate speciﬁcations in these two
lineages. Initially, we determined whether Glc or Gln is most crucial
for each lineage. Early EN, ME, and EC lineages did not robustly
convert 13C6-glucose into TCA cycle metabolites, suggesting that Glc
is not a major carbon source for the germ lineages (Fig. 1d,
Supplementary information, Fig. S2a). In contrast to Glc, Gln is
a major fuel source for all three cell lineages, with >70% of
13C5-glutamine metabolized to glutamate and subsequent TCA cycle
metabolites (Fig. 1e, Supplementary information, Table S2). Speci-
ﬁcally, the mass isotopologue distribution (MID) of 13C5-glutamine
shows increased m+ 5 αKG and m+ 4 succinate, fumarate, malate,
and citrate levels in ME, indicating that ME preferentially uses Gln
compared to EC (Fig. 1f). Increased m+ 5 citrate due to reductive
carboxylation9 was detected in EC compared to ME, suggesting that
Gln may be preferentially shunted toward lipid biosynthesis and/or
gluconeogenesis through citrate rather than into other TCA cycle
intermediates in EC (Fig. 1f).10 Overall, the data show that Gln is a
major contributor to the TCA cycle in all three lineages, yet displays
increased incorporation into ﬁrst turn TCA cycle metabolites in ME
compared to EC.
Since ME exhibits increased preference for Gln contribution into
the TCA cycle, we next asked whether Gln deprivation would
result in a bias in lineage potentiation in non-directed embryoid
body (EB) differentiation, which has been previously demon-
strated to recapitulate features of early embryogenesis.11 As
expected, Gln withdrawal from EB culture media at the start of
non-directed differentiation resulted in signiﬁcantly reduced levels
of TCA cycle metabolites, with the exception of citrate at 48 h
(Fig. 1g). Concurrent 1 mM dichloroacetate (DCA) treatment with
Gln withdrawal to inhibit pyruvate dehydrogenase kinase and
increase the ﬂux of Glc supplied pyruvate into the TCA cycle12
surprisingly did not replenish TCA cycle metabolite levels (Fig. 1g).
This ﬁnding is consistent with a prior study reporting that hPSCs
are highly dependent on both Glc and Gln oxidation, and that
pyruvate addition cannot rescue Glc and Gln depleted conditions.2
A mitochondrial stress test on EC and ME differentiated cells with
Gln removed from the culture media revealed a decrease in
maximal OCR and OCR/ECAR ratio in ME compared to EC,
consistent with increased reliance on Gln in ME for respiration
(Supplementary information, Fig. S2b, c). Additionally, differentia-
tion under Gln deprivation did not affect EB formation,
morphology, or viability (Supplementary information, Fig. S2d).13
Interestingly, in EBs differentiated under Gln deprivation, immu-
noblot analysis revealed a decrease in the SLUG protein level,
while qRT-PCR analysis showed signiﬁcantly decreased HAND1
expression, indicating that Gln is essential for ME production
(Fig. 1h, Supplementary information, Fig. S2e). Additionally, phase
contrast microscopy of ME lineage directed differentiation
Dear Editor,
Human pluripotent stem cells (hPSCs) generate energy mainly
by aerobic glycolysis, with glutamine oxidation in the tricarboxylic
acid (TCA) cycle providing additional ATP required for survival.1–3
During the exit from pluripotency and initial differentiation into
multiple germ lineage precursors, energy production shifts from
mainly aerobic glycolysis to mitochondrial oxidative phosphoryla-
tion (OXPHOS).1 Until recently, consensus in the ﬁeld was that as
PSCs exit pluripotency, a metabolic switch from aerobic glycolysis
to OXPHOS is required. However, a more detailed examination of
nascent ectoderm (EC) metabolism showed unexpected main-
tenance of a high, MYC-dependent glycolytic ﬂux, resembling
sustained hPSC metabolism, in contrast to mesoderm (ME) and
endoderm (EN),4 generating questions for the role(s) of mitochon-
drial metabolism in early hPSC tri-lineage differentiation. To
examine this issue, we differentiated hPSCs into early EN, ME, and
EC lineages using a non-limiting, nutrient-balanced culture media
that differed only by established lineage-driving cytokines,5,6 so
that intrinsic metabolic preferences were not derived from a
variance in nutrient composition (Supplementary information,
Data S1). Principal component analysis (PCA) of these early
lineages using RNA-Seq was equivalent to a previous study using
nutrient-balanced and chemically deﬁned growth media.4 Further-
more, transcriptomic and protein biomarker expression matched
established proﬁles for hPSCs and hPSC-derived EN, ME, and EC
(Supplementary information, Fig. S1a–c, Table S1),7 conﬁrming the
validity of our model system.
To quantify the impact of mitochondrial OXPHOS on lineage
potentiation, mitochondrial stress tests showed that ME has the
highest basal and maximal oxygen consumption rate (OCR),
greatest spare respiratory capacity, and largest approximate
respiration-to-glycolysis ratio (OCR/ECAR) compared to hPSCs,
EN, and EC (Fig. 1a, Supplementary information, Fig. S1d, e). To
compare nutrient preferences, we used media footprint analysis,
which showed decreased glucose (Glc) consumption, decreased
lactate production, increased glutamine (Gln) consumption, and
increased glutamate production in ME compared to EC (Fig. 1b).
Live cell interferometry quantiﬁcation of normalized biomass
accumulation (growth) rate revealed that ME and EC cell clusters
were statistically equivalent and higher than EN (Fig. 1c). Taken
together, the data reveal a striking metabolic plasticity in that ME
and EC differ dramatically in nutrient source and pathways for
energy and metabolite production, yet yield the same growth rate
during early lineage speciﬁcation.
Prior studies show that cell biomass accumulation during
proliferation depends mainly on the consumption of non-Gln amino
acids.8 Since our data reveal that ME and EC have equivalent growth
rates, we examined biomass accumulation-independent roles for Glc
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revealed widespread cell death under Gln deprivation, 
suggesting that Gln is indispensable for ME 
formation (Supplementary information, Fig. S2f). In 
contrast, Gln withdrawal led to an increase in EC 
specifying biomarker proteins PAX6 and MAP2B 
during 21 days of EB differentiation (Fig. 1h, 
Supplementary information, Fig. S2e). Increased EC 
production may be linked to a compensation for Gln 
deprivation by recovery of glycolytic metabolites 
(Fig. 1g, h, Supplementary information, Fig. S2g).
Together, this EB differentiation proﬁle suggests that Gln 
with-drawal skews potentiation of ME negatively and EC 
positively.
This report provides a deeper understanding of 
distinct metabolic shifts in early germ lineages by 
showing that mitochondrial respiration and Gln 
oxidation is essential for ME differentiation. Further 
studies are needed to elucidate the functional roles 
of metabolic reprogramming in early germ lineages, 
with possibilities including transcriptional program
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Fig. 1 Human pluripotent stem cell-derived mesoderm differentiation requires glutaminolysis and distinct mitochondrial metabolism.
a Oxygen consumption rate (OCR) measured by mitochondrial stress test of H9 hPSC and H9-derived endoderm (EN), mesoderm (ME), and
ectoderm (EC) lineages at 5 days of directed differentiation. Data are normalized by microgram of protein content per well. Injections of 1 µM
oligomycin, 0.33 µM FCCP, 0.5 µM FCCP, and 1 µM each Antimycin A/Rotenone were performed. Data represent n= 6 technical replicates of 1
biological experiment with additional n ≥ 2 biological experiments provided in Supplementary information, Fig. S1e. b Media footprint
analysis (relative metabolite consumption and production into media) of nutrient-balanced EN, ME, and EC samples, quantifying levels of (i)
glucose consumption, (ii) lactate production, (iii) glutamine consumption, and (iv) glutamate production at 5 days of directed differentiation.
Positive values indicate increased production of cellular metabolites into spent media, whereas negative values indicate cellular consumption
of media metabolites. Data are normalized to initial unspent fresh media levels as measured by UHPLC–MS, and represent n= 3 independent
experiments. Media of differentiated H9 hESCs were changed 24 h prior to spent media metabolite extraction. c Normalized single colony
biomass accumulation and growth rates (%/hour) of nutrient-balanced H9-derived EN/ME/EC samples measured over 24 h. Data represent
n= 29 EN, n= 45 ME, and n= 37 EC colonies. d, e Fractional contribution of 13C6-labeled metabolites from [U-
13C6] glucose (d) or
13C5-labeled
metabolites from [U-13C5] glutamine (e) after 18 h quantiﬁed by UHPLC-MS. f Mass isotopomer distribution (MID) of TCA cycle-associated
metabolites from [U-13C5] glutamine. The carbon labeling of TCA cycle-associated metabolites from [U-
13C5] glutamine is schematically
illustrated in black for the ﬁrst (1st) and second (2nd) turn or α-ketoglutarate (α-KG) reductive carboxylation (RC) into citrate. Media of
differentiated H9 hESCs were changed 18 h prior to intracellular metabolite extraction. g Relative levels of TCA cycle metabolites in H9 hPSCs
under 36 h and 48 h spontaneous differentiation in the presence or the absence of Gln in the culture media co-treated or untreated with
1mM DCA, quantiﬁed by UHPLC-MS. h Immunoblot of ME (SLUG) and EC (PAX6, SOX2 and MAP2) markers in H9-derived EB at 21 days of
differentiation in the presence or the absence of Gln in the culture media co-treated or untreated with 1mM DCA. *P ≤ 0.05, **P ≤ 0.01, ***P ≤
0.001, ****P ≤ 0.0001. p values are determined using unpaired Student’s t-test (c–e) or two-way ANOVA with multiple comparisons Bonferroni
correction (b, f, g). Data represent mean ± SD (a, b, d–g) or mean ± SEM (c) of independent experiments indicated above
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changes regulated by metabolite-sensitive epigenetic modiﬁers14
or carbon source-speciﬁc dependencies.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Cell Culture 
All work with human embryonic stem cells (hESCs) has been approved under the UCLA 
Institutional Biosafety Committee (IBC) and UCLA Embryonic Stem Cell Research Oversight 
(ESCRO) Committee under Protocol # 2007-003-12. H9 (WA09 – Female; RRID:CVCL_9773), 
H1 (WA01 – Male; RRD:CVCL_9771), HSF-1 (Male; RRID:CVCL-D003), hiPS2 (Male; RRID: 
CVCL_B508) and UCLA-1 (Female; RRID:CVCL_9951) primed human pluripotent stem cells 
(hPSCs) were provided low-passage and contamination tested through the UCLA BSCRC 
hESC Core Bank (Jerome Zack, UCLA). Following receipt, hPSCs were shifted to feeder-free 
Matrigel (Corning) in mTeSR1 medium (Stemcell Technologies) and passaged using Gentle 
Cell Dissociation Reagent (Stemcell Technologies).  
Trilineage Directed-Differentiation Protocol 
6-wells plates were coated with 1:10 Matrigel (Corning) and incubated for 30 minutes prior to
seeding. 80-90% confluent hPSCs were incubated in Gentle Cell Dissociation Reagent 
(Stemcell Technologies) for 8 minutes at 37C, dissociated to single cells using a 40μm cell
strainer, and harvested in plain media (DMEM/F12; Gibco) for counting. Cells were centrifuged 
at 450xg for 5 minutes. 
Ectoderm Differentiation 
1.2 x 106 cells were seeded in each well of a 6 well plate in mTeSR1 media (Stemcell 
Technologies) with 10 μM ROCK inhibitor (Y-27632; Stemcell Technologies). Media was 
changed to differentiation media 24 hours after seeding. hPSCs were differentiated over a 5-day 
period by culturing in a 50% DMEM/F12 and 50% IMDM-based medium (Gibco) supplemented 
with 450 μM monothioglycerol (Millipore Sigma), 1 mg/ml BSA (Gibco), 0.11 μM 2-
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mercaptoethanol (Gibco), 1% Glutamax (Gibco), 1% N2 supplement (Thermofisher), 2% B27 
supplement (Thermofisher), 10 μM SB43154 (Stemgent), and 0.2 μM Dorsomorphin
(Stemgent).  
Mesoderm Differentiation 
1.8 x 106 cells were seeded in each well of a 6 well plate in mTeSR1 media with 10 μM ROCK
inhibitor (Y-27632; Stemcell Technologies). hPSCs were differentiated over a 5-day period by 
culturing in a 50% DMEM/F12 and 50% IMDM-based medium (Gibco) supplemented with 450 
μM monothioglycerol (Millipore Sigma), 1 mg/ml BSA (Gibco), 0.11 μM 2-mercaptoethanol 
(Gibco), 1% Glutamax (Gibco), 0.7 µg/mL insulin (Millipore Sigma), 15 µg/mL transferrin 
(Millipore Sigma), 1 mL/100mL chemically-defined lipid concentrate (Gibco), 100 ng/mL VEGF-
165 (Stemcell Technologies), 100 ng/mL BMP4 (Peprotech), and 20 ng/mL FGF2 (Peprotech). 
Medium for the first 24 hours of differentiation was supplemented with 100 ng/mL Activin A 
(Stemcell Technologies). 
Endoderm Differentiation 
1.8 x 106 cells were seeded in each well of a 6 well plate in mTeSR1 media with 10 μM ROCK
inhibitor (Y-27632; Stemcell Technologies). hPSCs were differentiated over a 3-day period by 
culturing in a 50% DMEM/F12 and 50% IMDM-based medium (Gibco) supplemented with 450 
μM monothioglycerol (Millipore Sigma), 1 mg/ml BSA (Gibco), 0.11 µM 2-mercaptoethanol 
(Gibco), and 1% Glutamax (Gibco). Medium for the first 24 hours was supplemented with 100 
ng/mL Activin A (Stemcell Technologies), 2 µM CHIR99021 (Cayman Chemicals), and 50 nM 
PI-103 (Fisher Scientific). Medium after the first 24 hours was supplemented with 100 ng/mL 
Activin A (Stemcell Technologies), and 250 nM LDN 1931189 (Stemgent). 
Embryoid Body Differentiation 
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3.5 x 106 cells per well were seeded in AggreWell EB Formation Media (Stemcell Technologies) 
with 10 μM ROCK inhibitor (Y-27632; Stemcell Technologies) into 6-well AggreWell 400 plates 
(Stemcell Technologies) for consistent size and shape. Within 24 hours, embryoid bodies were 
harvested through a cell strainer and transferred to 6-well Ultra-Low Attachment plates (Corning
Costar) and grown in DMEM/F12 (Gibco) supplemented with 20% KnockOut Serum 
Replacement (Gibco), 1% Glutamax (Gibco), 1% Penicillin/Streptomycin (Corning), 1% Non-
Essential Amino Acids (Corning), and 0.1 mM 2-mercaptoethanol (Gibco). Media was changed 
every day throughout 21 days of differentiation. For DCA treated condition, media was 
supplemented with 1mM dichloroacetate (DCA; Millipore Sigma). For glutamine deprivation 
condition, DMEM/F12 without glutamine (Gibco) was used and Glutamax (Gibco) was excluded 
from media preparation.  
METHOD DETAILS 
Nutrient Balanced Media Formulation 
For all differentiation protocols indicated, a chemically defined, nutrient balanced base media 
(CDM2) was prepared using 50% DMEM-F12 and 50% IMDM media (Gibco). Media was 
supplemented with 1mg/mL BSA (Gibco), 1% chemically defined lipid concentrate CDLC 
(Gibco), 450 M monothioglycerol (Millipore Sigma), 0.7 µg/mL insulin (Millipore Sigma), 15 
µg/mL Transferrin (Millipore Sigma), 1% Glutamax (Gibco), and 0.18% 2-mercaptoethanol 
(Gibco). CDM2 base media was then filter sterilized through a 0.22 µM filter (Millipore Sigma) 
prior to use.  
Extracellular Flux Analysis 
HPSC, ME, EN, and EC cells were plated on a XF96 (Agilent) 96-well plate at 105-106 cells/well 
seeding density. The following day, respective media was replaced one hour prior to assay with 
nutrient balanced XF media (Agilent) supplemented with 1mM sodium pyruvate (Corning), 17.5 
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mM glucose, and 2mM glutamine (without glutamine in glutamine deprivation assays). Oxygen 
consumption rate (pmol/min) and extracellular acidification rate (mpH/min) were assessed using 
a Seahorse XF96 Extracellular Flux Analyzer mitochondrial stress test (Agilent) using the 
following drug concentrations: 1 µM oligomycin, 0.5 µM/0.33 µM FCCP, and 1 µM each of 
Rotenone/Antimycin A. Measurements are normalized to protein concentration measured by 
BCA (Pierce).  
Media Footprint Analysis 
Following a minimum of 24 hours of nutrient balanced media culturing, 20L of media was 
removed per sample and added to 300 L of 80% HPLC-grade methanol (Fisher Scientific). 
Samples were then vortexed, centrifuged, washed, evaporated, and processed as indicated in 
the Metabolite Extraction and UHPLC-MS Processing methods section below. Measurements 
are normalized to protein concentration measured by BCA (Pierce), followed by normalization to 
fresh unspent media for each of the trilineage formulations as an internal blank control.  
Biomass Accumulation 
Biomass accumulation and growth rate measurements were obtained using quantitative phase 
microscopy (OPM) using a live cell interferometer (LCI), as described previously 2. The LCI 
system consists of a Zeiss Axio Observer Z1 inverted microscope and an on-stage incubation 
chamber (Zeiss) with temperature, CO2 and humidity modulations (Zeiss). QPM images were 
captured by a SID4BIO (Phasics) quadriwave lateral shearing interferometry (QWSLI) camera. 
All cells were imaged using a 20x 0.4NA objective and a 660nm collimated LED (Thorlabs) light 
source. 2-4 hours prior to imaging, 25,000-30,000 hPSC and hPSC-derived D5 ME, EN, and EC 
cells were seeded into ibidi polymer-treated µ-slide 4 well plates (ibidi GmbH). Immediately prior 
to imaging, media is carefully changed to remove cells in suspension and sealed with anti-
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evaporation oil (ibidi USA). During imaging, the sample plate is moved by the motorized stage, 
collecting 15 images/well on each stop at the rate of 10min/row of four wells. Following data 
acquisition, phase images are automatically processed in a custom pipeline that includes 
background flattening, cell detection, colony segmentation, and biomass calculation. Normalized 
growth rate plots are generated by subtracting the biomass of each colony by its initial biomass 
at every captured time point.  
Flow Cytometry 
Cells were harvested using Gentle Cell Dissociation Reagent (Stemcell Technologies) and 
resuspended in plain DMEM (Corning). Samples were fixed using the Cytofix/Cytoperm Kit (BD 
Biosciences) and processed on a LSRII or LSRFortessa flow cytometer (BD Biosciences). 
Samples were analyzed using FlowJo software (FlowJo, Inc). Antibodies and isotype controls 
used and their dilutions are indicated below.  
RNA Extraction 
All cells were grown to 70-80% confluence and purified using the RNeasy Mini Kit (Qiagen) and 
RNase-free DNase (Qiagen) following the manufacturer’s protocols. All samples showed a
A260/280 ratio > 1.99 (Nanodrop; Thermo Scientific). For RNA-Sequencing, prior to library 
preparation, quality control of the RNA was performed using the Advanced Analytical 
Technologies Fragment Analyzer (Advanced Analytical, Inc.) and analyzed using PROSize 
2.0.0.51 software. RNA Quality Numbers (RQNs) were computed per sample between 8.1 and 
10, indicating intact total RNA per sample prior to library preparation. 
RNA-Sequencing Library Preparation 
184 
Strand-specific ribosomal RNA (rRNA) depleted RNA-Seq libraries were prepared from 1 µg of 
total RNA using the KAPA Stranded RNA-Seq Kit with Ribo-Erase (Kapa Biosystems, Roche). 
Briefly, rRNA was depleted from total RNA samples, the remaining RNA was heat fragmented, 
and strand-specific cDNA was synthesized using a first strand random priming and second 
strand dUTP incorporation approach. Fragments were then A-tailed, adapters were ligated, and 
libraries were amplified using high-fidelity PCR. All libraries were prepared in technical 
duplicates per sample (n = 30 samples, 60 libraries total), and resulting raw sequencing reads 
merged for downstream alignment and analysis. Libraries were paired-end sequenced at 2x150 
bp on an Illumina NovaSeq 6000.  
Immunoblotting 
Immunoblotting was performed as previously described 3. All images were captured using an 
Odyssey Fc with IRDye-conjugated secondary antibodies (LiCor). Antibodies used and their 
respective dilutions are listed below.  
Metabolite Extraction and UHPLC-MS Processing 
Intracellular metabolites were extracted with cold 80% methanol and analyzed using ultra-high 
performance liquid chromatography-mass spectrometry (UHPLC-MS) as previously described 4. 
Media of differentiated H9 hESCs were changed 18h prior to metabolite extraction. For 
experiments with glucose and glutamine tracing, unlabeled glucose and glutamine were 
replaced with [U-13C] glucose and [U-13C] glutamine isotopologues (Cambridge Isotope 
Laboratories), respectively, in a DMEM/F12 only base medium. After, cells were rinsed with cold 
D-PBS and 150mM ammonium acetate (pH 7.3) and then collected in cold 80% MeOH in water.
To the cell suspensions, 10nmol D/L-norvaline were added and vortexed three times on ice, 
followed by centrifugation (12,130g, 4oC). The supernatant was transferred into a glass vial and 
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Data was corrected for naturally occurring 13C in isotopologue distribution measurements 6. Data 
analysis was calculated using the formula statistical language R. Fractional contributions were 
measured using the formula described previously, where mi denotes the intensity of the 
isotopologue, and n marks the number of carbons in the metabolite 7.  
RNA-Sequencing Analysis  
Fibroblasts, iPSCs, and MSCs were each sequenced in biological triplicates and technical 
duplicates (n = 60 total samples) to account for variation in extraction and culturing. Raw 
sequencing reads were converted into fastq files and filtered for low quality reads and Illumina 
sequencing adapter contamination using bcl2fastq (Illumina). Reads were then quasi-mapped 
and quantified to the Homo sapiens GENCODE 28 (GRCh38.p12, Ensembl 92, April 2018) 
transcriptome using the alignment-free transcript level quantifier Salmon v0.9.1 8-10. A quasi-
mapping index was prepared using parameters “salmon index -k 31 –type quasi”, and 
comprehensive transcript level estimates were calculated using parameters “salmon quant -l A –
seqBias –gcBias --discardOrphansQuasi”. Transcript level counts were collapsed to gene level 
(HGNC) counts, transcripts per million abundances (TPM) and estimated lengths using R 
Bioconductor package tximport v1.6.0 11. 
Differential Gene Expression Analysis 
The resulting sample gene count matrix was size factor normalized and analyzed for pairwise 
differential gene expression using R Bioconductor package DESeq2 v1.18.1. Expression 
changes were estimated using an empirical Bayes procedure to generate moderated fold 
change values with design “~ Batch + Sample”, modeling batch effect variation due to day of 
RNA extraction 12,13.  Significance testing was performed using the Wald test, and resulting P 
values were adjusted for multiple testing using the Benjamini-Hochberg procedure 14. DEGs 
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were filtered using an adjusted false discovery rate (FDR) q value < 0.05 and an absolute log2 
transformed fold-change > 1.   
Gene Expression PCA 
Variance stabilized transform (VST) values in the gene count matrix were calculated and plotted 
for PCA using R Bioconductor packages DESeq2, FactoMineR, and factoextra 12,13. Whole 
transcriptome PCA was performed with comparison to existing RNA-sequencing data of nutrient 
balanced trilineage differentiations previously provided in GEO: GSE101655 1. RNA-sequencing 
samples were batch effect normalized across library preparation differences between this study 
and previously published reports 1 using limma v3.34.9 15. PCA of nucleus-encoded 
mitochondrial protein and mtDNA transcripts were extracted using localization evidence derived 
from MitoMiner v4.0, subsetting VST matrices using genes listed in MitoCarta 2.0 16,17. 
Scatterplots and MA plots of gene expression fold-changes between fibroblasts, iPSCs, and 
MSCs were performed, and Pearson/Spearman correlation coefficients calculated, using R 
package ggpubr v0.1.6 (https://cran.r-project.org/web/packages/ggpubr/index.html). Genes of 
interest were extracted and averaged clonal heatmaps were prepared using R Bioconductor 
packages pheatmap v1.0.8 and gplots v3.0.1 18,19. Venn diagram intersections of DEG lists were 
generated using Venny 2.1.0 (http://bioinfogp.cnb.csic.es/tools/venny/index.html) 
Statistical Testing 
Statistical testing for all data except for RNA-sequencing was performed using Prism 7 and 8 
(Graphpad). All RNA-sequencing statistical analysis are described in the Quantification and 
Statistical Analysis sections. Unpaired Student’s t testing was performed for all extracellular flux,
media footprint, and interferometry analysis. 2-way ANOVA with multiple comparisons 
Bonferroni adjustment was used for all metabolomics-based mass isotopomer and fractional 
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contribution distribution data. Unless otherwise indicated, all data represent the mean ± the 
standard deviation of n = 3 independent biological experiments.  
DATA AND SOFTWARE AVAILIABILITY 
RNA-Sequencing processed and raw files are deposited to the NCBI Gene Expression Omnibus 
(GEO) under accession GSE127270. Code used to process RNA-Sequencing data is provided 
under Atlassian Bitbucket at https://bitbucket.org/ahsanfasih/OxPhosMesoderm/src/master. 
Metabolomics and RNA-Seq processed data are provided in MS Excel format (Data Tables S1 
and S2). All other data requests should be directed to and will be fulfilled by the Lead Contact, 
Michael A. Teitell (MTeitell@mednet.ucla.edu). 
Key Resources Table 
REAGENT or 
RESOURCE 
SOURCE IDENTIFIER 
Antibodies 
Mouse anti-β-
tubulin; 1/1000 
Millipore Sigma Cat#T4026; RRID:AB_477577 
Rabbit anti-PAX6; 
1/500 
Cell Signaling 
Technology 
Cat#60433S 
Rabbit anti-SOX2; 
1/1000 
Cell 
Signaling Technol
ogy 
Cat#4900; RRID:AB_10560516 
Rabbit anti-OCT4; 
1/1000 
Cell 
Signaling Technol
ogy 
Cat#2840S; RRID:AB_2167691 
Rabbit anti-MAP2; 
1/500 
Cell 
Signaling Technol
ogy 
Cat#4542; RRID:AB_10693782 
Rabbit anti-SNAIL; 
1/500 
Cell 
Signaling Technol
ogy 
Cat#9585; RRID:AB_2239535 
PerCPCy5.5 
Mouse anti-Human 
PAX6 
BD Biosciences Cat#562388; RRID:AB_11153319 
Alexa Fluor 488 
Mouse anti-MAP2B 
BD Biosciences Cat#560399; RRID:AB_1645358 
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Alexa Fluor 488 
Mouse anti-
OCT3/4 
BD Biosciences Cat#561628; RRID:AB_10895977 
Alexa Fluor 
700 Mouse anti-
Human CD34 
BD Biosciences Cat#561440; RRID:AB_10715443 
V450 Mouse anti-
SOX2  
BD Biosciences Cat#561610; RRID:AB_10715443 
Alexa Fluor 488 
Mouse IgG1 κ 
Isotype Control 
BD Biosciences Cat#557782; RRID:AB_396870 
Alexa Fluor 700 
Mouse IgG1, κ 
Isotype Control 
BD Biosciences Cat#557882; RRID:AB_396920 
V450 Mouse IgG1, 
κ Isotype Control 
BD Biosciences Cat#560373; RRID:AB_1645606 
PerCP-Cy5.5 
Mouse IgG2a, κ 
Isotype Control 
BD Biosciences Cat#558020; RRID:AB_396989 
PerCP-Cy5.5 
Mouse IgG1 κ 
Isotype Control 
BD Biosciences Cat#550795; RRID:AB_393885 
Alexa Fluor 647 
Rat IgG2a, κ 
Isotype Control  
BD Biosciences Cat#557857; RRID:AB_396900 
IRDye 680RD 
Donkey anti-Rabbit 
IgG (H + L) 
LI-COR
Biosciences
Cat#926-68073; RRID:AB_10954442 
IRDye® 800CW 
Goat anti-Mouse 
IgG (H + L) 
LI-COR
Biosciences
Cat#925-32210; RRID:AB_2687825 
IRDye® 800CW 
Goat anti-Rabbit 
IgG (H + L), 0.5 mg 
LI-COR
Biosciences
Cat#926-32211; RRID:AB_621843 
IRDye 800CW 
Donkey anti-Goat 
IgG (H+L) 
LI-COR
Biosciences
Cat#926-32214; RRID:AB_621846 
IRDye 680RD 
Donkey anti-Mouse 
IgG (H+L) 
LI-COR
Biosciences
Cat#926-68072; RRID:AB_10953628 
IRDye 680RD Goat 
Anti-Mouse 0.5 mg 
LI-COR
Biosciences
Cat#926-68070; RRID:AB_10956588 
Chemicals, Peptides, and Recombinant Proteins 
Gentle Cell 
Dissociation 
Reagent 
Stemcell 
Technologies 
Cat#07174 
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mTeSR1 Stemcell 
Technologies 
Cat#85850 
DMEM/F12 Thermofisher Cat#11320-082 
IMDM Gibco Cat#12440053 
ROCK Inhibitor; Y-
27632 
Stemcell 
Technologies 
Cat#72304 
Monothioglycerol Millipore Sigma Cat#M6145 
BSA Fraction V, 
7.5% 
Gibco Cat#15260037 
2-mercaptoethanol Thermofisher Cat#21985-023 
GlutaMAX 
Supplement 
Thermofisher Cat#35050-061 
N2 Supplement Thermofisher Cat#A1370701 
B27 Supplement Thermofisher Cat#17504044 
SB43154 Stemgent Cat#04-0010-10 
Dorsomorphin Stemgent Cat#04-0024 
Human 
Recombinant 
Insulin 
Millipore Sigma Cat#11376497001 
Transferrin from 
human serum 
Millipore Sigma Cat#10652202001 
Chemically Defined 
Lipid Concentrate 
(CDLC) 
Gibco Cat#11905031 
Human 
Recombinant 
VEGF-165 
Stemcell 
Technologies 
Cat#78073.1 
Human 
Recombinant 
BMP-4 
PeproTech Cat#120-05ET 
Human 
Recombinant 
FGF2 
Stemcell 
Technologies 
Cat#78003 
Human 
Recombinant 
Activin A 
Stemcell 
Technologies 
Cat#78001.1 
CHIR99021 
(GSK3i) 
Cayman 
Chemicals 
Cat#13122 
PI-103 
Hydrochloride 
Tocris/Fisher 
Scientific 
Cat#29-301 
Stemolecule LDN-
1931189 
Stemgent Cat#04-0074 
KnockOut Serum 
Replacement 
Thermofisher Cat#10828-028 
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Penicillin/Streptom
ycin Solution, 100X 
VWR Cat#45000-652 
MEM Non-
Essential Amino 
Acids 
Gibco Cat#11140-050 
Sodium 
dichloroacetate 
(DCA), 98% 
Millipore Sigma Cat#347795 
Agilent XF Base 
Media, without 
phenol red 
Agilent 
Technologies 
Cat#103335-100 
Anti-evaporation 
Silicone Oil 
ibidi USA Cat#50051 
AggreWell EB 
Formation Medium 
Stemcell 
Technologies 
Cat#05221 
AggreWell Rinsing 
Solution 
Stemcell 
Technologies 
Cat#07010 
Matrigel Corning/Fisher 
Scientific 
Cat#CB-4023A 
RNAse-Free 
DNase Set 
Qiagen Cat#79254 
DMEM/F12, no 
glutamine 
Thermofisher Cat#21331020 
D-GLUCOSE (U-
13C6, 99%)
Cambridge 
Isotope 
Laboratories 
Cat#CLM-1396-1 
L-GLUTAMINE
(13C5, 99%)
Cambridge 
Isotope 
Laboratories 
Cat#CLM-1822-H-0.1 
Critical Commercial Assays 
RNeasy Mini Kit Qiagen Cat#74106 
Seahorse XF Cell 
Mito Stress Test 
Kit 
Agilent 
Technologies 
Cat#103015-100 
KAPA Stranded 
RNA-Seq with 
RiboErase 
KAPA Biosystems Cat#KK8484 
BCA Protein Assay 
Kit 
Pierce/Thermofish
er 
Cat#23225 
Deposited Data 
RNA-Sequencing 
Data for Nutrient 
Balanced hPSC 
and Trilineage 
Differentiation to 
EN/EC/ME 
This Paper GEO: GSE127270 
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RNA-Sequencing 
Data for hPSC 
Trilineage 
Differentiation 
Comparisons 
Stephen Dalton 
Lab 1 
GEO: GSE101655 
Experimental Models: Cell Lines 
H9 (WA09); 
Female 
UCLA BSCRC 
hESC Core Bank 
RRID:CVCL_9773 
H1 (WA01); Male UCLA BSCRC 
hESC Core Bank 
RRID:CVCL_9771 
HSF-1; Male UCLA BSCRC 
hESC Core Bank 
RRID:CVCL_D003 
hiPS2; Male UCLA BSCRC 
hESC Core Bank 
RRID:CVCL_B508 
UCLA-1; Female UCLA BSCRC 
hESC Core Bank 
RRID:CVCL_9951 
Software and Algorithms 
Seahorse Wave 
Desktop Software 
Agilent 
Technologies 
https://www.agilent.com/en/products/cell-analysis/cell-
analysis-software/data-analysis/wave-desktop-2-6 
ImageJ NIH https://imagej.nih.gov/ij/ 
Salmon v0.9.1 10 https://combine-lab.github.io/salmon/ 
Tximport v1.6.0 11 http://bioconductor.org/packages/release/bioc/html/txim
port.html 
DESeq2 v1.18.1 13 https://bioconductor.org/packages/release/bioc/html/DE
Seq2.html 
Pheatmap v1.0.8 19 https://github.com/raivokolde/pheatmap 
Gplots v3.0.1 18 https://cran.r-
project.org/web/packages/gplots/index.html 
Prism 7 and 8 Graphpad https://www.graphpad.com/scientific-software/prism/ 
TraceFinder v3.3 Thermofisher https://www.thermofisher.com/order/catalog/product/OP
TON-30491 
Matlab Scripts for 
Live Cell 
Interferometry 
Mathworks; 2,5 N/A 
Limma v3.34.9 15 https://bioconductor.org/packages/release/bioc/html/lim
ma.html 
R v3.4.4 The R Project for 
Statistical 
Computing 
https://www.r-project.org 
Bioconductor v3.6 12 https://www.bioconductor.org 
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Supplementary information, Fig. S1 Molecular and transcriptomic characterization of 
germ layers generated with nutrient-balanced media.  a Principal components analysis 
(PCA) plot of transcriptomic variance between H9 and H9-derived lineage-directed 
differentiations from this study (n = 5, GSE127270) and a previously established nutrient-
balanced strategy1 (n = 2, GSE101655).  b Heatmap of hPSC and lineage-restricted marker 
gene expression. Heatmap values are plotted as the variance stabilized transform (VST) 
subtracted by the gene row average mean between samples (Z score).  Values shown are 
unaveraged replicates (n = 5 each lineage). c Representative flow cytometry traces for 
expression of pluripotency (OCT4, SOX2), EC (SOX2, PAX6, MAP2) and ME (CD34) markers 
under EC and ME directed differentiation. d Representative OCR trace and quantification of 
basal OCR, maximal OCR, and maximal OCR/ECAR ratio determined by mitochondrial stress 
test of UCLA1 hPSCs at 5 days of lineage-directed differentiation. Data are normalized by µg of 
protein content per well. e Quantification and additional biological replicates provided of 
mitochondrial stress tests for H9 hPSC and H9-derived progenitors. Each row represents one 
independent biological experiment. Data represent n = 3 ME, n = 3 EN, n = 4 EC. Related to 
Fig. 1a. *p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. p values are determined using (e) 
unpaired Student’s t-test. Data represent mean ± SD of independent experiments indicated 
above.  
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1 Cliff, T. S. et al. MYC Controls Human Pluripotent Stem Cell Fate Decisions through 
Regulation of Metabolic Flux. Cell Stem Cell 21, 502-516 e509, 
doi:10.1016/j.stem.2017.08.018 (2017). 
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Supplementary information, Fig. S2 Impact of glutamine removal on metabolism and cell 
fate. a Schematic and mass isotopomer distribution (MID) percent labeled of select glycolysis, 
citrate, and significant TCA metabolites (fumarate, malate, aspartate) from [U-13C6] glucose 
labeling. Media of differentiated H9 hESCs were changed 18h prior to intracellular metabolite 
extraction. b-c Representative OCR trace and quantification of basal OCR, maximal OCR, and 
maximal OCR/ECAR ratio determined by mitochondrial stress test of H9 hPSCs and H9-derived 
EC and ME in presence or absence (-Gln) of glutamine in XF media. d Morphology of H9-
derived EB at 21 day differentiation in presence or absence of glutamine in culture media. Scale 
indicates 100 μm. e Relative transcriptional expression of transcription factors ME (HAND1) and 
EC (MAP2B, PAX6) in H9-derived EB at 21 day differentiation in presence (Control) or absence 
of glutamine (-Gln) and co-treated or untreated with 1mM DCA in the culture media. *p ≤ 0.05, ** 
p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 when compared to EB control, # p ≤ 0.05, ## p ≤ 0.01, ### 
p ≤ 0.001, #### p ≤ 0.0001 when compared to hPSC control. Relative expression quantification is 
normalized to Control (set to 1). f Phase contrast microscopy images of cytokine-induced 
directed differentiation of EC, ME, and EN in the presence (Ctr) or absence (-Gln) of glutamine. 
Images taken are at 40X magnification. Data represent n = 3 independent experiments. g 
Relative levels of glycolytic metabolites in H9 hPSCs under 36h and 48h spontaneous 
differentiation in presence or absence of Gln and co-treated or untreated with 1mM DCA in the 
culture media, quantified by UHPLC-MS.*p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. p 
values are determined using (b-e) unpaired Student’s t-test or (g) two-way ANOVA with multiple 
comparisons Bonferroni correction. Data represent mean ± SD of n = 3 independent 
experiments. 
